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Summary
Inflammatory bowel diseases (IBD) are a group of chronic, relapsing, immunologically-
mediated disorders of the intestine, the main forms being Crohn’s disease and ulcerative 
colitis. Recent studies underscore the importance of the damaged epithelial barrier and the 
dysregulated innate immune system in the pathogenesis of IBD. These two components 
cause defects in the interaction of the host with the bacterial flora. The epithelium must 
maintain a physical barrier between the lumen and the underlying mucosa. Defects in the 
mucus layer, integrity, and permeability are found in IBD and are thought to have direct 
implications on disease initiation and/or progress. Furthermore, it has become clear that the 
intestinal epithelial cell lining exerts an important role in the identification of bacteria and the 
appropriate counteraction. The involvement of the innate immune system can be explained 
by two theories. The first one states that an exaggerated innate response and a loss of 
tolerance for the commensal intestinal microflora are caused by defective down-regulation of 
pattern recognition receptor signalling. The second theory encompasses a defective innate 
immunity originating from failure of recognition of bacterial threats or an ineffective response, 
which results in persistence of the exogenous stimulus and an exaggerated secondary 
immune response. 
The first part of this thesis focuses on the interaction of therapeutic bacteria with the 
damaged epithelial barrier. Genetically modified Lactococcus lactis bacteria were developed 
in order to provide a local mucosal delivery of the anti-inflammatory cytokine interleukin (IL)-
10. Since local delivery of the cytokine in the tissue seems primordial, we focused on the in
vivo interaction of the bacteria with intestinal murine mucosa and observed differences 
between an intact and an inflamed (damaged) epithelial barrier. In healthy intestinal tissue, 
we found an occasional transcellular uptake in follicle-associated epithelium. Our data were 
suggestive of dendritic cell sampling, but not of sampling by M cells. In inflamed mucosal 
tissue, both confocal and electron microscopic analysis suggested an enhanced uptake of 
lactococci through the paracellular route, which is likely to be a result of the damaged 
mucosal barrier. We were able to show the presence of viable and IL-10-producing 
lactococci in ileal and colonic lamina propria. The absence of lactococci in mesenteric lymph 
nodes or in the spleen excluded a systemic circulation of the bacteria, being safe for 
administration in patients. 
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In the second part, the role of metallothioneins (MTs) as immunomodulators in intestinal 
inflammation is investigated. We found a significantly lower mRNA and protein expression in 
the epithelium of unaffected tissue of Crohn’s disease patients. In vitro studies with an MT-
knockdown intestinal epithelial cell line showed a defective secretion of the neutrophil 
chemokine IL-8 upon bacterial challenge. A time course study of dextran sodium sulphate-
induced colitis revealed that MTnull mice exhibited a significantly more severe histological 
inflammation in the early phase of colitis compared with wild type mice, a difference which 
was due to epithelial MTs. Both these in vitro and in vivo studies point to an 
immunomodulatory role for epithelial MTs in the acute intestinal immune response.
In ulcerative colitis, we did not find this impaired basal epithelial MT expression. Here, active 
inflammation caused a down-regulation of epithelial MT and an up-regulation of non-
epithelial MT which was also observed in other forms of intestinal inflammation. The 
inflammation-dependent down-regulation in the epithelium is in contrast with the known 
induction of MTs by proinflammatory cytokines and reactive oxygen intermediates, which are 
produced during inflammation. We found that transforming growth factor (TGF)-ȕ, one of the 
few inhibitors identified for MT mRNA production, could decrease epithelial MT expression in 
ex vivo experiments. Contrary to the decrease in the epithelium, an increase in MT-
expressing cells occurs in the lamina propria during active inflammation, predominantly 
caused by strongly MT-expressing fibroblasts of the granulation tissue. Since we did not find 
a correlation between MT expression and proliferation (a correlation which has been reported 
in vitro in the literature), we suggest that the role of MTs in these cells is a cytoprotective 
one, which would be beneficial for host cells in the inflammatory environment. Finally, we 
reviewed the MT regulatory mechanisms in health and in disease.
12 I  Summary
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Samenvatting
De ziekte van Crohn en colitis ulcerosa zijn de belangrijkste chronische ontstekingsziekten 
van de darm. Recente studies benadrukken het belang van schade aan de epitheelbarrière 
en defecten in het aangeboren immuunsysteem in het ontstaan van beide ziekten. Deze 
schade zorgt ervoor dat de interactie tussen de microbiële darmflora en de gastheer niet 
meer optimaal verloopt. Het darmepitheel dient een fysische barrière te vormen tussen het 
lumen en de onderliggende mucosa. Bij de ziekte van Crohn en colitis ulcerosa worden 
afwijkingen in de mucuslaag, de integriteit en de permeabiliteit van het epitheel gevonden, 
waarvan men denkt dat ze een directe invloed hebben op de initiatie en de progressie van de 
ziekte. Naast zijn rol als fysische barrière heeft het epitheel ook een belangrijke taak in de 
identificatie van bacteriën en de gepaste reactie hierop. Het aangeboren immuunsysteem 
kan op twee manieren een rol spelen in the pathogenese. Een eerste theorie stelt dat 
defecten in het uitschakelen van proinflammatoire signalen een overdreven aangeboren 
immuunantwoord veroorzaken en een verlies van tolerantie tegenover de commensale 
microbiota. Volgens de tweede theorie worden pathogenen niet goed herkend, waardoor er 
een inefficiënte opruiming volgt die ervoor zorgt dat de exogene stimulus blijft bestaan en er 
een overdreven secundair immuunantwoord op gang komt. 
Het eerste deel van deze thesis handelt over de interactie van therapeutische bacteriën met 
de beschadigde epitheelbarrière. Genetisch gemodificeerde Lactococcus lactis bacteriën 
werden ontwikkeld om te zorgen voor een lokale toelevering van het anti-inflammatoir 
cytokine interleukine (IL)-10 in de mucosa. Aangezien deze lokale toelevering uitermate 
belangrijk is voor de therapeutische werking van de bacteriën, hebben we de interactie 
onderzocht tussen deze bacteriën en de darmmucosa. We vonden dat de bacteriën op 
transcellulaire wijze kunnen opgenomen worden in gezond follikelgeassocieerd epitheel. 
Onze data suggereerden eveneens opname door dendritische cellen, maar niet door M 
cellen. In ontstoken mucosa bemerkten we een verhoogde opname door paracellulair 
transport. Dit was waarschijnlijk veroorzaakt door de beschadigingen aanwezig in de 
mucosale barrière. We konden aantonen dat er levende en IL-10-producerende lactococcen 
in de lamina propria aanwezig waren. Uiteindelijk kon de afwezigheid van lactococcen in de 
mesenterische lymfeknopen en de milt uitsluiten dat deze bacteriën in de systemische 
circulatie terechtkomen. 
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In het tweede deel onderzochten we de rol van metallothioneïnes (MTs) in darmontsteking. 
We vonden een significante daling in de mRNA en eiwitexpressie van MTs in het epitheel 
van gezond darmweefsel van patiënten met de ziekte van Crohn. Wanneer we bacteriële 
stimulaties uitvoerden op een darmepitheel cellijn met deficiënte MT expressie zagen we dat 
deze deficiëntie zorgde voor een daling in de secretie van het chemokine IL-8. Een 
gedetailleerde studie van dextraan sodiumsulfaat-colitis gaf aan dat MTnull muizen een 
zwaardere histologische inflammatie vertoonden dan wild type muizen in de vroege fase van 
colitis, een verschil dat te wijten was aan epitheliaal MT. Beide studies wijzen in de richting 
van een immunomodulatorische rol voor epitheliaal MT in het acute immuunantwoord van de 
darm.
Deze verminderde basale epitheelexpressie vonden we niet terug bij colitis ulcerosa. In deze 
en andere ontstekingsziekten van de darm vonden we dat actieve inflammatie zorgde voor 
een daling in de epitheelexpressie van MT tegenover een stijging in de expressie van MT in 
de lamina propria. De ontstekingsafhankelijke daling in het epitheel komt niet overeen met de 
gekende inductie van MTs door proinflammatoire cytokines en reactieve zuurstofradicalen 
die geproduceerd worden tijdens ontsteking. Wij vonden dat transforming growth factor 
(TGF)-ȕ de expressie van MT in epitheelcellen kon doen afnemen. In tegenstelling tot deze 
afname in het epitheel werd tijdens actieve inflammatie een toename in de expressie 
waargenomen in cellen van de lamina propria, voornamelijk veroorzaakt door fibroblasten 
van het granulatieweefsel die sterk positief waren. We suggereren dat MTs een 
cytoprotectieve rol hebben in deze cellen, wat een voordeel betekent in een inflammatoir 
milieu.
Uiteindelijk hebben we een overzicht gemaakt van de mechanismen die de expressie van 
MTs regelen in ziekte en gezondheid. 
14 I  Samenvatting
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inflammatory bowel diseases 
Crohn’s disease (1) and ulcerative colitis are chronic, relapsing, immunologically mediated 
disorders of the intestine that are collectively referred to as inflammatory bowel diseases 
(IBD) (2). What distinguishes IBD from inflammatory responses seen in the normal gut is an 
inability to down-regulate those responses. In healthy persons, the intestine becomes 
inflamed in response to a potential pathogen, then returns to a state of tolerance once the 
pathogen is eradicated from the gut. In individuals with IBD, however, inflammation is not 
down-regulated, the mucosal immune system remains chronically activated, and the intestine 
remains chronically inflamed (3). The main difference between Crohn's disease and 
ulcerative colitis is the location and nature of the inflammatory changes. Crohn's disease can 
affect any part of the gastrointestinal tract, from mouth to anus, although a majority of the 
cases starts in the terminal ileum. Regarding to disease location, Crohn’s disease is 
categorized into ileal, colonic, or ileocolonic disease (4). Ulcerative colitis, in contrast, is 
restricted to the rectum and the colon, and can be categorized based on the maximal extent 
of involvement into ulcerative proctitis, left sided (distal) ulcerative colitis, or extensive 
ulcerative colitis (pancolitis) (4). 
Microscopically, chronic intestinal inflammation displays mostly epithelial alterations. These 
can include an increased number of goblet cells, impaired mucus secretion, an increase in 
Paneth cell number, displacement of Paneth cells higher up in the crypts in the ileum and 
even appearance in the left colon, and the presence of the ulcer-associated cell lineage 
(UACL). Architectural alterations regarding villous shape and size include enlargement, 
blunting, broadening at the top (drumstick appearance), atrophy, and irregular or diffuse 
shortening, while crypts might be branching, shortened, atrophic, lost, or arranged in groups. 
The composition of the inflammatory cell infiltrate, which is less important for diagnosis, is 
patchy and consists of lymphocytes, plasma cells, and polymorphonuclear cells. In active 
inflammation, the inflammatory cell infiltrate is more striking and goes along with dilatation 
and congestion of capillary blood vessels. The severity of active inflammation rises with the 
increasing appearance of cryptitis, crypt abscesses, and ulcers. 
Crohn’s disease exhibits some characteristic features, but these are rarely all present in a 
single specimen and may even be entirely absent in some cases. The most characteristic 
microscopic features of the disease are its multifocal involvement, focal ulceration (with small 
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aphthoid ulcers in early disease and fissuring, serpiginous ulcers in more extensive disease), 
transmural inflammation in the form of lymphoid aggregates, and sarcoid granulomas (figure 
1A). In ulcerative colitis inflammation is restricted to the mucosal and submucosal layer, the 
latter often showing intense congestion and dilatation of capillaries and veins (figure 1B). 
Crypt abscesses are a common feature but not specific, whereas the consequences of 
cycles of epithelial destruction followed by epithelial repair can be useful histological signs. 
These include impaired mucus secretion, Paneth cell metaplasia, and dysplasia (5). 
Figure 1. Histological characteristics of active Crohn’s disease (A) and 
ulcerative colitis (B). 
(A) Chronic ileitis featuring irregular, distorted villi and crypts, some of which are grouped. Chronically 
inflamed lamina propria with lymphoid follicles (magnification 20x). Insert: typical sarcoid granuloma 
(magnification 200x). 
(B) Ulcerative colitis, same magnification as (A), showing an irregular atrophic mucosa with distorted and 
branched crypts, diffuse mucin depletion and numerous crypt abscesses. Diffuse inflammatory infiltration 
of the lamina propria. The inflammatory infiltrate is limited to the mucosa and superficial submucosa. 
18 I  chapter 1    general introduction
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risk factors for IBD 
The prevalence rate of IBD reaches up to 387 cases per 100,000 persons, the highest rates 
being reported in northern and western Europe as well as North America, whereas lower 
rates are recorded in Africa, South America and Asia (6). Although the incidence and 
prevalence are beginning to stabilize in high-incidence areas, they continue to rise in low-
incidence areas (6;7). The peak age of onset for IBD is 15 to 30 years old, although it may 
occur at any age. Ulcerative colitis is slightly more common in males, whereas Crohn’s 
disease is marginally more frequent in women (3). Epidemiologic observations indicate that 
both genetic and environmental factors are involved in the pathogenesis of IBD.
genetic factors 
A genetic component seems to be stronger in Crohn’s disease than in ulcerative colitis, since 
the concordance rate in identical twins is higher for Crohn’s disease (~50% compared to 
~16% for ulcerative colitis) (8). The increased incidence of IBD in first-degree relatives of 
probands with either disease, as well as associations of Crohn’s disease with other genetic 
disorders (ankylosing spondylitis, psoriasis, and eczema) all add up to the proof that genetic 
factors are involved. These findings also indicate that IBD is not inherited as a Mendelian trait 
but rather has a complex genetic basis with many contributing genes (3;9). Racial and ethnic 
differences were at first also thought to arise from genetic susceptibility. However, these 
differences seem to be narrowing, and studies of migrant populations suggest that they may 
be more related to lifestyle and environmental influences than true genetic differences (10-
12).
Advances in the genetics of IBD have occurred from genome wide scans and candidate gene 
approaches, delineating IBD susceptibility loci (IBD1-IBD9). A recent study combined the 
data of three genome wide association studies in Crohn’s disease, thus creating a very large 
data set and improving power to discover alleles with small effect sizes. This genome-wide 
meta-analysis strongly confirmed 11 previously reported loci and provided significant 
evidence for 21 new loci (table 1) (13). Besides these confirmed loci/associations, other 
genes have been associated with IBD which have functions that can be related to the 
pathogenesis (table 2). Studies in mouse experimental colitis that used transgenic and 
knockout techniques have added functional data on susceptibility genes (14;15). Work in 
these two independent systems has yielded partially overlapping results, with genes involved 
in both IBD and experimental colitis. The association of polymorphisms in several of these 
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Table 1. Convincingly replicated CD risk loci by genome-wide meta-analysis (13)
odds ratios SNP chromo-
some
no. of 
genes
gene of 
interest
CC TDT 
allocated function previous 
associations
(a) Previously published loci     
rs11465804 1p31 NA IL23R 2.50 2.77 interleukin-23 receptor (16-20) 
rs3828309 2q37 NA ATG16L1 1.28 1.30 autophagy-related  (18-22) 
rs9858542 3p21 35 MST1 1.20 1.20 macrophage stimulating 1 (hepatocyte 
growth factor-like) 
(19;20)
rs4613763 5p13 0 PTGER4 1.32 1.28 prostaglandin receptor EP4 (17) 
rs2188962 5q23 7 1.25 1.26   
rs11747270 5q31 3 IRGM 1.33 1.31 induces autophagy (19;20;23) 
rs4263839 9q32 2 TNFSF15 1.22 1.07 TNF-like factor, is induced by TNF and 
can activate NF-țB
(24)
rs10995271 10q21 1 ZNF365 1.25 1.53 Zinc-finger protein 365  
rs11190140 10q24 1 NKX2-3 1.20 1.28 homebox transcription factor, required 
for T- and B-cell localization in the 
spleen and mesenteric lymph nodes 
(19;20)
rs2066847 16q12 NA NOD2 3.99 2.57 pattern recognition receptor (18;19;25;26)
rs2542151 18p11 1 PTPN2 1.35 1.14 T-cell protein tyrosine phosphatase, a 
negative regulator of inflammatory 
responses
(19;23)
(b) Novel loci
rs2476601 1p13 7 PTPN22 1.31 1.17 T-cell protein tyrosine phosphatase 
rs2274910 1q23 2 ITLN1 1.14 1.62 intelectin-1 
rs9286879 1q24 0 1.19 1.08
rs11584383 1q32 3 1.18 1.20
rs10045431 5q33 1 IL12B 1.11 1.36 encodes IL-12p40 subunit of IL-12 and 
IL-23
rs3763313 6p21 7 BTNL2, 
SLC26A3,
HLA-DRB1,
HLA-DQA1
1.19 1.01
rs6908425 6p22 1 CDKAL1 1.21 1.09 poorly characterized; gene is a type 2 
diabetes susceptibility gene 
rs7746082 6q21 0 1.17 1.19
rs2301436 6q27 3 CCR6 1.21 1.16 chemokine receptor 6 
rs1456893 7p12 0 1.20 1.14
rs1551398 8q24 0 1.08 1.25
rs10758669 9p24 3 JAK2 1.12 1.21 Janus kinase 2, downstream signalling 
molecule of many cytokines and 
growth factors 
rs17582416 10p11 3 1.16 1.26
rs7927894 11q13 1 C11orf30 1.16 1.07
rs11175593 12q12 3 LRRK2,
MUC19
1.54 1.44 leucine-rich repeat kinase 2, mutant 
form induces autophagy; 
mucin gene 19 
rs3764147 13q14 3 1.25 1.19
rs2872507 17q21 17 ORMDL3 1.12 1.24 inducible T-cell co-stimulator ligand 
rs744166 17q21 4 STAT3 1.18 1.25 signal transducer and activator of 
transcription 3, downstream signalling 
molecule of many cytokines and 
growth factors 
rs4807569 19p13 2 1.02 1.26
rs1736135 21q21 0 1.18 1.10
rs762421 21q22 1 ICOSLG 1.13 1.21 inducible T-cell co-stimulator ligand 
Abbreviations: NA, not applicable; SNP, single nucleotide polymorphism; CC, Case Control; TDT, transmission 
disequilibrium test 
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genes (at least in Crohn’s disease) further highlights the complex polygenic nature of the 
disease. A recent study provides the first detailed illustration of the genetic relationship 
between Crohn’s disease and ulcerative colitis (20). It shows that several risk loci are 
common to ulcerative colitis and Crohn's disease (among which IL23R), whereas autophagy 
genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for 
Crohn's disease. 
Table 2. Genes interesting according to function (with single association) 
Gene Chromosome Allocated function Reference 
Crohn’s disease    
SLC22A4 & 
SLC22A5
5 solute carrier family 22 (organic cation transporter), 
members 4 and 5 (formerly OCTN1 and OCTN2); organic 
cation, carnitine transporters, possibly transport xenobiotic 
substances
(27)
DLG5 10 discs large homolog 5 (Drosophila); epithelial scaffolding 
protein; CARD-containing protein 
(28;29)
NCF4 22 regulatory component in superoxide production (18) 
Ulcerative colitis    
MDR1 7 multidrug resistance 1; efflux transporter for drugs and, 
possibly, xenobiotic compounds 
(30;31)
environmental triggers 
Differences in incidence of IBD across age, time, and geographic region suggest that 
environmental factors significantly modify the expression of Crohn’s disease and ulcerative 
colitis (6). Furthermore, the incomplete penetrance of IBD (e.g. in monozygotic twins) 
suggests that non-genetic triggers are necessary. Indeed, several studies implicate 
environmental factors in the pathogenesis of IBD. The strongest factor identified is smoking 
(32), being protective in ulcerative colitis but increasing risk in Crohn’s disease (33). 
Mechanisms behind the effect of smoking on IBD remain obscure, but potentially important 
effects of nicotine or smoking on cytokines (34;35), eicosanoids (36), mucosal 
microcirculation (37), small intestinal permeability (38), and colonic mucus (39;40) have been 
suggested, possibly involving nicotinic acetylcholine receptors in the bowel wall (41). The 
kind of involvement of these factors and/or processes can differ in Crohn’s disease versus
ulcerative colitis (see further), probably accounting for the opposite effects of smoking 
observed in the two disorders. 
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Another factor with a similar differential influence on Crohn’s disease and ulcerative colitis is 
appendectomy (42-44). A hypothesis on appendectomy is that the development of 
appendiceal inflammation or mesenteric adenitis might protect against ulcerative colitis 
and/or predispose to Crohn’s disease. Alternatively, removal of the appendix might influence 
the mucosal immune system of the gut (6;45). Recently, preterm birth and other perinatal 
circumstances were associated with the development of IBD (46). Whether other factors 
such as the use of antibiotics and non-steroidal anti-inflammatory drugs (NSAIDS), stress, 
diet, oral contraceptives, perinatal/childhood infections, or atypical mycobacterial infections 
play a role in expression of IBD remains unclear (6;47). 
epigenetic effects in IBD 
Emerging evidence suggests a key role for epigenetics in human pathologies, including in 
inflammatory disorders. Epigenetic mechanisms result in heritable modifications in the 
expression of genes that are independent from DNA coding variability. These phenomena 
have been recognized as important permissive and suppressive factors in controlling the 
expressed genome via gene transcription. Two major epigenetic mechanisms are the 
posttranslational modification of histone proteins in chromatin and the methylation of DNA 
itself (48).
As discussed above, the concordance rate of IBD in monozygotic twins is maximum 50%, 
which might be partly due to epigenetic effects. Moreover, the epigenome is influenced by 
environmental factors such as diet and smoking, which are (presumed) triggers of IBD. The 
specific presence of epigenetic modifications in IBD has only been studied in the context of 
IBD-associated colorectal cancer, and their occurrence seems to be a risk factor. One study 
found that methylation was a frequent and early event in IBD even before the occurrence of 
neoplasia (49). The importance of the epigenome in the pathogenesis of IBD will probably be 
pointed out in the near future as it will be for other diseases. 
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pathogenesis of IBD 
Genetic and environmental factors can play a role at different levels involved in the 
pathogenesis of IBD: the epithelial barrier, the innate immune response, the adaptive 
immune response, and regulation. In all of these components, a disturbed handling of host-
bacteria interactions seems to be important. 
involvement of bacteria 
There is abundant evidence that bacteria are significant contributors to the development of 
both IBD and experimental colitis. 
evidence for the role of bacteria in experimental colitis 
In at least 11 different animal models, colitis and immune activation fail to develop in the 
absence of commensal bacteria, and multiple experimental colitis models respond to 
antibiotics and probiotics (table 3). Bacterial association studies show that different bacterial 
species can cause different disease phenotypes in a single host, e.g. monoassociation of 
gnotobiotic IL-10-/- mice with the commensal bacteria Enterococcus faecalis and Escherichia
coli induced phenotypically distinct forms of colitis (E. faecalis: late onset, distal colonic; E.
coli: early onset, caecal) (50). Dual-association with both bacteria induced aggressive 
pancolitis and duodenal inflammation, implicating the likelihood that various commensal 
enteric bacterial species interact to induce and perpetuate mucosal immune responses that 
accompany intestinal inÀammation (51). On the other hand, variable responses to the same 
bacterial species in different models of colitis demonstrate the requirements for host 
specificity: E. faecalis and E. coli both induced colitis in monoassociated IL-10-/- mice, but not 
in HLA-B27 transgenic rats. By contrast, Bacteroides vulgatus induced colonic inflammation 
in HLA-B27 transgenic rats but not in IL-10-/- mice (52). These data show that some (but not 
all) endogenous bacteria can provide an antigenic stimulation in colitis, and that genetic 
predisposition is critical to determine the immune response to bacteria (53). In a similar way, 
various probiotic species have variable effects in the same host, and different hosts respond 
variably to the same probiotic species (54;55). A recent study sheds another light on the role 
of commensals in the development of IBD by showing that commensal bacteria are required 
for exacerbation but not development of ileitis in SAMP1/YitFc mice (56). All these data show 
that the occurrence of IBD depends upon a complex and specific interaction between the 
right micro-organism in the right host. 
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Table 3. The role of bacterial flora in experimental colitis models (adapted from (57), 
adjusted)
Model Role of bacterial flora Reference 
HLA-B27 transgenic bacterial flora necessary for development of intestinal 
inflammation
prevention of colitis by probiotic following antibiotic treatment 
(58)
(54)
IL-10 deficient bacterial flora necessary for development of intestinal 
inflammation
probiotic prevention and treatment of colitis 
(59)
(55;60;61)
SAMP1/Yit bacterial flora necessary for development of intestinal 
inflammation
(62)
C3H/HeJBir bacterial flora necessary for development of intestinal 
inflammation
(63)
IL-2 deficient bacterial flora necessary for development of intestinal 
inflammation
(64)
TCRĮ deficient bacterial flora necessary for development of intestinal 
inflammation
(65)
CD4+CD45RBhi adoptive 
transfer
amelioration in SCID recipients with reduced bacterial flora or 
treated with antibiotics 
(66)
mdr1a deficient antibiotics prevent and treat (67) 
DSS antibiotics can prevent or treat colitis; bacterial products or 
probiotics can ameliorate colitis 
cave: germ-free mice develop colitis to the same or even more 
severe degree as conventional mice 
(68-71)
(72)
STAT-4 transgenic immunization necessary to develop colitis 
enteric bacterial antigen-reactive Th1 cells mediate the colitis 
(73)
TGFȕRII/IL-10R2DKO fulminant colitis was completely inhibited by a combination of 
broad-spectrum antibiotics 
(74)
Abbreviations: DSS, dextran sodium sulphate; IL, interleukin; mdr, multidrug resistance; STAT, signal transducer 
and activator of transcription; TCR, T-cell receptor, TGFȕRII/IL-10R2DKO, double knockout for TGF-ȕ receptor II 
and interleukin-10 receptor 2 
evidence for the role of bacteria in human studies 
In IBD, the evidence that bacteria contribute to the pathogenesis of IBD is more indirect, but 
still considerable. First, luminal bacterial concentrations reach 107 to 108 organisms/g luminal 
contents in the terminal ileum, 1011/g in the colon, and 1010-11/g in ileal pouches (figure 2) 
(75). Lesions in IBD predominate in these areas of highest bacterial exposure (53). Further 
evidence for the importance of the microflora is the dysbiosis which is seen in patients with 
IBD. Several groups have documented a change in gut flora of IBD patients in both the faecal 
(or luminal) and the mucosal flora, which differ greatly (76-78). For example, in Crohn’s 
disease, the balance in faecal flora shifts towards more Bacteroides species (which reduce 
innate immunity) (78) and less bifidobacteria (which increase innate immunity) (76). 
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Figure 2. Human gastrointestinal bacteria: the interface between the host and the 
environment. (adapted from (75))
The luminal concentrations of the gastrointestinal microbiota are provided with the dominant identified species in 
each region. 
Comparisons of faecal floras from patients with Crohn’s disease, ulcerative colitis and 
infectious colitis showed significant differences (79), and active Crohn's disease and 
ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of 
the faecal flora (80). The mucosal flora also differs between IBD patients and healthy 
controls, containing a higher number of bacteria in patients (81-83), but being less diverse 
(84). It has been put forward that the mucosal microbiota may have a more important role in 
IBD as this ecosystem is closer to human cells (53). In tissue specimens of IBD patients, 
bacterial invasion of the mucosa was found as opposed to total absence of bacteria in tissue 
specimens of controls (81-83). Additionally, the early postoperative recurrence of Crohn’s 
disease has led to studies on the role of the faecal stream in the inflammatory process. It was 
shown that diversion of the faecal stream from inflamed bowel loops induces improvement of 
Crohn’s disease, whereas reanastomosis results in relapse (85-87). Comparative studies on 
reintroduction of small bowel effluent versus a sterile ultrafiltrate of it suggest that factors 
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greater than 0.22 microns in the faecal stream are responsible for the maintenance and 
exacerbation of inflammation in Crohn's disease (85). Finally, multiple antibiotic, probiotic and 
prebiotic treatment studies in IBD patients show favourable responses (reviewed in (88)), 
offering considerable promise for treating IBD. 
the damaged mucosal barrier in genetically susceptible individuals 
The host response to the microbiota can be ranked into several broad components: the 
epithelial barrier, the innate immune response, the adaptive immune response, and the 
regulatory mechanisms (figure 3). Experimental models reveal that severe impairment of a 
single component can result in disease, but many models demonstrate milder effects in more 
than one component (table 4). The current paradigm is that multiple defects (or ‘hits’) in these 
interacting components are thought to be required for development of IBD. 
disturbances at the level of the epithelial barrier 
The intestinal epithelial barrier must maintain a physical and immunological barrier between 
the underlying mucosa and luminal bacteria, at the same time distinguishing commensal 
bacteria and food proteins from trillions of potentially harmful organisms. Permeability can 
refer to the degree to which the epithelium is permissive to the passage of luminal 
substances or can refer more broadly to all of the protective functions of the intestinal 
mucosa. Factors contributing to normal permeability include an intact intestinal epithelium, 
surface mucus, peristalsis, and the secretion of host protective factors. The actual barrier 
includes the cells themselves plus the paracellular space. Tight junctions exist in the space 
between the cells, allowing for selective entry of fluids, nutrients, and select micro-organisms 
(89). Selective transport of luminal antigens or bacteria into the mucosa is performed by M 
(membranous or microfold) cells in the follicle associated epithelium (90), or by dendritic cells 
(DCs) which intercalate their dendrites between epithelial cells and form tight junctions (91). 
It has been shown in human ileum that follicle associated epithelium is more permeable to 
antigens and bacteria, not only because of the presence of M cells but also because of 
increased transcellular transport and increased transepithelial DC sampling (92). 
Differential cDNA screening and mRNA display of control, ulcerative colitis, or Crohn’s 
disease epithelial cells have shown differences in gene expression (93). Another study 
compared gene expression profiles in Crohn’s disease with ulcerative colitis and found 
differences in epithelia-specific genes (94). Both studies found a downregulation of genes 
involved in colonocyte energy metabolism in ulcerative colitis samples. In the Crohn’s
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disease profile, the over-expression of antimicrobial defensins was dominant. Proteome 
analysis has also identified a differential protein expression profile in the intestinal epithelium 
from IBD patients, revealing significant expression changes of proteins that are associated
Figure 3. Potential molecular pathways involved in inflammatory bowel disease (IBD) 
pathogenesis. (adapted from (95), adjusted)
In healthy individuals, bacterial invasions trigger cascades of immune events leading to chemokine secretion, 
bacterial clearance and apoptosis. Although there is still much to be discovered, genetic defects at four different 
levels are suspected to lead to chronic inflammation in IBD: 1) Mutations in transporters such as MDR1, OCTN1 
and OCTN2, or in genes involved in epithelial integrity (DLG5) may affect the permeability of the epithelial barrier. 
2) Mutations in environmental sensors and their signalling pathways, such as TLRs and CARD15/NOD2, may 
impair the innate immune system and cause a decrease in NF-țB activation and defensin production. 3&4) 
Mutations in genes involved in adaptive immunity, such as the human leukocyte antigen (HLA) genes and tumor 
necrosis factor (TNF)-Į within the major histocompatibility complex (MHC), as well as in genes coding for subunits 
of cytokines and cytokine receptors like IL-12 and IL-23R, may cause an imbalance between regulatory and 
effector cell immune responses important in the control of inflammatory reactions. TLR, Toll-like receptor; NF-țB,
nuclear factor-țB; MDR1, multidrug resistance gene; OCTN1 and 2, organic cation transporter 1 and 2; DLG5, 
drosophila discs large homolog 5. 
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Table 4. Mouse models of intestinal inflammation with defective epithelial barrier, altered innate 
immune response, excessive effector T-cell response, or altered regulatory mechanisms (adapted from (57), 
adjusted)
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Known defects Reference 
mdr1a deficient ?    altered epithelial barrier (30) 
GĮi2 deficient ? ? defective epithelial barrier; defective 
regulatory B cells 
(96)
dn N-cadherin ? intestinal epithelial cell apoptosis and 
epithelium gaps 
(97;98)
deletion of enteric 
glia nerves 
?    disrupted epithelium (99) 
DSS ?    direct damage to epithelial barrier (100) 
muc2 deficient ?    defective mucus layer (101) 
macrophage-PMN
Stat-3 deficient 
? ? increased response to LPS; resistant to IL-
10 regulation 
(102)
bone marrow Stat-3 
deficient
? ? increased response to LPS; impairment of 
innate immune function 
(103)
A20 deficient*  ? ?  increased response to LPS (104) 
IL-10 deficient  ? ? lack Tr1 activity; lack TGFȕ signalling (105) 
NF-țB p50-/- p65+/- ?   increased IL-12 production (106) 
TGFȕ1 deficient*  ? ? decreased regulatory T cells (107) 
C3H/HeJBir  ? ? impaired innate responses to TLR ligands; 
increased bacterial reactive T cells 
(63)
SAMP1/Yit ? ? epithelial cell defects; expanded B-cell 
population; increased activated T cells 
(62)
STAT-4 transgenic   ? excessive T-cell responses to enteric 
bacteria
(73)
CD40L transgenic*   ?  increased activated T cells (108) 
TNFǻARE*   ?  increased TNF-Į production (109) 
CD4+CD45RBhi
transfer
   ? decreased regulatory T cells (110) 
IL-2 deficient    ? decreased CD4+CD25+ T cell (111) 
IL-2 receptor Į
deficient
   ? decreased CD4+CD25+ T cell (112) 
TCRĮ deficient    ? loss of a regulatory B cell (113;114) 
TGFȕRII deficient*    ? decreased regulatory T cells (115) 
Smad3 deficient*    ? decreased regulatory T cells (116) 
Muc2/IL-10DKO ? ? combined defects in epithelial and 
immunoregulatory factors 
(117)
TGFȕRII/IL-10R2DKO    ? combined multiple genetic hits in immune 
regulation
(74)
Abbreviations: dn, dominant negative; DSS, dextran sodium sulphate; IL, interleukin; mdr, multidrug resistance; 
LPS, lipopolysaccharide; muc, mucin gene; NF-țB, nuclear factor țB; PMN, polymorphonuclear cell; STAT, signal 
transducer and activator of transcription; TCR, T-cell receptor, TGFȕRII/IL-10R2DKO, double knockout for TGF-ȕ
receptor II and interleukin-10 receptor 2, TLR, Toll-like receptor; TNF, tumour necrosis factor; Tr1, T regulatory 
cell type 1 
*multi-organ failure not limited to intestine 
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with signal transduction, stress response as well as energy metabolism (118). However, both 
expression and proteome analyses were carried out on samples from inflamed tissue, and as 
such several of the detected variations may reflect secondary rather than primary 
abnormalities. Therefore, follow-up studies with higher numbers of patients (including 
appropriate patient subsets) and well-chosen controls are necessary to confirm and 
understand the number of significantly regulated proteins (119). Thus, epithelial cell 
expression is altered in IBD. Defects in the epithelial barrier could lead to exposure of 
potentially harmful luminal contents to the mucosal immune system, resulting in its activation. 
abnormal mucus composition (increased adherence of bacteria) 
The epithelial cell lining is covered by a layer of glycocalyx, which is formed from mucins that 
bind the apical membrane of the cells. A thick layer of mucus, comprising diverse mucins, 
forms an additional system of protection and separates luminal bacteria from the epithelial 
surface throughout the colon in healthy individuals (82). The mucus is produced by goblet 
cells in the epithelium, and massive release of mucin granules is triggered by the presence of 
physical, chemical or infectious insults (120). The formation of a semi-permeable protective 
barrier and the repair of intestinal damage through intestinal trefoil factor (121) are the main 
functions of the mucus layer. Additionally, mucins interact with bacterial constituents, thereby 
trapping them in the mucus flow so that they are washed away by intestinal peristalsis (122). 
The secretion and dehydration of mucus is regulated tightly and viscosity gradients of the 
mucus layers exist in both vertical (surface to lumen) and longitudinal (proximal to distal 
colon) directions, determining a spatial organization of the intestinal microbiota and mucosal 
barrier function (123). Recently, it was found that secreted antimicrobial peptides are retained 
by the mucus and thereby provide an additional antibacterial barrier. This distribution is 
thought to facilitate a high local peptide concentration on vulnerable mucosal surfaces, while 
still allowing the presence of an enteric microflora (124). 
In IBD, protection of the mucosa is thought to be reduced as a result of specific changes in 
the thickness or composition of the intestinal mucus layer (125;126). The layer is thinner than 
normal in ulcerative colitis and thicker than normal in Crohn’s disease (127). A number of 
important biochemical changes such as glycosylation and sulphation have also been noted in 
IBD (128-131). The changes described are likely to alter the viscoelastic properties of the 
gels formed and influence interactions of mucins with microorganisms, electrolytes, defensive 
proteins and dietary components, hence reducing the effectiveness of supramucosal layer 
function (126). In patients with ulcerative colitis, the activity of mucosal inflammation 
correlates significantly with a decrease in synthesis and activity of the mucin gene MUC2,
encoding for an important structural component of the mucus layer (132;133). Mice deficient 
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for the Muc2 gene spontaneously develop colitis (101). In ileal Crohn’s disease, a decreased 
expression was reported in MUC3, MUC4, and MUC5B in both healthy and involved mucosa 
(134). The rectal mucus of ulcerative colitis patients features a lack of phosphatidylcholine 
compared to normal subjects or patients with Crohn’s disease, independent of the level of 
inflammation, suggesting primary involvement in pathogenesis (135). All these events could 
lead to adherence of bacteria to the mucosa and an increased exposure of the mucosal 
immune system to intestinal bacteria or bacterial components (136). The intestinal mucus 
layer from IBD patients has been shown to harbour high numbers of unspecific bacteria 
compared with lack of bacteria in normal mucus (81;82;137). 
decreased epithelial integrity
Epithelial damage is a hallmark of IBD. The proportions of differentiated intestinal epithelial 
cells such as goblet cells, Paneth cells (specialized crypt enterocytes secreting antimicrobial 
peptides and enzymes), and mature enterocytes may be altered. Rates of epithelial 
proliferation and apoptosis are changed (138-140) and can lead to crypt hyperplasia, loss of 
villi, ulcerations, and erosion of the epithelial layer (57). Oxidative stress, originating from 
reactive oxygen species (ROS) produced by phagocytic leukocytes that are present in large 
numbers in the inflamed mucosa can also result in intestinal injury, and might be elevated in 
IBD due to an imbalanced mucosal antioxidant response (141-144). Lesions of the intestinal 
epithelium allow penetration of commensal or pathogenic bacteria. The earliest observable 
lesions of recurrent Crohn’s disease are microscopic erosions and damaged M cells at the 
specialized follicle-associated epithelium (145). Recently, an increased uptake of non-
pathogenic bacteria was demonstrated in follicle associated epithelium of macroscopically 
normal ileum from patients with longstanding Crohn’s disease (146). These alterations of the 
intestinal epithelium often appear to be the consequence of the inflammatory response. 
However, it is also possible that a primary epithelial defect could be the trigger initiating the 
inflammatory process.
Some animal models show that impairment of epithelial integrity can result in intestinal 
inflammation (table 3). A number of models involve induction of acute epithelial damage via 
administration of chemical irritants or some other direct damage to the epithelial barrier, 
although in many cases a secondary immune component is also involved. Dextran sodium 
sulphate (DSS) (100) is the most commonly used, other models include treatment with acetic 
acid, oxazolone, trinitrobenzene sulphonic acid (TNBS)/ethanol, indomethacin, peptidoclycan 
polysaccharide, and carrageenan (57). Several lines of evidence indicate that the primary 
instigator of DSS colitis is damage to the epithelium, perhaps via direct toxicity (147). Early 
epithelial defects are also encountered in genetic models. Deletion of the mdr1a gene, which 
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encodes transmembrane transporter protein P-glycoprotein, results in spontaneous 
transmural colitis (30). Although this protein is also expressed in other cell types, the data 
suggest that the principal cause of colitis in this model is a primary epithelial defect 
(57;148;149). Mice deficient in GĮi2 (a signal transducer found in many cell types) develop a 
pancolitis at 8 to 12 weeks of age (96), and there are indications of a defective epithelial 
barrier prior to histological inflammation (150). Mice that transgenically express a mutant N-
cadherin protein have disruption of E-cadherin homotypic interactions, resulting in intestinal 
epithelial cell apoptosis and gaps in the epithelium (98). These mice develop intestinal 
inflammation and dysplasia (97). Finally, an important argument for a primary role of 
epithelial cell alterations is found in the SAMP1/Yit model of spontaneous ileitis. This mouse 
strain bears increased numbers of Paneth cells and goblet cells that are present before the 
onset of ileitis (151). Although the effect of these epithelial changes on the barrier prior to 
inflammation needs further evaluation, the early and severe alterations of the epithelium 
suggest that epithelial changes may be an initiating factor in this model of ileitis. 
increased permeability
Patients with Crohn’s disease have an increased intestinal permeability (152;153), which is 
also observed in 10 to 20% of unaffected relatives (154-159). In clinically asymptomatic 
Crohn’s disease patients, increased intestinal epithelial permeability precedes clinical relapse 
by as much as 1 year (160-162), indicating that a permeability defect may be an early event 
in disease reactivation. A case report of a healthy first-degree relative of Crohn’s disease 
patients who exhibited increased intestinal permeability at the age of 13 showed that a 
permeability defect can exist long before the onset of full-blown disease 8 years later, 
indicating that, at least in this case, an intestinal permeability defect may have been an early 
event in disease pathogenesis (163). Spouses of Crohn’s disease patients show a trend 
towards increased permeability (164), suggesting a role for environmental factors as well. 
Some environmental factors like smoking and non-steroidal anti-inflammatory drugs are 
thought to influence intestinal permeability and amplify abnormal ‘leakiness’ in Crohn’s 
disease (153). Enteric bacterial and parasitic infections have also been found to directly 
increase permeability (165;166). 
Epithelial permeability is predominantly defined by tight junction integrity. Recent studies 
provide evidence that the tight junction barrier is altered in active Crohn’s disease, implicating 
the claudin family of tight junction proteins (167;168). Altered claudin isoform expression 
patterns are more likely to be a consequence rather than a cause of active disease, and their 
expression can be altered by interleukin (IL)-13, interferon (IFN)-Ȗ and tumour necrosis factor 
(TNF)-Į (167-169). Regardless of these differences, TNF-Į and IFN-Ȗ can increase intestinal 
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epithelial permeability by mechanisms not involving altered claudin isoform expression, which 
are independent of apoptosis (139;170-174). Incubation of intestinal epithelial cell 
monolayers with both IFN-Ȗ and TNF-Į leads to reorganization of many tight junction 
proteins, including zonula occludens-1, junctional adhesion molecule 1, and occludin, next to 
claudin isoforms (139;175). The changes in paracellular permeability caused by IFN-Ȗ and 
TNF-Į are associated with marked increases in myosin light chain (MLC) phosphorylation 
and can be reversed using a specific membrane permeant inhibitor of MLC kinase (MLCK), 
indicating that these cytokines also utilize the MLCK-driven pathway to increase tight junction 
permeability (170). Intestinal epithelium of IBD patients showed increased expression and 
enzymatic activity of MLCK, correlating positively with disease activity (176). In contrast with 
claudin expression, MLCK expression was modestly increased in patients with histologically 
inactive IBD, suggesting that increased intestinal epithelial MLCK expression may be a stable 
characteristic of IBD patients.
Another pathway that has been connected with tight junction regulation is signalling through 
TLR2, one of the Toll-like receptors (TLRs, see further) that recognize bacterial cell wall 
constituents and activate the innate immune response. Data from in vitro and ex vivo models 
of intestinal epithelial cells revealed that TLR2 stimulation effectively preserves tight junction-
associated barrier assembly against stress-induced damage (177;178). Furthermore, in vivo
studies underscored that TLR2-mediated tight junction regulation critically determines 
susceptibility to intestinal injury and inflammation (178). These studies provide a molecular 
mechanism for commensal-induced enhancement of intestinal epithelial barrier function, 
which has been observed by diverse groups (61;179;180). In addition, TLRs serve as a 
means through which bacteria regulate normal intestinal barrier function and activate the 
normal genetic program of the intestinal epithelium (89;179;181;182). Oxidative stress is also 
associated with increased permeability. Apart from causing direct cellular injury, ROS can 
disrupt the epithelial barrier function by destabilizing tight junctions (183). 
Genetic factors that could be implicated in increased permeability include the solute carrier 
family 22 genes (SLC22A4 and SLC22A5, formerly organic cation transporter OCTN1 and 
OCTN2) (27), and the guanylate kinase DLG5 (Drosophila discs large homolog 5) gene (28). 
Mutations of the former genes alter transcription and carnitine transport function of their gene 
products, while mutations of the latter impair the ability of the DLG5 protein to maintain 
epithelial integrity. Both gene products seem to be important in epithelial permeability, and 
disruption of their function could lead to inappropriate exposure of the mucosal immune 
system to bacterial products (89). 
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defects in epithelial cell immune function 
Not only do intestinal epithelial cells form a physical barrier between the lumen and the 
mucosa, they also exert an important role in the identification of pathogens and 
counteraction, when necessary. As such, they are regarded as a part of the innate immune 
system. Defects in epithelial cell immune function that can lead to chronic inflammation will 
be discussed in the next chapter on the innate immune response. 
disturbances at the level of the innate immune response 
While most research investigating the mucosal immunology relevant to IBD during a number 
of years focussed on the T cell as the key player, recent advances in genetics and 
immunology in IBD have switched the emphasis to innate immunity as pivotal in the 
development of this disease. The innate immune system provides an immediate, but non-
specific response based on sensing, recognition, and clearing of microbial pathogens. Innate 
immune recognition relies upon germline-encoded receptors that recognize a limited number 
of highly conserved microbial structures, so-called pathogen-associated molecular patterns 
(PAMPs). The receptors, referred to as pattern recognition receptors (PRRs), include Toll-like 
(TLR, transmembrane) and Nod (nucleotide-binding oligomerization)-like (NLR, cytoplasmic) 
receptors. They are expressed on epithelial cells, macrophages, DCs, and B cells. Among 
the structures detected by PRRs are lipopolysaccharides (LPS), peptidoglycan (PG), 
lipoproteins, flagellin, and nucleic acids. Ligand binding to host cell receptors induces cellular 
signalling events that lead to the production and secretion of molecules involved directly in 
defence, in addition to recruitment and activation of phagocytic cells (particularly neutrophils), 
and activation of DCs to promote the generation of an adaptive immune response. These 
molecules vary greatly in composition and activity and include antimicrobial peptides, 
cytokines, chemokines, and eicosanoids (184). When these molecules are generated 
unnecessarily or in excess, however, they can lead to damage of the host tissue or an 
unnecessary activation of the immune system (figure 4a). Otherwise, failure of recognition of 
a bacterial threat or an ineffective response can result in persistence of the exogenous 
stimulus and an exaggerated secondary and compensatory immune response (figure 4b) 
(185).
NOD proteins 
The first susceptibility gene that was identified for Crohn’s disease is NOD2/CARD15 (25;26),
initially thought to be expressed only in the cytoplasm of macrophages (186). At present, 
however, it is known that NOD2 is also expressed in DCs (187), Paneth cells (188), and 
intestinal epithelial cells, with higher expression in the crypts than in the villi (187;189).
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Figure 4. Two models for the involvement of the innate immune response in Crohn’s 
disease (adapted from (185))
(a) In this model, NOD2 should down-regulate TLR signalling by an unknown mechanism. The mutated NOD2 
protein loses this negative regulation of TLR signalling (as a consequence of the Crohn’s disease-associated 
mutation), hence resulting in increased innate immunity to bacterial stimulation and predisposing to intolerance for 
the commensal intestinal microbiota, with intestinal inflammation as a consequence. (b) In the second model, both 
signalling pathways (NOD2 and TLR) are required for optimal bacterial defence. The mutated NOD2 receptor 
does not contribute to the pro-inflammatory gene transcription in response to bacteria, resulting in an inadequate 
innate response to bacterial invasion and enabling the accumulation of commensal bacteria. The poor innate 
response leads to the formation of the granulome and, thus, the activation and perpetuation of a deregulated 
secondary adaptive response. 
Polymorphisms of NOD2 associated with Crohn’s disease are deficient in their recognition of 
muramyl dipeptide (190), which ensures ileal expression of antimicrobial peptides and 
promotes cytokine and chemokine production by enterocytes and immunocytes. Crohn’s 
disease-associated NOD2 polymorphisms have also been linked with impaired expression of 
certain Paneth-cell derived antimicrobial peptides (191-193), although the association with 
reduced expression of antimicrobial Į-defensin has recently been contested (194). Most 
functional studies on mutant NOD2 have been performed in vitro on cell lines or on 
macrophages and monocytes from patients carrying NOD2 mutations and support a loss-of-
function phenotype. Three common mutations (Arg702Trp, Gly908Arg, Leu1007fsinsC), 
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accounting for about 80% of variants associated with Crohn’s disease, lead to defective PG 
and muramyl dipeptide (MDP) sensing, reduced nuclear factor (NF)-țB activation and 
impaired cytokine production (TNF-Į, IL-1ȕ, IL-8, and IL-10) upon stimulation (195-198). 
However, this loss-of function phenotype is not entirely consistent with the common clinical 
observations of elevated pro-inflammatory cytokine levels and presence of activated NF-țB
in the lamina propria of Crohn’s disease patients. Macrophages of Nod2 mutant mice that 
carry a mutation analogous to the most common Crohn’s disease susceptibility allele exhibit 
a gain-of-function phenotype with increased NF-țB and more efficient IL-1ȕ secretion upon 
stimulation (199). The following hypotheses have been put forward to reconcile this apparent 
paradox: a) defective NOD2 signalling may lead to delayed clearance and uncontrolled 
proliferation of micro-organisms in the intestine, with a prolonged adaptive immune response; 
this model is compatible with the impaired expression of antimicrobial peptides by Paneth 
cells that has been linked with NOD2 mutations; b) defective NOD2 signalling could dampen 
anti-inflammatory signals, such as secretion of IL-10 or transforming growth factor (TGF)-ȕ
(197); c) some studies show that MDP activation of NOD2 negatively regulates TLR2 
responses and that absence of such regulation leads to TLR2-mediated NF-țB activation and 
heightened T helper type 1 (Th1) cell responses (200;201). This hypothesis is further 
expanded by the findings that MDP activation of NOD2 regulates innate responses to 
intestinal microflora by downregulating multiple TLR responses, not just TLR2 (202). d) 
mutations have different effects in different contexts, i.e. in the mucosa versus the periphery 
(89); e) additional Crohn’s disease-susceptibility genes and environmental factors affect 
disease expression in humans (89;203).
Current knowledge on the consequences of mutant epithelial NOD2 function is indirect and 
comes mostly from mouse models. Nod2 mutant mice, carrying a mutation that is analogous 
to the most common Crohn’s disease susceptibility allele, show no sign of spontaneous 
inflammatory lesions, but are more sensitive to DSS-induced colitis (199). Nod2-deficient
mice neither show spontaneous inflammatory lesions, yet these animals are susceptible to 
bacterial infection via the oral route but not through intravenous or peritoneal delivery (192). 
Furthermore, host recognition of MDP was dispensable for the bacteria-induced cytokine 
production and bactericidal function of macrophages, suggesting a predominant role of 
NOD2 within the intestinal epithelial barrier. A protective, antibacterial function for epithelial 
NOD2 in the gut is further supported by the observation that forced overexpression of NOD2 
by intestinal epithelial cell lines protects against Salmonella infection (189). Recent evidence 
proves that the subcellular localization of NOD2 in epithelial cells, i.e. cytosolic versus 
membrane-bound, is crucial in correctly inducing a proinflammatory response (204). An 
indirect influence of NOD2 on epithelial innate immune function is shown in a study on small 
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intestinal allograft rejection, which resembles Crohn’s disease clinically and pathologically. 
The likelihood of allograft failure in patients was about 100-fold higher in recipients with 
mutant NOD2 alleles compared to recipients with wild-type NOD2 loci, suggesting a role for 
NOD2-expressing cells of haematopoietic origin in the regulation of epithelial immune 
function (205). This regulation may happen by regulating expression of epithelial 
antimicrobial peptides, since rejection in NOD2 mutant recipients was characterised by 
decreased expression of these peptides prior to epithelial injury and inflammation. 
Another NOD protein which has been the focus of research in Crohn’s disease is NOD1, 
which mediates the epithelial response to invasive Gram-negative bacteria (206;207). 
Mutations in NOD1 have not been found in IBD (208), although there is a study that reports 
an association between a polymorphism in NOD1 and susceptibility to IBD (209). 
TLRs
It is likely that innate immune PRRs are not triggered one-at-once by single ligands but rather 
that complex activation of multiple receptors takes place due to the many TLR and NOD 
ligand motifs present on a micro-organism (210;211). Different reports have shown synergy 
between NOD2 activation and several TLR ligands in cellular responses (198;212;213), and 
the synergistic effect between NOD2 stimulation and CpG DNA (TLR9 ligand) is lost in 
Crohn’s disease patients homozygous for NOD2 mutations (214). Mammalian TLRs 
comprise a family of 13 individual receptors which are each selectively activated by different 
PAMPs (figure 5) (215).
Evidence for protective (epithelial) effects of TLR comes from mouse models, since in vitro
studies are limited by the difficulty in culturing primary epithelial cells. Intact TLR signalling is 
necessary for the healing of injured intestinal epithelium and the clearance of intramucosal 
bacteria (216). In the absence of effective TLR signalling, there is diminished chemokine 
expression, diminished neutrophil recruitment, and subsequent increased translocation of 
bacteria to mesenteric lymph nodes (217). TLR/MyD88 deficient mice developed markedly 
increased histological inflammation in the DSS model of colitis, suggesting protective effects 
of this innate signalling cascade at the epithelial cell level (181). The latter findings are 
consistent with observations that TLR4 mutant C3H/HeJ mice are more sensitive to DSS-
induced colitis than wild-type mice (63;218). Also TLR9 triggering resulted in protection from 
experimental colitis, and this protection was found to be a result of TLR9-induced activation 
of protective type I interferon (IFN-Į/ȕ) (219). Furthermore, apical TLR9 stimulation of 
intestinal epithelial cells confers intracellular tolerance to subsequent TLR challenges (220). 
Polymorphisms in TLR4 and TLR9 have been linked with Crohn’s disease and/or ulcerative 
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Figure 5. TLR ligand specificities (adapted from (215))
TLRs recognize a diverse array of PAMPs from bacteria, viruses, protozoa, and fungi. For 
detection of bacteria, heterodimeric TLR2/1 binds triacyl lipopeptides, whereas TLR2/6 
dimers bind diacyl lipopeptides and lipoteichoic acid. Homodimeric TLR2 binds 
peptidoglycan, atypical LPS, phenol-soluble modulin from Staphylococcus epidermidis, and 
porin proteins from Neisseria. In addition, TLR4 binds LPS, TLR5 binds Àagellin, and TLR9 
binds bacterial CpG DNA. TLR11 detects an unidenti¿ed protein(s) from uropathogenic 
Escherichia coli. Viral dsRNA, RSV F protein, ssRNA, and unmethylated CpG DNA are 
sensed by TLRs 3, 4, 7/8, and 9, respectively. Finally, heterodimeric TLR2/6 binds fungally 
derived zymosan and Trypanosoma cruzi GIPLs, whereas TLR11 also senses a pro¿lin-like
protein from Toxoplasma gondii. Abbreviations: dsRNA, double-stranded RNA; LPS, 
lipopolysaccharide; GIPLs, glycolipids; PAMP, pathogen-associated molecular pattern; RSV 
F, respiratory syncytial virus fusion; ssRNA, single-stranded RNA; TLR, Toll-like receptor. 
colitis, and although the association is not straightforward with different studies showing 
different associations (221-223), recent studies provide evidence that association with a 
TLR4 polymorphism cannot be set aside (224;225). An association between a number of 
variants in the TLR1, 2, and 6 genes and disease phenotype in ulcerative colitis and Crohn’s 
disease was found in a Belgian study, although none of the polymorphisms was involved in 
disease susceptibility (226). IBD may be associated with distinctive changes in TLR 
expression and function in intestinal epithelial cells as well as other types of cells in the gut. 
Epithelial cell expression of TLR4 is strongly up-regulated in Crohn’s disease and ulcerative 
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colitis (227). It is thought that host-derived feed-back mechanisms are critical in maintaining 
epithelial cell homeostasis, i.e. hypo-responsiveness of the intestinal epithelium towards 
bacterial signals under normal conditions. Several TLR pathway intrinsic mechanisms have 
been proposed for this mechanism (228-233), and lack of adequate control signals at the 
epithelial cell level may lead to the development of chronic intestinal inflammation. 
Another way in which TLRs are involved in the regulation of tolerance to commensal bacteria 
is through their effects on DCs. Besides sampling luminal contents, these potent antigen-
presenting cells play a key role in shaping intestinal immune responses including the 
generation of regulatory T cells in the gut. DCs that encounter invading microbes capture 
bacterial antigens and migrate to lymphoid organs, where they home to the T cell areas. 
While migrating to the lymph nodes, they shift from an endocytic/phagocytic immature stage 
to a mature stage of efficient T cell stimulation (234). Maturation of DCs can be induced by 
stimuli from bacteria, and TLR2 and TLR4 interaction with the appropriate ligand is essential 
for bacteria-induced maturation of DCs (235). 
signalling defects 
The various signal transduction cascades that are triggered upon stimulation of TLRs and 
NODs include the mitogen-activated protein kinases and the NF-țB system. The molecular 
mechanisms in gut epithelium that control epithelial integrity and intestinal immune 
homeostasis are critically regulated by NF-țB. Numerous studies have been performed on 
the role of NF-țB signal transduction in host defence and chronic inflammation, and the 
results support the hypothesis that the acute and transient activation of NF-țB may be 
protective for the host, while sustained and uncontrolled NF-țB signalling in the intestinal 
epithelium may indeed contribute to the immunopathology of experimental colitis (119). IL-10 
deficient mice for instance show lack of activation of STAT (signal transducer and activator of 
transcription)-3 through IL-10 and subsequently enhanced NF-țB activation (236;237). 
Conditional STAT-3 knockout mice that are targeted to either macrophages and neutrophils 
or to bone-marrow derived cells that also include DCs, endothelial cells, and B cells, both 
develop a severe enterocolitis (102;103). A primary NF-țB signalling defect in intestinal 
epithelial cells was shown to disrupt immune homeostasis in the gastrointestinal tract, 
causing an IBD-like phenotype in mice (238). It was demonstrated that intestinal epithelial 
cells can directly influence responses of innate (dendritic) cells and adaptive (CD4+ T) cells in 
the gut through the NF-țB pathway (239). Intestinal epithelial cells from IBD patients 
stimulated the proliferation and cytokine secretion by CD4+ T cells to a significantly bigger 
degree than normal intestinal epithelial cells (240). 
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antimicrobial peptides 
Reduced expression of antimicrobial peptides can compromise mucosal host defences. 
Patients with ileal Crohn’s disease have reduced ileal expression of the Į-defensins HD5 and 
HD6, produced by Paneth cells, in affected (inflamed) ileum compared to unaffected ileum 
and ileum from healthy controls (191;193). This specific decrease was independent of the 
degree of inflammation and was not observed in other intestinal inflammatory disorders. The 
functional consequence of the low Į-defensin levels was a diminished antibacterial activity in 
ileal mucosal extracts (193). Furthermore, in a transgenic mouse model changes in HD5 
expression levels had a pronounced impact on the luminal microbiota, indicating a role for 
Paneth-cell defensin expression in bacterial dysbiosis (see earlier). A recent study found the 
reduction in Į-defensin expression to be dependent on the inflammatory state of the tissue 
and to be due to loss of surface epithelium as a consequence of secondary changes rather 
than being the inciting event prior to inflammation (194). As opposed to ileal Crohn’s disease, 
colonic Crohn’s disease is characterized by an attenuated induction of inducible ȕ-defensins
caused by a reduction in ȕ-defensin gene copy number (241;242). These changes appear to 
be primary and rather specific for Crohn’s disease since in coeliac disease the adherence of 
bacteria to the mucosa is actually associated with an increase in defensin expression (243). 
impaired neutrophil recruitment/function 
Neutrophils constitute the first line of defence to penetrating microbial and organic debris 
(244). A few decades ago, a reduction in the number of neutrophils migrating to the sites of 
skin abrasions was observed in patients with Crohn’s disease, including those in complete 
remission (245-247). Ulcerative colitis patients demonstrate no impairment of neutrophil 
recruitment. The migration defect in Crohn’s disease patients was not explained by 
abnormalities in neutrophil function, since the neutrophils themselves behaved normally 
during in vitro assays of chemotaxis (248;249), suggesting alterations in the inflammatory 
environment. An impaired production of IL-8, a potent neutrophil chemoattractant, was found 
in new inflammatory lesions in bowel biopsies and in skin of Crohn’s disease (250). Direct 
subcutaneous injection with heat-killed E. coli into the forearm of Crohn’s disease patients 
consistently failed to induce an acute inflammatory response. These findings were not 
present in healthy subjects or patients with other chronic inflammatory conditions, including 
ulcerative colitis and rheumatoid arthritis. This outcome supports the hypothesis that there is 
a major defect in the handling of bowel flora in Crohn’s disease in the body. The theory that 
impaired neutrophil recruitment is a primary defect in Crohn’s disease matches with its 
characteristic presence of granulomata, which could result from uptake and encirclement of 
abnormally persisting exogenous material in the intestinal mucosa by macrophages (251). It 
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also nicely corresponds with the observation that smoking clearly predisposes to the 
development of Crohn’s lesions (see earlier). Smoking is both directly immunosuppressive, 
reducing concentrations of IL-8 within the intestinal mucosa (252), and vasoconstrictive, 
diminishing mucosal blood flow (253). Both IL-8 and blood flow are closely correlated to rates 
of neutrophils emigration into the tissues (254). 
Recently, a strong association was reported between the NCF4 gene and Crohn’s disease 
that could implicate impaired neutrophil function (18). The NCF4 gene encodes the p40phox 
protein which is a component of the nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase complex. In response to bacterial infection, the neutrophil NADPH oxidase 
assembles on phagolysosomes to catalyze the transfer of electrons from NADPH to oxygen, 
forming superoxide and downstream ROS. In vitro studies showed that this protein has a 
positive role in coupling FcȖ receptor-mediated phagocytosis to activation of the NADPH 
oxidase (255), and depletion of endogenous p40phox reduced ROS production and impaired 
bacterial killing (256). Neutrophils from mice deficient for p40phox exhibit severe defects in 
NADPH oxidase regulation and oxidant-dependent bacterial killing (257). Furthermore, these 
mice were deficient in clearing an in vivo infection with Staphylococcus aureus bacteria,
resembling an equally severe defect as that observed in chronic granulomatous disease. 
disturbances at the level of the adaptive immune response
If the antigens are not eliminated, a second phase of the immune response takes over. The 
adaptive immune system allows a stronger immune response as well as immunological 
memory, where each pathogen is “remembered” by it’s signature antigen (258). This phase 
involves the participation of B and T lymphocytes, which are responsible for humoral 
(antibody-mediated) and cell-mediated immunity, respectively. It is long-lasting and 
developing during several days, a period during which B lymphocytes produce and secrete 
antibodies and T lymphocytes either activate macrophages or directly destroy infected cells. 
The adaptive immune response is antigen-specific and requires the recognition of specific 
“non-self” antigens during antigen presentation. Given the nature of the inflammation in IBD, 
research has been focussed for years on the role of the adaptive immune response and on 
mucosal effector T cells. 
increase of Th1/Th2 infiltrate (the Th1/Th2 paradigm) 
The Th1 response is characterized by the production of IFN-Ȗ, which activates the 
bactericidal activities of macrophages, induces B cells to make opsonizing antibodies, and 
leads to “cell-mediated immunity”. The Th2 response is characterized by the release of IL-4, 
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which results in the activation of B cells to make neutralizing antibodies, leading to "humoral 
immunity" (259). The inflammation in Crohn’s disease is associated with a shift towards an 
excessive Th1 cell response in the mucosa, characterized by increased expression of Th1 
cytokines such as IL-12, TNF-Į and IFN-Ȗ (260-263). Although polymorphisms in the TNF-Į
gene have been found in certain populations (264-266), and they may result in differences in 
the levels of TNF-Į expression (267;268), the contributions of these polymorphisms are 
generally not thought to explain the prevalence of cytokine expression abnormalities found in 
Crohn’s disease (89).
Most animal models of IBD are characterized by increased levels of Th1 cytokines (269). 
Practically all these models develop colonic rather than ileal inflammation, which is a more 
common feature of Crohn’s disease (89). Two exceptions where ileitis is developed are 
TNFǻARE mice and SAMP1/Yit mice, both Th1-dependent models which are currently the 
closest to mimicking Crohn’s disease. TNFǻARE mice produce increased concentrations of 
TNF-Į and develop ileitis and arthritis (109). The SAMP1/Yit mouse model develops a 
spontaneous ileitis and, over many generations of brother-sister mating, mice also develop 
peri-anal disease (270;271). Transgenic models with an excessive effector T cell function 
that develop colitis include STAT-4 transgenic mice and CD40 ligand transgenic mice. Mice 
transgenic for STAT-4, a crucial transcription factor in the IL-12 signalling pathway, 
expressed strikingly increased nuclear STAT-4 levels in lamina propria CD4+ T lymphocytes 
upon immunization and developed chronic transmural colitis characterized by infiltrates of 
mainly CD4+ T lymphocytes of the Th1 phenotype (73). CD40 ligand is a member of the TNF 
family and is expressed primarily by activated T lymphocytes. Mice overexpressing CD40 
ligand in T cells and some B cells develop multi-organ inflammation and severe colitis, with 
the ability to extend to ileitis (108). 
Recently, Crohn’s disease has also been associated with the presence of Th17 cells, a novel 
subset of CD4+ T cells that are protective against extracellular microbes and may relate to 
Th1 cells regarding development and/or function (272). These cells have been linked with 
autoimmune disorders in mice but their properties in humans are only partially known. IL-17, 
characteristic for Th17 cells, has been detected in sera and colon biopsies of IBD patients 
(273;274). In addition, the presence of IL-17–producing CD4+ T cells was demonstrated in 
the gut of subjects with Crohn’s disease, some of which produce both IL-17 and IFN-Ȗ
(subtype Th17/Th1) (272). Differentiation of the Th17 subset is induced through activation of 
orphan nuclear receptor RORȖt signalling, depending on the pleiotropic cytokine TGF-ȕ,
which is also linked to the development of Foxp3+ regulatory T cells (see further) (275-277). 
A successful trial in Crohn’s disease patients with anti-IL12p40 (subunit of both IL-12 and   
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IL-23 that drive Th1 and Th17 polarization, respectively) indicates that Crohn’s disease may 
not be a classical Th1 T cell response but a Th1 and Th17 driven inflammation (278;279). 
Another T-cell derived cytokine that is overproduced in IBD is IL-21, necessary to up-regulate 
Th17-associated molecules during gut inflammation (280). Interestingly, IL-21-deficient mice 
were largely protected against both TNBS and DSS colitis. 
Ulcerative colitis is not accompanied by an increase in Th1 cytokines, but has more of a Th2 
character. This is insinuated by the finding of increased IL-5 secretion by lamina propria cells 
of ulcerative colitis patients (262). The major Th2 cytokine IL-4 was, however, not found in 
excess. An animal model resembling ulcerative colitis, i.e. oxazolone-induced colitis, is 
initially dominated by an IL-4 response and can be prevented by anti-IL-4 antibody 
administration (281). As colitis progresses, the IL-4 response declines and is replaced by    
IL-13, another Th2 cytokine. This latter cytokine is produced by natural killer T (NKT) cells, 
which can function as cytotoxic cells and can produce IFN-Ȗ or IL-4/IL-13 under various 
circumstances (282). An increased production of IL-13 was also found in lamina propria cells 
isolated from inflamed tissue of ulcerative colitis patients, most likely originating from the NKT 
subset (283). Furthermore, lamina propria cells enriched for NKT cells from these patients 
could be shown to be cytotoxic for epithelial cells and such cytotoxicity was enhanced by    
IL-13. This cytokine was put forward as the key effector Th2 cytokine in ulcerative colitis that 
effects epithelial tight junctions, apoptosis, and cell restitution (169). On the basis of these 
data, a possible immunopathological mechanism that is thought to operate in ulcerative 
colitis is that antigen in the mucosal microflora activates NKT cells, that in turn cause 
cytolysis of epithelial cells and the characteristic ulcerations associated with the disease 
(284).
defective T cell apoptosis 
The function of T cells is not only dependent on their activation, but also limited by apoptosis, 
which can be initiated by various factors. T-cell activation leads to cell proliferation, a process 
necessary to expand the respective immune cell population, as well as for cytokine 
production and cell differentiation. Lamina propria T cells from Crohn’s disease patients often 
exhibit an increased cell proliferation and a decreased cell death (285-287). In addition, 
Crohn’s disease T cells cycle faster, display aberrant activation of cell cycle regulatory 
proteins, and exhibit less caspase activity but more telomerase activity compared with normal 
cells (288). The resistance to apoptosis of lamina propria T cells probably occurs at the level 
of the mitochondria in the mitochondrial pathway to programmed cell death (286;288;289). 
Because apoptosis of activated T cells is an important mechanism of peripheral immune 
tolerance, this finding may explain why the inflammatory reaction in Crohn’s disease patients 
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is resistant to resolution. Intervening in the process of T cell apoptosis has shown to be 
therapeutically effective in Crohn’s disease patients (290). 
In contrast, T cells from ulcerative colitis patients have a limited capacity to expand and this 
correlates with a strong activation induced apoptosis in these cells. Furthermore, ulcerative 
colitis T cells cycle slower, display more caspase activity, but have no telomerase activity 
(288). The caspase mediated pathway of apoptosis is believed to be impaired in ulcerative 
colitis lamina propria T cells, whereas the (activation induced) mitochondrial pathway is intact 
(289). Thus, regulation of programmed cell death seems fundamentally different in mucosal T 
cells from patients with Crohn’s disease compared with patients with ulcerative colitis. 
defects in antigen presenting cells 
Antigen presenting cells (APCs) influence the decision by naïve T cells to differentiate into 
Th1 or Th2 cytokine-producing cells. Macrophages and DCs can do this through their own 
elaboration of cytokines or cell surface ligands which initiate a program of gene expression in 
T cells. The production of IL-12 by DCs or macrophages is required for IFN-Ȗ expression and 
essential for Th1-type CD4+ T cell differentiation in Crohn’s disease (291). Interestingly, it 
appears that the IL-12p40 subunit, which is shared by the related cytokine IL-23, is 
constitutively expressed by DCs in the terminal ileum in mice, the area which is 
predominantly affected in Crohn’s disease. This expression depended on the presence of 
luminal bacteria since it was absent in germ-free mice (292). Mice deficient for IL-23p19 (the 
other subunit of the IL-23 heterodimer) were highly susceptible for the development of 
experimental T cell-mediated TNBS colitis and showed even more severe colitis than wild-
type mice by endoscopic and histologic criteria (293). Subsequent studies revealed that DCs 
from p19-deficient mice produce elevated levels of IL-12, and that IL-23 down-regulates IL-12 
expression upon TLR ligation. Finally, in vivo blockade of IL-12p40 in IL-23-deficient mice 
rescued mice from lethal colitis. In human IBD, IL-12 expression is increased in APCs 
isolated from the lamina propria of Crohn’s disease patients (294). IL-23, which is also 
produced by DCs and macrophages, is involved in the possible maintenance and/or 
expansion of Th17 cells (272). In a human anti-IL-12p40 trial of Crohn’s disease patients, 
successful treatment correlated with dramatic decrease in both IL-12 and IL-23 production by 
macrophages (278;279). 
disturbances at the level of immune regulation 
Regulation of the acquired immune response is necessary to maintain immune homeostasis. 
Regulatory T cells (Tregs, sometimes referred to as suppressor T cells) are a specialized 
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subpopulation of T cells that act to suppress activation of the immune system and thereby 
maintain immune system homeostasis and tolerance to self-antigens (295;296). Tregs can 
be functionally defined as T cells that produce IL-10 or TGF-ȕ and mediate antigen-specific 
decreases in T-effector responses. They come in many forms, including those that express 
CD8 (CD8+ Tregs), those that express CD4, CD25 and Foxp3 (CD4+CD25+ or naturally 
occurring Tregs), and other T cell types that have suppressive function. CD4+CD25+ Tregs
are present not only in the spleen but also in the intestinal lamina propria (297). Next to T 
cells, B cells can also have regulatory effects on immune function (298). Disruption of 
immune homeostasis and tolerance to self-antigens results in unchecked immune responses 
and chronic intestinal inflammation. 
regulatory T cells 
In murine models, the protective role of Tregs has been absolutely shown, e.g. in the 
CD4+CD45RBhi adoptive transfer model. Based on surface CD45RB expression, normal 
CD4+ T cells can be separated into naïve cells, expressing high levels of CD45RB 
(CD4+CD45RBhi), and memory cells, expressing low levels of CD45RB (CD4+CD45RBlo).
Adoptive transfer of CD4+CD45RBhi cells into SCID or RAG-/- mice results in colitis and 
wasting (110;299). In this adoptive transfer model, colitis is abrogated by cotransfer of the 
CD4+CD45RBlo T-cell subset, and administration of either anti-TGF-ȕ or anti-IL-10 receptor 
antibody could reverse the prevention of colitis by these T cells (300;301). Also naturally 
occurring Tregs and a CD4+ T-cell subset generated in vitro through IL-10 addition (T 
regulatory cells 1 or Tr1) can prevent and treat intestinal inflammation in the same colitis 
model (302;303). Other models that indicate involvement of a defective regulation in chronic 
intestinal inflammation are IL-10 deficient mice and TGF-ȕ1 deficient mice. The mechanisms 
underlying the enhancement of a T cell response in IL-10 deficient mice are likely due in part 
to the lack of IL-10-regulatory function and in part to their innate immune defect (see earlier). 
These mice lack Tr1 cell activity, TGF-ȕ/Smad signalling, and fail to inhibit proinflammatory 
gene expression in intestinal epithelial lymphocytes (304). TGF-ȕ, a cytokine involved in 
growth and differentiation, has pleiotropic effects including inflammation, fibrosis, and 
immunosuppression, depending on tissue location and concentration. TGF-ȕ1-deficient mice 
develop a multiorgan inflammation and die by 5 weeks of age, with or without the presence of 
a microbial flora (107;305;306). Blocking of TGF-ȕ signalling in T cells resulted in the 
development of severe colitis with wasting and diarrhoea (115), and in the GĮi-2 model of 
colitis, TGF-ȕ is also involved (307). A cytokine involved in the TGF-ȕ-mediated induction of 
Foxp3+ regulatory T cells is IL-2 (308;309), and IL-2-deficient as well as IL-2 receptor Į
deficient mice both are characterized by a decreased Treg population and develop intestinal 
inflammation (112;310;311). Interestingly, recent data accumulates that establishes the 
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existence of reciprocal developmental pathways for the generation of Foxp3+ Tregs and Th17 
effector cells (275-277). Th17 differentiation is induced by TGF-ȕ in the presence of 
proinflammatory cytokines such as IL-6 (312). In contrast, Treg cell differentiation is induced 
by TGF-ȕ in the absence of IL-6 and/or presence of retinoic acid (313). Although these data 
show the importance of TGF-β in regulatory T cell function for the suppression of intestinal 
inflammation, the cytokine seems not crucial since in certain situations CD4+CD25+ T cells 
are able to suppress intestinal inflammation by a mechanism independent of Treg cell-
derived TGF-ȕ1 (314).
Active IBD is associated with a decreased number of peripheral blood Treg cells and an only 
moderate expansion in intestinal lesions compared with acute diverticulitis (315). Since no 
functional defects were found in this and other studies in IBD patients (296;316), this study 
concluded that active IBD is characterized by a numerical defect in compensatory 
mechanisms. This theory is consistent with the observations that patients with IBD have 
defective generation of Tregs in vivo (317-319). This defect was also observed in a subset of 
unaffected family members of Crohn’s disease patients but not in the control population 
without a family history of IBD. These results suggest that oral tolerance might be genetically 
regulated and that first-degree relatives of Crohn’s disease patients might share the genetic 
defect without exhibiting the clinical symptoms. Candidates for such a genetic involvement 
could be IL-10 and TGF-ȕ, given their role in the generation of the regulatory phenotype of T 
cells (302;303;320). Although there are signs of a diminished IL-10 synthesis in IBD (321), 
this is most likely not due to polymorphisms in the IL-10 gene. Except one study reporting a 
lower frequency of a high IL-10 producer allele in ulcerative colitis patients (322), the majority 
of studies did not find any influence of IL-10 genetic variants on the appearance of ulcerative 
colitis or Crohn’s disease (323-325). Increased levels of TGF-ȕ have been found in affected 
mucosa from IBD patients (326;327). This does however not lead to higher TGF-ȕ signalling, 
because Smad7, an inhibitor of TGF-ȕ1 signalling, is overexpressed in the gut of IBD 
patients and blocks this signalling pathway, resulting in a maintained NF-țB activation and a 
subsequent chronic production of proinflammatory cytokines (328;329). Smad7 is not 
transcriptionally regulated in human gut but its increase in patients with IBD is due to 
posttranscriptional acetylation and stabilization by a protein called p300, which prevents 
Smad7 ubiquitination and degradation in the proteasome (330). 
regulatory B cells 
Functionally characterized by their specific feature of antibody production, B cells were not 
considered in the past to be a major source of cytokines. This idea was revised by the 
demonstration that, like Th1/Th2 cells, B cells also possess the potential ability to produce 
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large amounts of several cytokines under certain inflammatory conditions (331). Through 
murine models of intestinal inflammation, the existence of a B cell subset was demonstrated 
that was induced in gut-associated lymphoid tissues and was characterized by CD1d up-
regulation (332). This B cell subset appeared under a chronic inflammatory environment, 
produced IL-10, and suppressed progression of intestinal inflammation by down-regulating 
inflammatory cascades associated with IL-1 up-regulation and STAT-3 activation rather than 
by altering polarized T helper responses. This study for the first time indicated that B cells, by 
producing cytokines such as IL-10, can act as regulatory cells in immunologically mediated 
inflammatory reactions. Since this report, IL-10 producing regulatory B cells have been 
identified in several kinds of inflammations in humans and mice (333). Last year, a novel IL-
12-producing regulatory B-cell subset was identified that develops under Th2-mediated 
intestinal inflammatory conditions and in the presence of IL-10 and is involved in the 
regulation of intestinal inflammation (334). Through the production of cytokines such as IL-10 
and IL-12, B cells are believed to dampen T-cell activation (333). The involvement of 
regulatory B cells in ileitis and colitis has been proven in different animal models, including 
TCRĮ deficient mice, GĮi2 deficient mice, and the CD4+CD45RBhi transfer model (335-339). 
Further studies are needed to define the role of regulatory B cells in human IBD. 
disturbances at other levels 
The discovery of new genetic factors in Crohn’s disease and ulcerative colitis reveals novel 
possible implications of certain processes that are now beginning to be studied. With the 
identification of ATG16L1 and IRGM as new susceptibility genes in Crohn’s disease, the 
relevance of autophagy in IBD has gained interest (18;21-23). Autophagy is a unique process 
of membrane trafficking in which the membrane compartment (autophagosomes) engulfs 
both organelles and cytosolic macromolecules and delivers them to the lysosome for 
degradation (340). The appearance of bacteria in the cytoplasm of APCs triggers specialized 
autophagy or ‘xenophagy’. This process shows a lot of agreements with the cytoplasmic 
recognition of bacterial antigens through intracellular PRRs such as NOD2. The TLR4 
signalling pathway has already been identified as a sensor for autophagy/xenophagy 
associated with innate immunity (341). Alternatively, the major function of autophagy is the 
regulation of self-responses by clearing apoptotic cells (340;342). In this process, cytosolic 
proteins such as self-antigens and pathogens in host cells are constitutively and efficiently 
delivered for MHC class II presentation to activate the adaptive immune system (343;344). 
This role of autophagy in self-responses sheds a new light on the apparent autoimmune 
phenomena that occur in IBD (reviewed in (345)) There is reasonable evidence for a role of 
autoreactivity against colonic epithelial cells in ulcerative colitis, whereas immune reactivity 
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against intestinal flora is the prominent feature of Crohn’s disease. Taken together, 
autophagy may be an important process in IBD pathogenesis, inducing not only innate 
immune responses against exogenous antigens but also acquired immune responses 
against self-antigens. 
Angiogenesis and inflammation are codependent processes (346). New blood vessels can 
maintain the chronic inflammatory state by transporting inflammatory cells to the site of 
inflammation and supplying nutrients and oxygen to the proliferating inflamed tissue. In turn, 
inflammatory mediators can also, either directly or indirectly, promote angiogenesis. 
Recently, angiogenesis has been described as a novel component of IBD. Morphological, 
phenotypic and functional evidence of potent angiogenic activity in both Crohn’s disease and 
ulcerative colitis mucosa was found, indicating that the local microvasculature undergoes an 
intense process of inflammation-dependent angiogenesis (347). Many factors are involved in 
this phenomenon, including growth factors, cytokines, chemokines, adhesion molecules, 
integrins, matrix-associated molecules, and signalling targets. These factors are produced by 
various vascular, inflammatory, and immune cell types that are involved in IBD pathology 
(348). Examination of the relationship between angiogenesis and inflammation in 
experimental colitis shows that initiating factors for these responses simultaneously increase 
as disease progresses and correlate in magnitude. Importantly, treatment with anti-
angiogenic agents significantly reduced angiogenic activity and associated histological 
inflammation during experimental colitis (349;350). Vascular endothelial growth factor 
(VEGF) is an angiogenic molecule that has been found increased in Crohn's disease and 
ulcerative colitis mucosa and serum. A study on VEGF polymorphisms concluded that these 
are not implicated in susceptibility to IBD and do not predict serum VEGF levels, and thus 
increased serum VEGF and angiogenesis do not appear genetically determined (351). A 
recent study questioned whether a pro-inflammatory E. coli could regulate the expression of 
VEGF in human intestinal epithelial cells. Results demonstrated that a certain entero-
adherent strain induced the up-regulation of bioactive VEGF in cultured human intestinal 
cells in both a time- and bacteria concentration-dependent manner. Thus, these results 
suggest a link between an entero-adherent, pro-inflammatory E. coli strain and angiogenesis 
(352).
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conclusion
Although the pathogenesis of IBD is not completely revealed yet, extensive research on a 
pallet of topics has shown the involvement of an inappropriate host-microbe communication, 
which is likely to be the result of environmental triggers combined with defects situated at the 
level of the epithelial barrier, innate immune responses, adaptive immune responses, and/or 
immune regulation. Especially for Crohn’s disease, a number of defects in mucosal immunity 
have been established. Environmental as well as genetic factors may permit the exposure of 
the lamina propria to commensal flora. Defects in innate immunity can result in the activation 
and accumulation of pathogenic CD4+ T cells that mediates acute and chronic intestinal 
inflammation. Both deficient and excessive innate responses are proposed as mechanisms 
for this pathogenic T-cell activation, featured by persistence of the exogenous stimulus and 
an exaggerated secondary and compensatory immune response in the first case and 
unnecessary and excessive generation of proinflammatory molecules leading to damage of 
the host tissue or an unneeded activation of the immune system in the second case. 
Furthermore, dysregulated adaptive immune responses themselves or disturbed immune 
regulation can also take part in the pathogenesis of IBD, but a primary versus a secondary 
(inflammation-dependent) involvement of these processes needs more clarification. This last 
distinction needs to be made as well for new emerging processes such as autophagy and 
angiogenesis.
The ultimate goal of medical research is to understand disease mechanisms and to apply the 
knowledge of these mechanisms in therapeutic strategies. The numerical studies on IBD 
pathogenesis have already translated into clinical benefit for patients in the form of biologic 
therapy. Novel therapeutic approaches for IBD focus on manipulating enteric microflora, 
repairing barrier function, and targeting the different components of the immune response 
(353). Future studies will identify specific markers that permit the stratification of patients 
based on distinct pathogenic mechanisms. 
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Roles for metallothioneins     
in intestinal inflammation 
metallothioneins
Metallothioneins (MTs) are a superfamily of small proteins that are present in virtually every 
living organism. A typical feature is their highly conserved number and position of cysteine 
residues, enabling them to incorporate monovalent and divalent metal atoms and to reduce 
reactive oxygen and nitrogen species. So far, 19 human isoforms have been cloned, 11 of 
which are known to be functional (i.e. MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M, 
MT1X, MT2A, MT3, and MT4). The majority of these genes cluster together on a single locus 
on chromosome 16 (16q13) (1). Heterogeneity of isoforms results from posttranslational 
modifications and/or variations in metal composition. The most widely expressed isoforms 
are MT-1 and MT-2, of which MT-2 appears to be expressed more on the basal level. These 
isoforms are highly inducible, whereas the MT-3 and MT-4 proteins are constitutively 
expressed and are found mainly in the brain, kidney, and reproductive organs (MT-3) and in 
certain squamous epithelia (MT-4). Human MT isoforms are regulated independently of each 
other, and can be induced by metals, stress hormones, cytokines, reactive oxygen species, 
and chemicals. In mice, the situation is more simple. Only four functional murine MT genes 
are known (MT1, MT2, MT3, and MT4), and the MT1 and MT2 isoforms are co-ordinately 
regulated (2;3). 
MT regulation in inflammation 
One of the most striking observations that link MTs to inflammation is their rapid up-
regulation in response to a variety of stresses including inflammation. The observation that 
hepatic expression of MTs is dramatically elevated in response to bacterial infection, an 
effect mediated by endotoxin (lipopolysaccharide-LPS), has lead to the classification of MTs 
as acute phase proteins. LPS induction of MT gene expression in mice occurred in each of 
ten organs examined (liver, kidney, pancreas, intestine, lung, heart, brain, ovary, uterus, and 
spleen) (4). This induction by LPS was shown to be mediated by several pro-inflammatory 
cytokines, including interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-Į, and interferon 
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(IFN)-Ȗ (4), nitric oxide (NO) (5), as well as the stress hormones glucocorticoids (6). These 
factors have been shown to up-regulate MTs independently of LPS, but they seem to act 
synergistically and result in different levels of MT expression, depending on the tissue and 
the combination of factors (4;7-9). Reactive oxygen species (ROS), generated during the 
inflammatory response, may activate MT expression through multiple pathways, including 
directly by stimulating an antioxidant response element and specific metal response 
elements in the promoter region as well as indirectly by events associated with second-
messenger protein kinase pathways (10;11). During radiation injury to the small intestine, 
which implicates ROS and leads to acute inflammation, metallothioneins were induced (12). 
All these data illustrate that MT regulation in inflammation is a rapid but complex process 
with different results in differing tissues. One constant, however, is that MT induction by 
inflammatory mediators seems to be conditional upon the presence of zinc (3). 
MT functions relevant in inflammation and possibly in inflammatory bowel 
diseases
The first function of MTs that was put forward as playing a role in inflammation was their 
central position in zinc homeostasis, redistributing the intracellular zinc pool. In that way, MTs 
can have two opposite roles: they can either increase the intracellular zinc pool, thereby 
facilitating metabolic processes during the acute phase response, or sequester zinc to allow 
maximal activity of enzymes which would be otherwise inhibited by zinc (3). Besides the 
immense number of enzymes that use or are inhibited by zinc, clarifying these postulations is 
hampered by the fact that the affinity of MTs for zinc probably differs depending on the 
stimulus by which MTs were induced. In an in vivo displacement assay of cadmium (whose 
affinity for MT is stronger than that of zinc), it was shown that oxidative stress-induced MT 
displaced zinc to cadmium, whereas MT induced by fasting stress or by restraint stress did 
not (13). This study did not make a distinction between different MT isoforms, although 
metal-binding capacities of isoforms can vary (14;15), as can their gene-regulation (see 
chapter 4 part 3). Conformational changes of MT under certain stimuli might also explain the 
observed influence on zinc affinity. It has been shown that the binding of ATP (which reflects 
the energy state of a cell) to MT elicited conformational changes and altered zinc binding in 
MT (16). Zinc deficiency is a potential complication of Crohn’s disease and may result from a 
variety of processes, including reduced dietary intake, impaired absorption, increased 
excretion, hypoalbuminemia, or an internal redistribution of zinc (17;18). Although the 
consequences of this deficiency on the pathogenesis of the disease are not clear (19), it 
could be implicated through the involvement of zinc in immune function, redox signalling and 
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wound healing (20-23). Studies where zinc was administered to rats or mice with chemically 
induced colitis showed a dose-dependent therapeutic effect (24-28). Furthermore, zinc was 
shown to induce MT synthesis in ileal and colonic mucosa of control rats and to a lesser 
extent in that of colitic rats (29). A placebo-controlled double-blind cross-over trial was 
conducted with seven Crohn’s disease patients and seven ulcerative colitis patients that had 
inactive to moderately active disease and received oral zinc supplementation (30). Although 
supplementation increased plasma zinc concentrations and slightly (but not significantly) 
increased mucosal MT concentration, there were no changes in histological inflammation or 
disease activity. 
MTs are reported to modulate the activation of the transcription factor nuclear factor (NF)-țB,
which has a pivotal role in immune and inflammatory responses and as such also in 
inflammatory bowel diseases (IBD) (see previously). However, published results vary 
concerning the relationship between MT expression level and NF-țB activity. The modulatory 
effect might be based upon a direct interaction (31), regulation of zinc concentrations (32), or 
modulation of the redox balance through antioxidant functions (33). Data supporting a 
positive regulatory role for MTs on NF-țB activity are the zinc-induced inhibition of this 
activity, which is attenuated by MTs (32). The requirement of MTs for the zinc-induced 
expression of macrophage colony stimulating factor, a chemokine downstream of NF-țB,
illustrates this positive regulatory role (34). On the other hand, data exist that MTs may 
function as a negative regulator of NF-țB, showing that MTs inhibited the activation of NF-țB
by TNF-Į (35;36) and that splenocytes from MTnull mice displayed elevated levels of NF-țB
activity (37). Although these reports seem contradictory, explanations for this discrepancy 
could be found in the distinct redox regulation of NF-țB activation between the cytoplasm 
and the nucleus (33), a balance which may be modulated by the antioxidant capacities of 
MTs. Another explanation might be found in differences in the cell types used. All these 
studies, however, indicate that MTs are an important regulator of NF-țB activity. 
As just mentioned, the antioxidant capacities of MTs might influence the inflammatory 
response through modulating NF-țB activity, but a more obvious role for MTs as antioxidants 
is the sequestration of harmful oxygen and nitrogen intermediates which are generated 
during the inflammatory response. In order to kill bacteria and parasites, infiltrating 
neutrophils and macrophages produce free oxygen radicals (hydrogen peroxide, NO, and 
superoxide anion) which are extremely cytotoxic to host cells (38;39). MTs could, together 
with other known molecules such as super oxide dismutase, vitamin E and ascorbate, 
provide a cytoprotection for host cells, preventing cellular damage and allowing survival and 
growth in an inflammatory environment (40). The increased presence of ROS, an imbalance 
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in antioxidant expression, and oxidative DNA and protein damage have been reported in IBD 
(41-44). In Crohn’s disease, oxidative protein damage as measured by lipid peroxidation was 
associated with the concentration of MTs (42). ROS can disrupt the epithelial barrier function 
by destabilizing tight junctions (45), thus increasing permeability, a phenomenon which is 
observed in patients with Crohn’s disease (46). Experiments in animal models of IBD have 
already confirmed the possibility to use antioxidants as therapeutic agents. In IL-10 deficient 
mice, local mucosal administration of the antioxidant enzyme superoxide dismutase (SOD) 
by genetically modified Lactobacillus bacteria significantly reduced the severity of 
inflammation (47). Mice overexpressing human SOD demonstrated attenuated inflammation 
when subjected to a mild form of dextran sodium sulphate (DSS)-induced colitis, and a 
remarkable survival benefit from severe DSS colitis (48). 
In certain oxidative and inflammatory environments MTs have been shown to reduce 
apoptosis (49), and in cases where inflammation-dependent apoptosis is detrimental, 
induction of MTs might provide a benefit. Since Crohn’s disease is characterized by defective 
T cell apoptosis, whereas T cells from ulcerative colitis patients show a strong activation 
induced apoptosis, the role of MTs might be different in these two diseases. 
Under certain conditions such as cell proliferation, differentiation, and after cell injury, MTs 
are translocated from the cytosol to the nucleus. MT regulation during cell cycle progression 
has been demonstrated in normally cycling cells, with maximal nuclear accumulation within 
the S and G2 phases, whereas high cytoplasmic expression occurred during late G1 and 
G1/S transition and basal amounts were found in the G0 phase (50;51). Hepatocytes show a 
transient nuclear localization of MTs at the G1-to-S phase transition during the priming phase 
of liver cell regeneration after partial hepatectomy (52). Two premises for the nuclear 
retention of MTs have been proposed. First, it might reflect the role of MTs as chaperones to 
provide zinc for crucial enzymes and transcription factors involved in cell division (53). 
Otherwise, it has been proposed that it might protect DNA from oxidative damage (54). 
Besides their intracellular functions, MTs could also be involved in inflammation and IBD 
through specific extracellular effects (55). For example, MTs have been shown to directly and 
specifically mediate leukocyte chemotaxis (56). Extracellular MTs can stimulate lymphocyte 
proliferation (57). MT binds to the plasma membrane of both T and B lymphocytes, but, in the 
absence of a costimulatory agent, MT induces lymphoproliferation only in B cells. MT also 
enhances the capacity of naive B lymphocytes to differentiate into plasma cells (58). On the 
other hand, MTs can suppress cytotoxic T cell function in vitro and a T-dependent humoral 
response in vivo (59-61). 
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protective functions of MTs in animal models of inflammation 
The availability of MTnull mice (knockout for MT1 and MT2) has permitted the investigation 
of the involvement of MTs in animal models of inflammation. In an animal model for multiple 
sclerosis, a chronic inflammatory and demyelinating disease of the central nervous system in 
which oxidative stress plays a pathogenic role, MTs were demonstrated to be protective (62). 
MTnull mice were more susceptible to Helicobacter pylori-induced gastritis and showed more 
severe inflammation of the stomach than wild type mice (63). This correlates with the 
reported antibacterial activity that was associated with MT function. This activity might be 
mediated directly by MTs themselves (64) or indirectly through nitric oxide production (65). In 
the collagen-induced arthritis model, repeated administration of MT1 and 2 during the course 
of disease dramatically reduced the incidence and severity of the disease (66). MTs 
suppressed the disease through the generation of IL-10- and transforming growth factor 
(TGF)-ȕ-producing type 1 regulatory T-like cells (67). In all of these models, MTs seem to be 
protective against local inflammation. In the TNF-induced lethal shock model (a model for 
systemic inflammatory response syndrome), however, MTs seem to sensitize (68). An 
explanation for this finding was not found, although it is contradictory to the reported 
resistance that MTs confer to the cytotoxic effects of TNF in vitro (69) and to the protective 
effects of MTs in another model of systemic inflammatory response syndrome (LPS-induced 
lethal shock in sensitized mice) (70). 
MT expression in IBD 
Given their possible functions in IBD pathogenesis, the expression of MTs has been studied 
in patient samples by different research groups. These studies have yielded contradictory 
results (table 1) and as such the role of MTs in IBD is not yet clarified. First of all, two studies 
report an increase in MT expression in IBD (71;72), while the rest demonstrates a 
downregulation. Most of the studies that used samples of both Crohn’s disease patients and 
ulcerative colitis patients reported no differences between the two patient groups, except for 
two studies (both using DNA microarrays). These two studies, however, describe distinct 
findings, i.e. decreased MT expression in ulcerative colitis and normal expression in Crohn’s 
disease (73) versus normal expression in ulcerative colitis and increased MT expression in 
Crohn’s disease (72). The influence of medication is also not clear yet, given that one study 
reports an influence of steroid therapy on MT expression (74) whereas a second study 
contests this (75). A study describing down-regulation of MTs in vitro in colon epithelial cells 
after stimulation with azathioprine did not discuss this effect in patients, although two 
azathioprine-treated patients were included in the study (72). The results of this study should 
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Table 1. MT expression in IBD patients 
study subjects methods results 
Clarkson et
al. 1985 (74) 
ileal resection specimens of 
13 CD patients (6 had 
received steroid therapy; 5 
had not), 2 UC patients, and 3 
controls
IHC on resection 
specimens
less MT immunoreactivity in patients with 
IBD than controls; patients on steroid 
therapy had more immunoreactivity; 
immunoreactivity in enterocytes and 
lamina propria 
Elmes et al.
1987 (75) 
ileal resection specimens of 
17 CD patients (11 had 
received steroid therapy; 6 
had not), and 5 controls 
IHC on resection 
specimens
decreased intestinal MT in IBD patients; 
no significant difference when patients 
had received steroid therapy; 
immunoreactivity in enterocytes and 
basement membrane region 
Mulder et al.
1991 (79) 
19 ileum and 16 colon 
specimens from 29 CD 
patients; 12 colon specimens 
and 1 ileum specimen from 12 
UC patients; colon specimens 
from 18 control patients 
RIA on homogenized 
mucosa (dissected 
from resection 
specimens)
MT content was decreased in non-
inflamed IBD mucosa compared with 
control mucosa; further decrease was 
found in inflamed mucosa; no 
differences between UC and CD; no 
significant effect of medication or tissue 
localisation
Sturniolo et
al. 1998 (80) 
colonic biopsies of 24 UC 
patients and 10 controls 
Ag-hem on biopsies Reduced MT concentrations in patients 
with active disease as compared with 
controls and patients in remission; 
reduced MT concentrations in inflamed 
versus non-inflamed mucosa taken from 
the same patient 
Brüwer et al.
2001 (71) 
22 CD patients, 48 UC 
patients, 10 controls 
IHC on resection 
specimens
MT overexpression in the fibroblasts of 
all ulcerative and/or fissural lesions in 
UC and CD; MT overexpression in 
intestinal epithelial cells of 40% of UC 
and CD lesions correlated significantly 
with the grade of inflammation. 
Lawrance et
al. 2001 (73) 
colonic resection specimens 
with moderately severe 
histological inflammation from 
12 UC and 6 CD patients (with 
moderately severe clinical 
disease); and from 6 controls 
DNA microarray decrease of MT1H and MT1G mRNA 
expression in UC; no difference in CD 
Ioachim et
al. 2003 (76) 
ileum, colon or rectum 
resection specimens from 10 
CD patients, 41 UC patients, 5 
controls
IHC Decreased MT expression in UC and CD 
compared with normal mucosa; no 
difference in MT expression between UC 
and CD; in UC, a gradually decreased 
expression from remission, to resolving 
and to active phase was observed; only 
epithelial MT expression 
Kruidenier et
al. 2003 (77) 
resection specimens from 19 
CD patients, 15 UC patients, 
18 controls 
RIA on tissue 
homogenates and 
IHC on resection 
specimens
RIA: Lower tissue MT content in 
inflamed CD and UC mucosa compared 
with non-inflamed and control mucosa; 
IHC: decreased MT-positive epithelial 
cell numbers at inflamed sites in CD and 
UC patients; no detection of MT in 
lamina propria 
Dooley et al.
2004 (72) 
2 sets of colon samples: a) 
control (1 uninvolved colon 
from CD patient), 1 CD 
patient, and 1 UC patient; b) 
control, 1 azathioprine-treated
CD patient, and 1 
azathioprine-treated UC 
patient; drug-treated CaCo-2 
cells
microarray and qRT-
PCR with consensus 
primer sequences 
for multiple 
metallothionein
genes.
Microarray: up-regulation of MT1F, 
MT1G, MT1H in CD in tissue set a); 
down-regulation of MT1F, MT1H, MT1L 
in azathioprine-treated CaCo-2 cells; 
confirmed by qRT-PCR 
Abbreviations: CD: Crohn’s disease, UC: ulcerative colitis, IHC: immunohistochemistry, RIA: radio-immunoassay, 
Ag-hem: Silver-heme saturation assay, qRT-PCR: quantitative reverse transcriptase-polymerase chain reaction 
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be interpreted with care, considering the small data-set used. Finally, the 
immunohistochemical studies do not agree whether MT expression is confined to the 
epithelium (76;77), or whether expression in the lamina propria occurs as well (71;74;75). 
The study of MT protein expression in IBD is even complicated by the possible destructive 
influence of the oxidative environment on the immunodominant epitope of the protein. 
Therefore, it is not sure whether the absence of immunoreactivity equals absence of MT 
protein, or whether it reflects a failure of the antibody to recognize the present protein. In the 
DSS model of colitis, MTs were not protective in two separate studies comparing MTnull 
mice with wild type mice (28;78). 
conclusion
Although several functional associations of MTs can confer a role for this family of proteins in 
the pathogenesis of IBD, the results of human and experimental colitis studies are not 
decisive. However, it is clear that a deviant MT expression exists in this disease, and as such 
it is important to meticulously clarify these aberrations in Crohn’s disease and in ulcerative 
colitis. Furthermore, investigating whether the regulation of MTs in these diseases is 
dependent or independent on inflammation will add knowledge on their involvement in IBD. 
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This thesis combines the research conducted in two fields, both related to the defective 
mucosal barrier in IBD. The first part focuses on the interaction of therapeutic IL-10 
producing bacteria with the intestinal mucosa. In the second part, we took a closer look at the 
expression and function of MTs, that can be considered immunomodulatory proteins, in 
intestinal inflammation. 
Interaction of the mucosal barrier with therapeutic bacteria 
Genetically modified Lactococcus lactis secreting IL-10 has been demonstrated to provide 
localized delivery of a therapeutic agent through active in situ synthesis in murine colitis (1). 
A safety study conducted at the Academic Medical Centre in Amsterdam showed that the 
bacteria were well tolerated and some clinical efficacy could be demonstrated (2). Further 
clinical trials with this potential therapeutic agent are planned.
The exact mechanism by which the beneficial effect of the IL-10 producing L. lactis on the 
mucosa is mediated is complex and many aspects remain to be unveiled. At the time we 
started this study, preliminary data existed that showed the presence of small amounts of   
IL-10, delivered by the bacteria, in intestinal tissue homogenates. Based on these findings, 
we formulated different hypotheses for the mechanism of action of these therapeutic 
bacteria. First, the lactococci could produce IL-10 at the luminal side, with a subsequent 
diffusion of the cytokine to responsive cells in the epithelium. Alternatively, the lactococci 
may be taken up by M cells or DCs with consecutive production of IL-10 in situ in intestinal 
lymphoid tissue. A third route might involve paracellular transport of intact bacteria. All three 
routes are known to be enhanced in inflammation.
In chapter 3, we aimed to determine the interaction of L. lactis with the intestinal mucosa. We 
were interested whether this interaction would be different in a healthy mucosa compared 
with an inflamed (damaged) mucosa. Therefore, we performed in vivo experiments in healthy 
mice and in two mouse models of chronic (entero)colitis. Samples were extensively 
examined with both electron and confocal microscopy to test the three formulated 
hypotheses. To test whether bacteria present in intestinal mucosa could deliver IL-10 in situ
in the tissue, viability and activity of L. lactis in lamina propria homogenates were assessed. 
Finally, given the possible uptake of the bacteria in the mucosa, we wanted to assess their 
presence in systemic lymphoid tissues. 
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Roles for metallothioneins as immunomodulators in intestinal inflammation 
In search of new candidate genes for Crohn’s disease, we came upon the family of the MTs. 
Their location within the susceptibility locus IBD1, together with their presumed protective 
functions in inflammation made them an interesting family to study. In order to elucidate the 
role of MTs in Crohn’s disease, we first studied their expression and compared it with the 
expression in normal controls in chapter 4 part 1. We analyzed mRNA levels and performed 
immunohistochemical stainings, making a distinction between expression in unaffected and 
affected tissue to clarify whether aberrant MT expression is dependent or independent on 
inflammation.
To study the functional consequences of aberrant MT expression in Crohn’s disease, we 
induced a dextran sodium sulphate colitis in MT-null mice. We examined whether these mice 
demonstrated a different course of colitis compared with wild type mice of the same genetic 
background, and tried to correlate this to colonic MT expression, which we studied in detail. 
In addition, we created a knockdown intestinal epithelial cell line. To investigate whether a 
decreased MT expression could influence the response of the epithelial barrier on bacteria, 
we challenged this cell line with invasive bacteria. 
Next to studying MT protein expression in Crohn’s disease, we studied this in ulcerative 
colitis and in two other intestinal inflammatory conditions, i.e. diverticulitis and ischaemic 
inflammation (chapter 4 part 2). We attempted to provide a detailed expression pattern of 
MTs in the intestine under normal and inflammatory conditions, describing the MT levels in 
different cell types during the course of inflammation. 
The results of the studies in chapter 4 part 1 and part 2 revealed that an important role is 
reserved for MT gene regulation, regarding to expression in disease as well as to expression 
in different cell types. Therefore, we reviewed the regulation of MT gene expression in health 
and disease in chapter 4 part 3. For this review, we started from an in silico comparison of 
human and murine MT promoters. 
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ORIGINAL ARTICLE
Paracellular Entry of Interleukin-10 Producing Lactococcus
lactis in Inﬂamed Intestinal Mucosa in Mice
Anouk Waeytens, MBE,* Liesbeth Ferdinande, MD,* Sabine Neirynck, PhD,† Pieter Rottiers, PhD,‡
Martine De Vos, MD, PhD,§ Lothar Steidler, PhD,† and Claude A. Cuvelier, MD, PhD*
Background: Genetically modiﬁed Lactococcus lactis secreting
interleukin-10 (IL-10) has been demonstrated to provide localized
delivery of a therapeutic agent through active in situ synthesis in
murine colitis. At present, many aspects of the exact mechanism by
which the beneﬁcial effect of the IL-10-producing L. lactis on the
mucosa is mediated remain to be clariﬁed.
Methods: Our aim was to determine the interaction of L. lactis
with the intestinal mucosa. Therefore, we administered IL-10-pro-
ducing L. lactis to healthy mice and in 2 mouse models of chronic
colitis. Parafﬁn sections of ileum and colon samples were examined
with confocal and transmission electron microscopy. Ileum and
colon homogenates were prepared after ﬂushing and after removal
of mucus layer and epithelium. These homogenates and homoge-
nates of mesenteric lymph nodes and spleen were plated on agar and
immunoblotting for L. lactis and IL-10 was performed.
Results: Both confocal and electron microscopy showed the pres-
ence of lactococci in inﬂamed intestinal mucosa of mice with colitis.
We recovered viable bacteria that could still produce IL-10 from
homogenates of inﬂamed ileum and colon of which mucous and
epithelial layers were removed. We did not ﬁnd lactococci in mes-
enteric lymph nodes or in the spleen of mice with colitis.
Conclusions: This study demonstrates uptake of IL-10-secreting
L. lactis by the paracellular route in inﬂamed mucosal tissue. We
suggest that IL-10 production by L. lactis residing inside the mucosa
in the vicinity of responsive cells can improve the local action of
interleukin-10 in inﬂamed tissue and the efﬁciency of the treatment.
(Inﬂamm Bowel Dis 2007;00:000–000)
Key Words: Lactococcus lactis, inﬂammatory bowel disease, inter-
leukin-10 therapy, intestinal mucosa
Inﬂammatory bowel disease (IBD), including Crohn’s dis-ease and ulcerative colitis, is characterized by chronic,
nonspeciﬁc inﬂammation of the gastrointestinal tract. Con-
ventional therapy for IBD consists of aminosalicylates and
corticosteroids combined with immunosuppressive agents for
maintenance. In most cases this means lifelong treatment
with systemically administered medication, involving inefﬁ-
cient drug delivery and possible unpleasant side effects.
Novel therapeutic strategies for IBD focus on targeting in-
ﬂammatory cytokines, antiinﬂammatory cytokines, antigen
processing/presentation/recognition, apoptosis, and repair/
restitution of barrier function.1 One of the biological agents
under investigation is interleukin-10 (IL-10). The principal
function of this cytokine is to contain and eventually termi-
nate inﬂammatory responses by suppressing the expression of
proinﬂammatory cytokines, chemokines, adhesion molecules,
and antigen-presenting and costimulatory molecules in mono-
cytes/macrophages, neutrophils, and T cells.2 The observa-
tion that IL-10-deﬁcient mice develop chronic enterocolitis
indicated that IL-10 is an essential immune modulator in the
intestinal tract and formed the rationale behind IL-10 admin-
istration in animal models of IBD.3 The results of these
studies showed that IL-10 was successful in preventing but
not reversing intestinal inﬂammation, mainly by downregu-
lating an intestinal proinﬂammatory Th1 response.4–6
Systemic IL-10 treatment has been shown to yield
rather disappointing results in multicenter trials,7,8 probably
due to low ﬁnal concentrations of IL-10 in the intestine. Some
years ago a new therapeutic approach to IBD was described
that uses genetically modiﬁed Lactococcus lactis bacteria
secreting IL-10.9 The local delivery of this cytokine by food-
grade bacteria seems to offer a solution to overcome the
problem of systemic IL-10 treatment. Previous studies have
shown that intragastric administration of IL-10-producing L.
lactis caused a 50% reduction in colitis in the chronic dextran
sodium sulfate model and prevented the onset of colitis in
IL-10-deﬁcient mice.9 A safety study conducted at the Aca-
demic Medical Center in Amsterdam showed that the bacteria
were well tolerated and some clinical efﬁcacy could be dem-
onstrated.10
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The exact mechanism by which the beneﬁcial effect of
the IL-10-producing L. lactis on the mucosa is mediated is
complex and many aspects remain to be unveiled. Previously,
we could detect small amounts of IL-10 in intestinal tissue
homogenates by enzyme-linked immunosorbent assay
(ELISA), but not in the lumen.9 One possibility is that the
lactococci produce IL-10 at the luminal side in close prox-
imity to responsive cells in the epithelium. Alternatively, the
lactococci may be taken up by membranous (M) cells or by
dendritic cells (DCs) and subsequently produce IL-10 in situ
in intestinal lymphoid tissue. A third route might involve
paracellular transport mechanisms. All three routes are
known to be enhanced in intestinal inﬂammation.
To determine the interaction of L. lactis with the intes-
tinal mucosa, we administered human (h)IL-10-producing L.
lactis to healthy mice and in 2 mouse models of chronic
colitis. We analyzed ileum and colon samples by transmis-
sion electron microscopy (TEM) and confocal laser scanning
microscopy (CLSM), paying special attention to the possible
uptake by M cells or DCs. Plating and subsequent immuno-
blotting were carried out to assess viability and activity of L.
lactis in tissue homogenates of epithelium-stripped ileum and
colon, mesenteric lymph nodes (MLNs), and spleen from
IL-10-deﬁcient mice.
MATERIALS AND METHODS
Bacteria
An hIL-10-producing L. lactis MG1363 (LL-hIL-10) culture11
was prepared by inoculating a stock suspension 1/1000 in
M17 broth (Becton Dickinson, Franklin Lakes, NJ) supple-
mented with 0.5% glucose (GM17) and was grown overnight.
The culture was then washed twice in sterile phosphate-
buffered saline (PBS, pH 7.4) and resuspended in BM9
medium9 to a concentration of 2  1010 CFU/mL.
Animals
Two mouse models of IBD were used in this study. First, we
induced a chronic dextran sodium sulfate (DSS) colitis.12
Twelve-week-old Balb/c mice (Charles River, Boston, MA)
received 4 administration cycles of DSS, each cycle consist-
ing of 7 days of 4% DSS (MW  36,000–50,000, MP
Biomedicals, Irvine, CA) in tap water followed by 10 days of
tap water (DSS-Balb/c, n  3; control animals: con-Balb/c, n
 3). After the last cycle mice received tap water for an
additional 11 days. During the experiment weight loss and
stool consistency were monitored. Alternatively, IL-10-deﬁ-
cient 129Sv/Ev (IL-10/) mice (bred in-house) were used as
a model for chronic enterocolitis (n  13).3 They were used
at 26 weeks of age, when chronic colitis had fully developed.
Healthy 129Sv/Ev (IL-10WT) mice served as control animals
(n  6). The animal studies were approved by the Ethics
Committee for Animal Studies of the Faculty of Medicine
and Health Sciences (ﬁle no. ECP 03-49).
Intestinal Loops
To study the interaction of L. lactis with the mucosa by
means of TEM and CLSM, in vivo ligated loops were con-
structed in the terminal ileum of IL-10/, IL-10WT, DSS-
Balb/c, and con-Balb/c. Mice were deprived of food for 24
hours and then anesthetized. After laparotomy, 1 ileal loop of
2 cm per mouse was formed and injected with 0.2 mL of
BM9 buffer containing 4  109 LL-hIL-10 (2 IL-10/, 2
IL-10WT, 2 DSS-Balb/c, and 2 con-Balb/c) or buffer alone
(sham control, 1 IL-10/, 1 IL-10WT, 1 DSS-Balb/c, and 1
con-Balb/c). The abdomen was closed and the animals were
placed in a climate room of 37°C. After 60 minutes the
animals were killed through cervical dislocation and the loops
were removed. Tissue samples were immediately ﬁxed in 2%
glutaraldehyde and 4% formaldehyde in 0.1 M sodium caco-
dylate buffer for TEM analysis or in 4% buffered formalin for
CLSM analysis.
Intragastric Inoculation
In order to study the presence of lactococci in larger pieces of
intestine and in systemic tissue, IL-10/ (n  10) and
IL-10WT mice (n  3) received lactococci through intragas-
tric inoculation (IG). Following food deprivation for 24
hours, mice were given 0.1 mL of BM9 buffer containing 2
 109 LL-hIL-10 or buffer alone (sham control) by IG 10
times with intervals of 30 minutes. Two and 20 hours after
the last inoculation mice were sacriﬁced by cervical disloca-
tion and spleen, mesenteric lymph nodes (MLNs), ileum
(only after 2 hours), and colon (only after 2 hours) were
isolated. After 2 washes in PBS, spleen and MLNs were
mixed in 1 mL BM9. At this step in the protocol, samples of
ileum and colon were taken and ﬁxed in 4% buffered forma-
lin for CLSM analysis. The remaining ileum and colon were
ﬂushed thoroughly with Hanks’ balanced salt solution
(HBSS, Invitrogen, Carlsbad, CA) and one-third of the tissue
was mixed in 1 mL PBS. The rest of the tissue was incubated
for 20 minutes with 1 mM 1,4-dithiothreitol (DTT, Roche
Diagnostics, Basel, Switzerland)/HBSS and half of the tissue
was mixed in 1 mL PBS. The remaining tissue was then
incubated twice in 10 mM EDTA (Invitrogen)/HBSS for 20
minutes and mixed in 1 mL PBS. After each incubation step,
pieces of ileum and colon were taken and ﬁxed in 4% buff-
ered formalin for histological evaluation.
Histology
Pieces of ﬁxed mucosa were embedded in parafﬁn wax and
hematoxylin and eosin (H&E) staining was carried out ac-
cording to routine procedures. A gastrointestinal histological
score ranging from 0 to 4 was used in a blinded fashion to
evaluate intestinal inﬂammation, as validated for IL-10/
mice13 and the DSS model.14 Scores are expressed as medians
 interquartile range. Statistical signiﬁcance between differ-
ent groups were evaluated by the Mann–Whitney U-test.
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Differences were considered signiﬁcant at a P-value of
0.05.
Transmission Electron Microscopy
Glutaraldehyde/paraformaldehyde ﬁxed loop samples were
postﬁxed in osmium tetroxide, dehydrated in a series of
alcohol, and embedded in Epon (Aurion, Wageningen, The
Netherlands). Semithin 1-m sections were stained with
Toluidine blue (Roth, Karlsruhe, Germany) and were used for
selection of areas where bacteria were present. Ultrathin
sections were contrasted with uranyl acetate and lead citrate
and examined in a Zeiss TEM900 at 50 kV (Carl Zeiss,
Oberkochen, Germany). A culture of LL-hIL-10 was pro-
cessed in the same way to serve as a morphological charac-
terization of the L. lactis bacteria to identify these in our
intestinal loop samples.
Confocal Laser Scanning Microscopy
Parafﬁn wax sections of 30 m of formalin-ﬁxed intestinal
mucosa sampled from intestinal loop and IG experiments
were rehydrated and then quenched with 50 mM NH4Cl.
Nonspeciﬁc binding sites were blocked with 0.4% Fish Skin
Gelatin (Sigma, St. Louis, MO), after which sections were
incubated for 1 hour with rabbit anti-L. lactis antibody (anti-
MG1363, raised at the Applied Molecular Bacteriology Unit,
DMBR, Ghent). Alexa Fluor 488 antirabbit (Molecular
Probes, Eugene, OR) was used as secondary antibody. DNA
was stained with 4	,6-diamidino-2-phenylindole (DAPI,
Sigma) and sections were mounted with Vectashield (Vector
Laboratories, Burlingame, CA).
Visualization was performed on a Bio-Rad (Hercules,
CA) Radiance 2100 Blue Diode CLSM system (Carl Zeiss)
using a 60 plan apo oil immersion objective. Images were
taken with Bio-Rad Lasersharp 2000 software (Carl Zeiss)
using a sequential scanning method and processed with Im-
ageJ (W.S. Rasband, US National Institutes of Health, Be-
thesda, MD [http://rsb.info.nih.gov/ij/]).
Immunoblotting
IG homogenate (100 L) from spleen, MLNs, ileum (ﬂushed,
DTT/EDTA-treated), and colon (ﬂushed, DTT/EDTA-
treated) was plated out on GM17 agar supplemented with 5
g/mL erythromycin to selectively grow the erythromycin-
resistant LL-hIL-10. Plate colonies were transferred to nitro-
cellulose membranes (Millipore, Billerica, MA) on which
immunoblotting was performed using rabbit anti-MG1363 or
rabbit anti-hIL-10 (Santa Cruz Biotechnology, Santa Cruz,
CA) as primary antibody and horseradish peroxidase-antirab-
bit (Santa Cruz Biotechnology) as secondary antibody. For
visualization we applied BM Chemiluminescence blotting
substrate (Roche Diagnostics) and Hyperﬁlm ECL (Amer-
sham Biosciences, Uppsala, Sweden). Negative controls were
carried out similarly with omission of primary antibody.
RESULTS
Assessment of Inﬂammation in the Chronic DSS
Model and IL-10/Mice
During the consecutive DSS-cycles, DSS-Balb/c mice lost
weight and got loose stool after drinking DSS and regained
weight during the recovery (water) phase of the cycles. His-
tological examination showed signs of acute ileitis, charac-
terized by focal inﬁltrates of mononuclear cells and granulo-
cytes, elongation of villi, and mucosal thickening (Fig. 1A).
In the distal colon, DSS-Balb/c mice presented with chronic
inﬂammation, featuring architectural crypt distortion, an in-
creased number of lymphoid follicles, and an extensive in-
ﬂammatory inﬁltrate (Fig. 1B). Con-Balb/c mice showed
normal histological ﬁndings. Histological inﬂammatory
scores for the colon were signiﬁcantly different between
DSS-Balb/c and Con-Balb/c (2.50  2.25 versus 0.50
 1.25, P  0.014).
IL-10/ mice, which spontaneously develop entero-
colitis at the age of 3 to 8 weeks,3 were used at 26 weeks, at
which timepoint 3 out of 13 mice had developed rectal
prolapse. In our studies, IL-10/ mice showed less severe
inﬂammation at corresponding ages than that observed in the
literature,15 probably because of different housing.9 Ileal sec-
tions revealed mild inﬂammation with inﬂammatory cell in-
ﬁltration in the lamina propria (Fig. 1C), whereas in colon
tissue we observed a more severe inﬂammation represented
by an inﬂammatory inﬁltrate reaching to the submucosa,
mucus cell depletion, and architectural crypt distortion (Fig.
1D). Neither macroscopic nor microscopic examination re-
vealed the occurrence of tumors. Moreover, dysplasia was not
seen in H&E sections. Sections from IL-10WT control mice
showed normal histological ﬁndings. Histological inﬂamma-
tory scores for the colon were signiﬁcantly different between
IL-10/ mice and IL-10WT mice (2.40  1.20 versus 0.00
 0.00, P  0.008).
H&E slides of tissue obtained after DTT/EDTA treat-
ment proved that these treatments adequately removed mucus
and epithelium, respectively (Fig. 1E,F).
Interaction of L. lactis with Normal Mucosa
To investigate whether lactococci would be taken up by M
cells in the follicle-associated epithelium (FAE), we ﬁrst
created terminal ileum loops in a region with Peyer’s Patches
in healthy con-Balb/c mice and injected LL-hIL-10 in these
loops. TEM of intestinal tissue showed numerous bacteria in
the lumen, some of which adhered to the glycocalyx (data not
shown). Bacteria that were abundantly present in the sections
and that had morphological features identical to those of a
Lactococcus culture were assumed to be lactococci, also
because we did not detect such bacteria in sham controls that
had not received LL-hIL-10. FAE of healthy mice showed
transcellular uptake of lactococci (Fig. 2A), although this was
a rare observation. We also occasionally recognized transep-
Inﬂamm Bowel Dis L. lactis Interaction with Murine Mucosa
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ithelial dendrites close to luminal lactococci (Fig. 2B). In
addition, we observed L. lactis in the lumen adjacent to M
cells but not in contact with or inside M cells.
We wanted to conﬁrm the ultrastructural ﬁndings on
larger tissue areas by confocal analysis. For that reason we
performed ﬂuorescent anti-lactococcal staining on thick (30
m) sections of ileal tissue originating from loop experi-
ments. Confocal analysis of loops inoculated with hIL-10-
producing L. lactis showed a great amount of cocci in the
lumen positive for the anti-MG1363 antibody. Sham controls
showed no positive staining. Lactococci were not detected in
the FAE or underlying lymph follicles by confocal micros-
copy (data not shown).
hIL-10-Producing L. lactis Enters Inﬂamed Intestinal
Mucosa
Next we examined if and how epithelial damage due to
inﬂammation inﬂuences the interaction of the Lactococcus
bacteria with the mucosa. Therefore, we repeated the intes-
tinal loop experiments in 2 mouse models for colitis: Balb/c
mice in which we had induced a chronic DSS colitis and
IL-10/ mice. In previous studies we found that mice with
chronic DSS colitis showed signs of acute ileitis next to
chronic colitis. In ileal samples of colitic mice (DSS-Balb/c
and IL-10/ mice) lactococci were seen entering acutely
injured epithelium in a paracellular way. The bacteria were
detected in small groups between cells and debris inside
inﬂamed mucosal tissue, inside lymph vessels, and inside
phagosomes in mucosal cells that morphologically resemble
dendritic cells (Fig. 2C–F).16 Some single bacteria, other than
L. lactis (based on their morphology), could also be detected
in inﬂamed tissue, between cells, and inside phagocytosing
cells.
Confocal analysis of sections of inﬂamed ileum con-
ﬁrmed the data obtained with TEM: next to an abundant
occurrence in the lumen, MG1363-positive L. lactis bacteria
were present in the epithelium and the lamina propria of
inﬂamed tissue. Collections of Z-series of 30-m sections
clearly demonstrated that the bacteria were present inside the
tissue, between cells, and were not lying on top of the
sections (Fig. 3A–C). The regular detection of lactococci
inside inﬂamed ileal tissue prompted us to examine inﬂamed
colon and to look for lactococci in MLNs and spleen. For that
purpose we intragastrically administered LL-hIL-10 to IL-
FIGURE 1. Representative micrographs of ileal (A,C,E) and colonic (B,D,F) mucosa from a DSS-Balb/c and an IL-10/mouse, H&E-
stained. A: Acute inﬂammation in DSS-Balb/c ileum presented by elongated villi and thickened mucosa. B: Distortion of crypt
architecture, an increasednumber of lymphoid follicles, andanextensive inﬂammatory inﬁltratedemonstrate chronic inﬂammation
in the colon of DSS-Balb/cmice. C: Mild chronic inﬂammation in the ileum of an IL-10/mouse illustrated by an increased amount
of inﬂammatory cells in the lamina propria. D: Severe chronic inﬂammation in the colon characterized by a diffuse inﬁltrate of
mononuclear and polymorphonuclear cells reaching to the submucosa, atrophy and branching of crypts and depletion of mucus
cells. E,F: DTT/EDTA-treatment of ileum and colon, respectively, efﬁciently removed mucous and epithelial layers. Scale bars 100
m.
Waeytens et al. Inﬂamm Bowel Dis
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10/ mice and took samples in the ileum and the colon. We
speciﬁcally chose this model to be able to study IL-10 deliv-
ery since these mice lack endogenous IL-10. With CLSM, we
regularly found the bacteria in the lamina propria of colon
sections from IL-10/ mice, offering further evidence for
the paracellular uptake of lactococci in inﬂamed intestinal
tissue (Fig. 3D–F).
Lactococcus lactis Present in Inﬂamed Mucosa Are
Viable and Actively Secreting hIL-10
To investigate whether the lactococci that were found in
inﬂamed mucosa were alive, we prepared ileum and colon
homogenates from IL-10/ mice that received LL-hIL-10
intragastrically. Homogenates were prepared after ﬂushing
intact tissue twice with HBSS and after removal of the
mucous layer and the epithelium by DTT and EDTA. Plating
of these homogenates on GM17E plates not only unveiled
LL-hIL-10 colonies but phenotypically differing colonies as
well. Therefore, we performed immunoblotting with a spe-
ciﬁc antibody for L. lactis. In this way, we could detect
2.5–3.75 106 lactococcal CFU in ﬂushed ileum and colon
homogenates and 1.5  104 in DTT/EDTA-treated ileum
homogenates (Fig. 4A). In DTT/EDTA-homogenates of co-
lon we could show the presence of 3  104 and 138 CFU in
only 2 out of 5 mice. The numbers of bacteria recovered did
not correlate with histological inﬂammatory scores. Immuno-
FIGURE 2. Transmission electron
micrographs of intact mucosa from
loops in control mice (A,B) and of
inﬂamed mucosa originating from
ileal loops in DSS-Balb/c mice (C–E)
and IL-10/mice (F). A: L. lactiswas
identiﬁed as morphologically re-
sembling bacteria of a culture of LL-
hIL-10 (insert, bar  1 m) and
present in large quantities in the
loop samples. In healthy ileal mu-
cosa, L. lactis was abundantly
present in the lumen. Additionally,
lactococci were found to be inter-
nalized (asterisk) by enterocytes of
the FAE demonstrating transcellu-
lar passage. Note the actin accumu-
lation at the contact site (arrow)
(mv: microvilli, nu: nucleus). B: A
transepithelial dendrite (d) close to
lactococci, suggesting DC uptake
of lactococci. C–F: After 60minutes,
L. lactis is demonstrated inside
acutely inﬂamed ileal mucosa. The
micrographs represent focal obser-
vations. Average bacterial counts
per block scannedwere 12.2 (range
0–33) for IL-10/mice (n 9) and
29.4 (range 0–106) for DSS-Balb/c
mice (n 18). C: L. lactis (asterisks)
in a strip of lamina propria (lp) be-
tween 2 crypts (ent: enterocytes,
bm: basement membrane, er:
erythrocytes). D: L. lactis in a lym-
phatic vessel (ly) in the submucosa
(cf, collagen ﬁbers; en, endothe-
lium). E: L. lactis inside phagosomes
and being engulfed by (arrow) a
presumed dendritic cell (dc) in the
lamina propria (bv, blood vessel). F:
L. lactis (asterisks) between inﬂam-
matory cells, erythrocytes and de-
bris in the lamina propria between
enterocytes in inﬂamed ileum.
Scale bars 3 m.
Inﬂamm Bowel Dis L. lactis Interaction with Murine Mucosa
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blotting with an antibody against hIL-10 revealed that these
lactococci could still produce IL-10 (Fig. 4B). Negative con-
trols showed no signal.
Lactococcus lactis Do Not Enter Systemic Tissue
The presence of lactococci in mucosal tissue of inﬂamed
samples caused us to examine the MLNs and the spleen.
Therefore, we isolated MLNs and spleen from IL-10/ mice
that had received LL-hIL-10 intragastrically, both 2 and 20
hours after the last dose, since MacPherson and Uhr17 re-
ported maximal commensal CFU about 20 hours after intra-
gastric gavage. Plating and subsequent immunoblotting for
lactococci of MLN or spleen homogenates revealed no lac-
tococcal CFU, although CFU from other bacteria were found
on the plates.
DISCUSSION
In this study we examined the penetration of lactococci in
healthy versus inﬂamed intestinal tissue. The results we ob-
tained with TEM show that, after administration by loop
construction, L. lactis is occasionally taken up in a transcel-
lular way in healthy FAE in the terminal ileum by entero-
FIGURE 3. Confocal images of thick sections from ileum (A–C) and colon (D–F) from IL-10/mice that received L. lactis intragas-
trically. A: Some lactococci (green ﬂuorescence) are adhering to (arrowhead), entering (hollow arrow) and inside (arrow) inﬂamed
ileum (nuclei: blue ﬂuorescence). At the place of the box a series of optical sections was taken in 0.2-m steps, of which XY sections
at 16 m (B) and at 10.8 m (C) from the glass slide are shown. Corresponding XZ (bottom) and YZ (right) cross-sections that were
taken in the directions of the black arrows clearly show that lactococci are inside of the tissue. D: Inﬂamed colon shows the presence
of lactococci (arrow) in the lamina propria (lp) below the surface epithelium. XY sections at 26 m (E) and at 17.2 m (F) with their
corresponding XZ and YZ cross-sections demonstrate that the bacteria are residing inside the tissue. Enterocytes (ent), lamina
propria (lp), blood vessel (bv). Scale bars 10 m.
Waeytens et al. Inﬂamm Bowel Dis
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cytes, similar to the recently reported uptake of nonpatho-
genic bacteria.18 However, this was a rare observation. We
also occasionally recognized transepithelial dendrites close to
luminal lactococci, suggesting DC sampling as described by
Rescigno et al.19,20 Other authors could not detect transepi-
thelial dendrites in response to pathogen challenge in Balb/c
mice in contrast to C57BL6 mice.21 The fact that we spotted
this event in Balb/c mice could be due to the nonpathogenic
character of the lactococci or to the different origin of Balb/c
mice used in this study. In our samples we could not detect
uptake of lactococci by M cells. We did observe L. lactis in
the lumen adjacent to M cells, suggesting this is not a major
entry route for this bacterium. The fact that we could not conﬁrm
the presence of lactococci in ileal tissue of healthy mice with
confocal microscopy could be because the anti-MG1363 anti-
body might not recognize internalized lactococci, but only lac-
tococci that are residing free in the lumen or tissue.
Both confocal and electron microscopic analysis sug-
gest that the uptake of bacteria is predominantly mediated by
the paracellular route in inﬂamed mucosal tissue in mice. The
entrance of the bacteria in inﬂamed tissue is related to the
defective barrier in inﬂamed mucosa, allowing unrestrained
uptake of antigens and proinﬂammatory molecules, including
luminal bacteria. In IBD, protection of the mucosa is thought
to be reduced as a result of speciﬁc changes in the thickness
or composition of the intestinal mucus layer.22 The mucus
layer can be diminished or become weaker and the number of
bacteria can be increased within the intestinal lumen or in the
residual mucus layer. When these events take place, bacteria
may adhere to the mucosa and increase exposure of the
mucosal immune system to intestinal bacteria or bacterial
components.23 The defective mucosal barrier is also a result
of dysfunctional epithelial tight junctions, which give rise to
an increased paracellular permeability that seems to be inde-
pendent of activity of disease.24 Finally, loss of surface epi-
thelial cells due to erosion allows unrestricted passage of
luminal antigens and bacteria to the underlying lamina pro-
pria.
Our experimental data correspond with the ﬁndings of
other groups,25–27 in that we ﬁnd L. lactis as well as other
bacteria in inﬂamed mucosal tissue in small groups between
the cells and inside phagocytosing cells. One group found
that in IBD specimens gut bacteria, including nonpathogenic
endogenous bacteria, were present in both the mucosa and the
submucosa and that bacterial invasion was pronounced in the
area of erosions and in crypt abscesses.25 They observed
some bacterial cells in epithelial cells or phagocytes of the
lamina propria. Bacteria were seen either as cell clusters or as
single cells scattered throughout the inﬂamed tissue. By plat-
ing and subsequent immunoblotting, we detected viable lac-
tococci in ﬂushed ileum and colon homogenates and in DTT/
EDTA-treated ileum homogenates. In DTT/EDTA-
homogenates of colon we showed the presence of viable
lactococci in only 2 out of 5 mice. Three might have been
false-negative due to the high bacterial background in the
colon. These results match the ﬁndings of other studies that
report the highest mean concentrations of mucosal bacteria in
the ileum of IBD patients.26,27 In those studies, individual
FIGURE 4. Viability and hIL-10 production of LL-hIL-10 recov-
ered from inﬂamedmurinemucosa. LL-hIL-10was administered
to IL10/ mice by intragastric inoculation, and homogenates
of ileumand colonwereprepared after ﬂushing andDTT/EDTA-
treatment. A: The number of viable LL-hIL-10 was determined
byplatingandsubsequent immunoblottingwitha speciﬁc anti-
MG1363 antibody. B: LL-hIL-10 recovered from DTT/EDTA-
treated ileum and colon is still able to produce hIL-10, as shown
by immunoblotting with an anti-hIL-10 antibody.
Inﬂamm Bowel Dis L. lactis Interaction with Murine Mucosa
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differences in concentrations of mucosal bacteria were found
as well, differing markedly from patient to patient.
Data from animal models and the potent antiinﬂamma-
tory properties of IL-10 suggested that this cytokine could be
a new candidate for therapeutic suppression of mucosal in-
ﬂammation in Crohn’s disease. Moreover, data from the ﬁrst
study to report on the effects of the clinical application of
IL-10 in human disease indicated that such treatment might
be efﬁcacious.28 Several large multicenter trials were per-
formed testing multiple IL-10 dosages in patients with
Crohn’s disease and the overall outcome was that IL-10
therapy was safe and well-tolerated.7,8,29 However, IL-10
treatment did not result in signiﬁcantly higher remission rates
or clinical improvement compared with placebo treatment.
One of the possible explanations for these disappointing
results is the restricted bioavailability of IL-10 at the intesti-
nal mucosa. However, increasing the dose of systemically
administered IL-10 is not possible because of side effects,
probably because high doses of IL-10 (20 g/kg) induce the
production of the proinﬂammatory cytokine interferon-.30,31
The local delivery of therapeutic concentrations of IL-10 may
overcome this problem. The amount of IL-10 delivered by a
treatment protocol with L. lactis that decreased inﬂammation
in DSS colitis with 50% was estimated to be 0.28 ng or
1 U IL-10 per mouse. This amount is several times lower
than the optimized amount of systemically administered
IL-10 in the same model with an equal reduction in inﬂam-
mation (1.25  104U per mouse).9
So far, intestinal mucosal delivery of IL-10 has been
provided by 3 approaches: 1) active synthesis in situ by L.
lactis9; 2) gene transfer6,32,33; and 3) gelatin microspheres.34
L. lactis has proven to be an effective delivery vehicle for the
treatment of Crohn’s disease in 2 mouse models9 and has
since been the subject of improvements regarding biological
containment11 and formulation.35–37 A Phase I trial using the
bacteria in Crohn’s disease patients was carried out recent-
ly.10 Although commensals can be taken up by DCs to be
transported to MLNs17 and we did observe lactococci being
phagocytosed by DCs, we could not recover lactococci from
MLNs in our experiments. Since we did not recover lacto-
cocci from murine MLN or spleen homogenates after oral
challenge, we state that L. lactis is restricted to the mucosal
compartment and is unlikely to elicit a systemic immune
response, being safe for administration in humans. This is in
good agreement with its GRAS (generally recognized as
safe)-status.
Plating of homogenates from epithelium-stripped mu-
cosa and subsequent immunoblotting for hIL-10 revealed that
the lactococci we recovered were viable and could still pro-
duce IL-10. In previous ELISA studies, we could detect small
amounts of IL-10 in intestinal tissue homogenates but not in
the lumen.9 Furthermore, evidence exists that the bacterial
context of IL-10 presentation is necessary for the therapeutic
action.10 We hypothesize that an important source of the
IL-10 acting as a therapeutic on the mucosa is produced by
those bacteria that have entered the nutrient-rich mucosa.
IL-10 produced in the lumen and subsequently diffusing to
responsive cells in the epithelium or the lamina propria may
not be excluded as a mechanism, but the effect of the latter
may not be as considerable as IL-10 production directly in
situ in intestinal tissue, in the close proximity of responsive
cells, given its known paracrine ways of action. Although
IL-10 can directly affect the function of T cells, many of its
limiting effects on ongoing immune responses and inﬂam-
mation occur indirectly through modulation of cytokine pro-
duction and function of antigen-presenting cells such as DCs
and macrophages.2 Most likely, IL-10-producing L. lactis
modulates CD4 T-cell function via downregulatory effects
on DCs, since DCs exposed to LL-hIL-10 and maturation
factors showed a profound ability to suppress the prolifera-
tion of responder (CD4) T cells.38 Further investigation on
the downstream targets of IL-10 is currently being carried out
to reveal the exact mechanism of the IL-10-producing L.
lactis.
In conclusion, this study provides more insight into the
interaction of IL-10-producing L. lactis with the intestinal
mucosa. We demonstrated that L. lactis can enter healthy
mucosa via a transcellular route and uptake is enhanced
through the paracellular route in inﬂamed intestinal tissue.
We recovered viable lactococci from DTT/EDTA-stripped
inﬂamed mucosa that could still produce IL-10. These results
suggest that IL-10 production by L. lactis in the mucosa
nearby target cells might improve the efﬁcacy of the IL-10
treatment.
ACKNOWLEDGMENT
We thank Inge Bruggeman, Betty De Prest, Isabelle
Rottiers, and Dorothea Van Limbergen for technical assis-
tance.
REFERENCES
1. Kucharzik T, Maaser C, Lugering A, et al. Recent understanding of IBD
pathogenesis: implications for future therapies. Inﬂamm Bowel Dis.
2006;12:1068–1083.
2. Moore KW, de Waal MR, Coffman RL, et al. Interleukin-10 and the
interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.
3. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deﬁcient mice de-
velop chronic enterocolitis. Cell. 1993;75:263–274.
4. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses
prevents inﬂammatory bowel disease in scid mice reconstituted with
CD45RBhi CD4 T cells. Immunity. 1994;1:553–562.
5. Herfarth HH, Mohanty SP, Rath HC, et al. Interleukin 10 suppresses
experimental chronic, granulomatous inﬂammation induced by bacterial
cell wall polymers. Gut. 1996;39:836–845.
6. Barbara G, Xing Z, Hogaboam CM, et al. Interleukin 10 gene transfer
prevents experimental colitis in rats. Gut. 2000;46:344–349.
7. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin
10 in the treatment of patients with mild to moderately active Crohn’s
disease. The Interleukin 10 Inﬂammatory Bowel Disease Cooperative
Study Group. Gastroenterology. 2000;119:1473–1482.
8. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efﬁcacy of
Waeytens et al. Inﬂamm Bowel Dis
8
THESIS_ANOUK.indd   92 05-03-2009   10:58:13
chapter 3    interaction with therapeutic bacteria I 93
recombinant human interleukin 10 in chronic active Crohn’s disease.
Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology.
2000;119:1461–1472.
9. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by
Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352–
1355.
10. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic
bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroen-
terol Hepatol. 2006;4:754–759.
11. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of
genetically modiﬁed Lactococcus lactis for intestinal delivery of human
interleukin 10. Nat Biotechnol. 2003;21:785–789.
12. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the
induction of reliable experimental acute and chronic ulcerative colitis in
mice. Gastroenterology. 1990;98:694–702.
13. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are
necessary for development of spontaneous colitis and immune system
activation in interleukin-10-deﬁcient mice. Infect Immun.
1998;66:5224–5231.
14. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric
bacteria induce and perpetuate experimental colitis in rats and mice.
Infect Immun. 2001;69:2277–2285.
15. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in
interleukin-10-deﬁcient mice are associated with aberrant cytokine pro-
duction and CD4() TH1-like responses. J Clin Invest. 1996;98:1010–
1020.
16. Cruickshank SM, English NR, Felsburg PJ, et al. Characterization of
colonic dendritic cells in normal and colitic mice. World J Gastroen-
terol. 2005;11:6338–6347.
17. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal den-
dritic cells carrying commensal bacteria. Science. 2004;303:1662–1665.
18. Keita AV, Gullberg E, Ericson AC, et al. Characterization of antigen and
bacterial transport in the follicle-associated epithelium of human ileum.
Lab Invest. 2006;86:504–516.
19. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight
junction proteins and penetrate gut epithelial monolayers to sample
bacteria. Nat Immunol. 2001;2:361–367.
20. Rescigno M, Rotta G, Valzasina B, et al. Dendritic cells shuttle microbes
across gut epithelial monolayers. Immunobiology. 2001;204:572–581.
21. Vallon-Eberhard A, Landsman L, Yogev N, et al. Transepithelial patho-
gen uptake into the small intestinal lamina propria. Journal of Immu-
nology. 2006;176:2465–2469.
22. McCormick DA, Horton LW, Mee AS. Mucin depletion in inﬂammatory
bowel disease. J Clin Pathol. 1990;43:143–146.
23. Sartor RB. The inﬂuence of normal microbial ﬂora on the development
of chronic mucosal inﬂammation. Res Immunol. 1997;148:567–576.
24. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithe-
lial barrier in intestinal disease. Laboratory Investigation. 2004;84:282–
291.
25. Kleessen B, Kroesen AJ, Buhr HJ, et al. Mucosal and invading bacteria
in patients with inﬂammatory bowel disease compared with controls.
Scand J Gastroenterol. 2002;37:1034–1041.
26. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal ﬂora in inﬂam-
matory bowel disease. Gastroenterology. 2002;122:44–54.
27. Swidsinski A, Loening-Baucke V, Lochs H, et al. Spatial organization of
bacterial ﬂora in normal and inﬂamed intestine: a ﬂuorescence in situ
hybridization study in mice. World J Gastroenterol. 2005;11:1131–
1140.
28. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous
interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease
Study Group. Gastroenterology. 1997;113:383–389.
29. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in
the prevention of postoperative recurrence of Crohn’s disease. Gut.
2001;49:42–46.
30. Lauw FN, Pajkrt D, Hack CE, et al. Proinﬂammatory effects of IL-10
during human endotoxemia. J Immunol. 2000;165:2783–2789.
31. Tilg H, Van Montfrans C, van den Ende A, et al. Treatment of Crohn’s
disease with recombinant human interleukin 10 induces the proinﬂam-
matory cytokine interferon gamma. Gut. 2002;50:191–195.
32. Lindsay JO, Ciesielski CJ, Scheinin T, et al. Local delivery of adenoviral
vectors encoding murine interleukin 10 induces colonic interleukin 10
production and is therapeutic for murine colitis. Gut. 2003;52:981–987.
33. Van Montfrans C, Rodriguez Pena MS, et al. Prevention of colitis by
interleukin 10-transduced T lymphocytes in the SCID mice transfer
model. Gastroenterology. 2002;123:1865–1876.
34. Nakase H, Okazaki K, Tabata Y, et al. New cytokine delivery system
using gelatin microspheres containing interleukin-10 for experimental
inﬂammatory bowel disease. J Pharmacol Exp Ther. 2002;301:59–65.
35. Huyghebaert N, Vermeire A, Neirynck S, et al. Evaluation of extrusion/
spheronisation, layering and compaction for the preparation of an oral,
multi-particulate formulation of viable, hIL-10 producing Lactococcus
lactis. Eur J Pharm Biopharm. 2005;59:9–15.
36. Huyghebaert N, Vermeire A, Neirynck S, et al. Development of an
enteric-coated formulation containing freeze-dried, viable recombinant
Lactococcus lactis for the ileal mucosal delivery of human interleukin-
10. Eur J Pharm Biopharm. 2005;60:349–359.
37. Termont S, Vandenbroucke K, Iserentant D, et al. Intracellular accumu-
lation of trehalose protects Lactococcus lactis from freeze-drying dam-
age and bile toxicity and increases gastric acid resistance. Appl Environ
Microbiol. 2006;72:7694–700.
38. Braat H, Steidler L, Neirynck S, et al. Turbo-probiotics as a tool for
cell-based (mucosal) delivery of interleukin-10. Gastroenterology. 2005;
128:A5.
Inﬂamm Bowel Dis L. lactis Interaction with Murine Mucosa
9
THESIS_ANOUK.indd   93 05-03-2009   10:58:14
Chapter 4 
roles for metallothioneins as 
immunomodulators
in intestinal inflammation 
THESIS_ANOUK.indd   95 05-03-2009   10:58:14
Chapter 4.1 
impaired epithelial metallothionein expression as a 
possible aetiopathogenic mechanism
in Crohn’s disease 
Article submitted 
THESIS_ANOUK.indd   97 05-03-2009   10:58:14
chapter 4.1    MT deficiency in Crohn’s disease I 99
Impaired epithelial metallothionein expression as a possible 
aetiopathogenic mechanism in Crohn’s Disease 
Condensed title: Metallothionein deficiency in Crohn’s Disease 
Debby Laukens1,2,3*, Anouk Waeytens4*, Harald Peeters3, Sara Bogaert3, Charlotte 
Aelbrecht3, Jasmien Taildeman4, Liesbeth Ferdinande4, Ellen Van Belle4, Kenny Knecht5,
Paul Van Hummelen6, Wim Waelput4, Dirk Elewaut7, Erik Remaut1,2, Pieter Rottiers1,2, Claude 
Cuvelier4 and Martine De Vos3.
*Both authors contributed equally to this work. 
1Department for Molecular Biomedical Research, Flanders Institute for Biotechnology (VIB), 
Gent, Belgium 
2Department of Molecular Biology, Ghent University, B-9000 Gent, Belgium. 
3Department of Gastroenterology, Ghent University Hospital, B-9000 Gent, Belgium 
4Department of Pathology, Ghent University Hospital, B-9000 Gent, Belgium 
5Applied Maths BVBA, B-9830 Sint-Martens-Latem, Belgium 
6MicroArray Facility, VIB, B-3000 Leuven, Belgium 
7Department of Rheumatology, Ghent University Hospital, B-9000 Gent, Belgium 
Corresponding author: 
Debby Laukens, Department of Gastroenterology, Ghent University Hospital, De Pintelaan 
185 3K12IE, B-9000 Gent, Belgium, Tel: +3293322064, Fax: +3293324984, E-mail: 
debby.laukens@ugent.be
Key words: Metallothionein, Crohn’s disease, gene expression 
Word count: 3,948 
THESIS_ANOUK.indd   99 05-03-2009   10:58:15
100 I  chapter 4    metallothioneins in intestinal inflammation
ABSTRACT
Background: This study sought to identify new candidate genes for Crohn’s disease (CD) by 
integrating known disease loci with gene expression in endoscopically normal colon biopsies 
of CD patients. The expression and functional role of metallothionein (MT) was studied in 
healthy, CD, and inflammatory conditions. 
Methods: Colon biopsies of CD patients and healthy controls were subjected to microarray 
analysis. Detailed expression of MT in the intestine and blood were studied using quantitative 
PCR, ELISA, immunohistochemistry and immunogold electron microscopy. Dextran sodium 
sulphate (DSS)-induced colitis in MT-/- mice and bacterial challenge of MT-knockdown HT29 
cells were used as in vivo and in vitro models, respectively, for functional analyses of MT. 
Results: Microarray analysis identified 18 differentially expressed genes located near a 
previously identified locus for CD. We focused on the reduced expression of MT in the colon, 
ileum and blood of CD patients. In inflamed tissue, reduced MT expression was seen in the 
epithelium, while granulation tissue was highly positive. Reduced epithelial MT in non-
inflamed tissue was only observed in CD patients. Surprisingly, MT-/- mice were less 
susceptible to DSS-induced mortality, although they suffered more severe histological 
changes in the colon at an early stage of the disease, coincident with the highest epithelial 
MT expression in wild type mice. Bacterial challenge of MT-knockdown HT29 cells resulted in 
reduced IL-8 secretion as compared to control HT29 cells. 
Conclusions: We suggest that deficient epithelial MT expression may be a mechanism of 
aetiopathogenesis in CD patients. A role for epithelial MT during the process of colitis and 
bacterial challenge was demonstrated. 
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A new approach to identify potential susceptibility genes for multifactorial diseases like 
Crohn’s disease (CD) is the integration of the variation in gene expression in unaffected 
tissue samples with previously documented susceptibility loci (1). Two of the candidate genes 
that were identified in this way are located near the IBD1 locus and belong to a family of 
highly conserved proteins with immunomodulating properties, the metallothioneins (MTs) (2). 
These intracellular proteins can be rapidly induced by a variety of stimuli, and are considered 
acute stress proteins. They are involved in zinc homeostasis and help to protect cells against 
toxic levels of metal ions and radicals by binding and sequestering these molecules. In 
addition, MTs can be secreted through as yet unknown mechanisms (2). These extracellular 
MTs were shown to have antibacterial, immunomodulating and chemotactic properties (3-5). 
In humans, 18 MT genes have been identified (MT1A-MT1X, MT2A, MT3 and MT4). 
Metallothionein 3 and MT4 are constitutively expressed in the brain and squamous 
epithelium, respectively, while MT1 and MT2 are ubiquitously expressed and highly inducible 
by cytokines, hormones, metals and general stress (6). 
While two previous studies have shown an up-regulation of MT in CD tissue, others found a 
down-regulation (7-12). MT levels were also decreased in CD tissue when quantified by 
radioimmunoassay, microarray and silver-saturation assay (13-15). These contradictory 
findings could have resulted from the differential regulation of MT in different cell fractions or 
from diverging grades of inflammation of the samples used in the different studies. We 
wondered whether abnormal MT expression in CD is an aetiopathogenic event or secondary 
to inflammation. We studied the mRNA expression of different MT isoforms, as well as the 
cellular localization of MT proteins in various inflammatory conditions. The functional 
consequences of decreased MT expression were studied in two models: MT-/- mice and HT29 
epithelial cells expressing siRNA targeted to endogenous MT. 
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MATERIALS AND METHODS 
Patients. This study was approved by the local ethics committee (EC UZG 2004/242 and 
2006/362). All individuals who participated in this study were Caucasians. CD and acute 
infectious enterocolitis were diagnosed according to clinical, endoscopic and histological 
criteria. CD patients were classified according to the Vienna classification (16). Disease 
location was defined as the maximal spread of inflammation before the first resection. Control 
tissue was obtained from patients who underwent ileocolonoscopy for follow up of polyp 
detection or screening for colorectal carcinoma. Biopsies were collected during colonoscopy 
and immediately placed in RNAlater (Ambion, Foster City, CA) for RNA extraction or in 
formalin for immunohistochemical analysis. Archived, formalin-fixed, and paraffin-embedded 
tissue was also processed for immunohistochemistry. 
RNA extraction. Total RNA was extracted from biopsies and whole blood using the Qiagen 
RNeasy Mini and Midi Kit, respectively. Concentration and purity of the extracted RNA were 
determined spectrophotometrically. The quality of RNA used for microarray analysis was 
checked on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Microarrays. Microarray analyses were performed by the VIB MicroArray Facility 
(www.microarrays.be). The microarray (VIB Crohn 7K2) was specifically designed for the 
study of colonic gene expression (GEO accession number GPL5134) (17). Hybridization and 
scanning protocols are detailed on the aforementioned website. GeneMaths® XT (Applied 
Maths, St-Martens-Latem, Belgium) was used to perform all subsequent analyses.
qPCR. One μg of RNA was converted to cDNA with oligodT priming (Gibco, Carlsbad, CA). 
One tenth of the cDNA was used for real-time quantification with SYBR green (Eurogentec, 
Seraing, Belgium). A two-step program was run on the iCycler (Bio-Rad, Hercules, CA), and 
reactions were run in duplicate and normalized to GAPDH levels. Primer sequences are 
listed in Supplementary Table 1. 
Induction assays. Ficoll-paque (Amersham Biosciences, Buckinghamshire, UK) isolated 
PBMCs were seeded in 6-well plates at 106 cells per well and treated the next day with H2O2,
ZnSO4, dexamethasone (all Sigma, St. Louis, MO), human IL-6 (Peprotech, Germany), 
human TNF (produced in-house) or human IFN-Ȗ (Biosource, Belgium). Cells were lysed 
after 2, 4 or 6 hrs and MT1M mRNA expression was assessed by qPCR. Normalized Ct 
values were corrected for background at each time point, and plotted against time. Induction 
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was calculated as the area under the curve (AUC) for the three time points: AUC = 
0

3
(m1.x)dx + 
3

6
(m2.x + b)dx + 
6

24
(m3.x + c)dx. 
Immunohistochemistry. Immunohistochemical staining of human samples was carried out 
on the NexES IHC automated staining system (Ventana Medical Systems, Tucson, AZ) with 
mouse monoclonal anti-metallothionein clone E9 (Zymed, San Francisco, CA) or mouse IgG1
negative control (Dako, Glostrup, Denmark) as an isotype specific control. Murine tissue 
sections were stained manually. Relative proportions of positively-staining epithelial cells and 
lamina propria cells were measured separately using a semi-quantitative grading system: 0: 
no MT-positive cells; 1: single MT-positive cells or foci (1 to 5%); 2: moderate number of foci 
of MT-positive cells (6 to 40%); 3: large number of cells are MT-positive (40 to 70%); 4: 
majority of cells are MT-positive (>70%). Sections were scored by two observers who were 
blinded for diagnosis and clinical data. Cohen’s kappa between observers was 0.65 (18). 
Histological evaluations of inflammation for all samples are summarised in Supplementary 
Table 2. 
Immunofluorescence. Double immunostaining for Ki67 (rabbit monoclonal anti-Ki67 clone 
SP6, Lab Vision, Fremont, CA) or CD68 (FITC-conjugated mouse monoclonal anti-CD68 
clone KP1, Dako) and MT was performed on paraffin sections, together with the appropriate 
negative controls. 
Immunogold electron microscopy. Tissue samples were immediately fixed in 4% 
formaldehyde and embedded in Lowicryl K4M (Agar Scientific, Essex, UK). Ultra thin sections 
were stained with anti-MT or the matched isotype control antibody. Sections were examined 
in a Zeiss TEM900 at 50kV (Carl Zeiss, Oberkochen, Germany). 
Acute dextran sodium sulphate (DSS) colitis. Animal experiments were approved by the 
Ethics Committee for Animal Studies of the Faculty of Medicine and Health Sciences (ECP 
03/10). Colitis was induced in MT-/- mice (129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J, strain 002211, 
The Jackson Laboratory, Bar Harbor, MA) versus wild type (WT) mice (129S1/SvImJ, strain 
002448, The Jackson Laboratory). Five percent DSS (M.W. 36,000-50,000; MP Biomedicals, 
Irvine, CA) was administered in the drinking water of 9 to 18 week-old mice. Parameters used 
to calculate the disease activity index (DAI) were monitored daily (19). One, 2, 3, 5, and 7 
days after DSS administration, mice were sacrificed by cervical dislocation. Samples from 
anus to caecum were taken for histology and myeloperoxidase (MPO) measurements. 
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Epithelial damage and inflammatory infiltration was scored semi-quantitatively (20). MPO 
activity was determined as described (21).
For survival experiments, colitis was induced by administration of DSS for 8 or 10 days. In 
one experiment, mice received 2 mg/kg or 30 mg/kg ZnSO4 twice a day by gavage starting 
two days before the induction of colitis. 
Small interfering RNA. Short hairpin RNA (shRNA) fused to an H1 promoter was 
synthesized by PCR on the pSUPER vector (Tronolab, Lausanne, Switzerland). The PCR 
fragments were cloned into pLVTH-siGFP (Tronolab). To produce virus for delivery of the 
shRNA, HEK293T cells (ATCC CRL1573) were transfected by the calcium phosphate 
method with pCMV-d8.91 (Tronolab), PMDG2 (Tronolab) and the shRNA construct. After 48 
hrs, supernatant was harvested and filtered. One day before viral transduction, HT29 cells 
(ATTC HTB38) were seeded at 5x104 cells per well in a 24-well plate. They were overlaid 
with viral supernatant and centrifuged for 1 hr at 32°C. This procedure was repeated with the 
72-hr viral supernatant. Cells expressing high levels of GFP were sorted with the EPICS altra 
cell sorter (Beckman Coulter, Mijdrecht, The Netherlands). 
ELISA. Cells were infected with adherent-invasive E. coli LF82 (MOI100) for 1 hr, after which 
bacteria were killed using 100 μg/ml gentamycin. After 8, 24 and 48 hrs, IL-8 secretion in 
supernatant was measured using sandwich ELISA (BD Biosciences, Franklin Lakes, NJ). For 
each time point, values were calculated by extracting the mean IL-8 secretion by uninfected 
cells from the mean IL-8 secretion by infected cells. For the determination of MT in sera, a 
competition ELISA protocol was used (22). 
Statistics. Statistical analyses were performed using SPSS. Differences between groups in 
qPCR experiments, ELISA, immunohistochemical scores (mean of two observers) and 
induction AUCs were calculated using the Mann-Whitney U test. Median ± SD is given in the 
text. Correlations between metric data were calculated using Pearson’s Rho, and those 
between rank data with Spearman’s Rho. For comparison of normally distributed variables in 
the DSS experiment (colon length and MPO activity), the t-test or one-way ANOVA was 
performed. Significance of differences in DAI and ELISA IL-8 concentrations between time-
series was calculated using a general linear model. Two-tailed probabilities were calculated, 
and P-values of less than 0.05 were considered statistically significant. 
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RESULTS
Identification of potential candidate genes for CD 
Gene expression in normal colon biopsies of 16 CD patients (Supplementary Table 3, 
median age: 33 yrs, range 16-53, 31% male) and 11 healthy controls (median age: 53 yrs, 
range    21-76, 27% male) was analyzed on a microarray chip containing 6,779 expressed    
sequence tags (data are accessible at the MIAME database 
http://www.mged.org/Workgroups/MIAME/miame.html). We characterized genes that were 
differentially expressed between CD patients and controls (P<0.01, n=240) and selected for 
further analysis the genes that were located near a chromosomal region that has been linked 
to CD in at least two independent studies or in a Flemish cohort of patients living in the same 
area of Belgium (Supplementary Table 4) (23-51). We employed an arbitrary distance of five 
megabases around markers that showed the highest linkage. In this way, 18 genes were 
selected (Table 1), and all clones of the respective genes were sequence verified and 
annotated correctly. 
Table 1. Differentially expressed genes in colon biopsies of CD patients located near a 
locus for CD 
unigene gene symbol gene description chromosomal
location
expression
in CD 
P-value
Hs.486246 PHTF1 putative homeodomain transcription factor 1 1p13 ↑ 0.000099
Hs.77955 MEF2D MADS box transcription enhancer factor 2, 
polypeptide D 
1q22 ↓ 0.0035
Hs.106674 BAP1 BRCA1 associated protein 3p21.31-
p21.2
↓ 0.0017
Hs.438691 GMPPB GDP-mannose pyrophosphorylase B 3p21.31 ↓ 0.0013
Hs.302047  PLCL3 phospholipase C-like 3 3q25.31 ↓ 0.0048
Hs.318567 NDRG1 N-myc downstream regulated gene 1 8q24.3 ↓ 0.00038
Hs.84072 TM4SF3 transmembrane 4 superfamily member 3 12q12.1 ↑ 0.0046
Hs.85951 XPOT exportin, tRNA (nuclear export receptor for 
tRNAs)
12q14.1 ↑ 0.0021
Hs.419776 NAP1L1 nucleosome assembly protein 1-like 1 12q21.1 ↓ 0.0088
Hs.159481 GALGT UDP-N-acetyl-alpha-D-galactosamine 12q13.3 ↓ 0.00054
Hs.438737 MT1F metallothionein 1F  16q12.2 ↓ 0.001
Hs.188518 MT1M metallothionein 1M 16q12.2 ↓ 0.00058
Hs.100914 CEP192 Centrosomal protein 192kDa 18p11.21 ↑ 0.000042
Hs.512640 PRKCSH protein kinase C substrate 80K-H 19p13.2 ↓ 0.00042
Hs.134074  SLC35E1 solute carrier family 35, member E1  19p13.11 ↑ 0.006
Hs.437     TCF15 transcription factor 15 (basic helix-loop-helix) 20p13 ↓ 0.0024
Hs.102336  ARHGAP8 Rho GTPase activating protein 8  22q13.31 ↓ 0.0093
Hs.28491 SAT spermidine/spermine N1-acetyltransferase Xp22.1 ↑ 0.0035
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Metallothionein mRNA is down-regulated in colon tissue and blood leukocytes 
of CD patients 
In the microarray screen of CD tissue, we found a down-regulation of two closely related 
metallothionein (MT) transcripts, MT1F and MT1M. A detailed expression study of inducible 
MT isoforms using quantitative real-time PCR (qPCR) was performed on colon biopsies and 
blood leukocytes of 46 CD patients (median age: 36 yrs, range 10-71, 37% male) and 19 
controls (median age: 61 yrs, range 32-76, 37% male). Primers for MT isoforms were 
designed and evaluated for specificity by direct sequencing and agarose gel electrophoresis. 
Additionally, the presence of a single melting peak after denaturation of the amplicons 
following qPCR confirmed the specificity of the reaction in each sample. We obtained specific 
primer sets for MT1M, MT1F, MT1E, MT1J and MT2A. 
The highest mRNA expression in colon biopsies was observed for MT1E, followed by 
MT2A>MT1J>MT1F>MT1M. A significant correlation was found between the expression of 
MT1M mRNA and the other isoforms tested (Table 2). A significantly lower expression of 
MT1M was observed in biopsies taken from endoscopically normal colon tissue of CD 
patients as compared to healthy control tissue, predominantly in patients with colonic disease 
(L2 and L3, P=0.0076, fig 1A). No correlation was found with drug intake, including 
azathioprine (n=8). A similar down-regulation of MT1F mRNA was measured in peripheral 
blood leukocytes (P=0.026, fig 1B). MT1M mRNA levels in blood were too low for reliable 
quantitative measurement. CRP levels were normal in CD patients as well as in controls. 
Table 2. Correlations of MT isoform expression in colon biopsies of CD patients and 
controls
 MT1F MT1J MT1M MT2A 
MT1E        0.631 0.496 0.500 0.499 
P value <0.01 <0.01 <0.01 0.058 
N 65 55 66 15 
MT1F         0.589 0.378 0.784 
P value  <0.01 <0.01 <0.01 
N  55 62 15 
MT1J           0.609 0.805 
P value   <0.01 <0.01 
N   53 13 
MT1M           0.615 
P value    <0.05 
N    15 
THESIS_ANOUK.indd   106 05-03-2009   10:58:20
chapter 4.1    MT deficiency in Crohn’s disease I 107
Metallothionein mRNA is inducible in blood leukocytes of CD patients
As MT mRNA expression was decreased in the colon, ileum and blood leukocytes of CD 
patients with colonic involvement, we examined whether there was a defect in MT induction. 
Therefore, peripheral blood mononuclear cells (PBMCs) isolated from ten CD patients (L1: 4, 
L2: 2, L3: 4) and nine controls were stimulated with known MT inducers (10 ng/ml IL6,     
1000 U/ml TNF, 200 μM ZnSO4, 200 U/ml IFN-Ȗ, 100 μM H2O2 and 2 μM dexamethasone) 
Figure 1. Metallothionein mRNA 
expression is down-regulated in 
CD patients with colonic 
involvement.
Quantitative real-time PCR was used to 
measure (A) MT1M expression in unaffected 
colon biopsies from CD patients and healthy
controls and (B) MT1F expression in blood 
leukocytes of CD patients with colonic 
involvement and healthy controls (P=0.026). 
CD colitis: L3 + L2 (n=28 in A, n=11 in B), 
healthy controls (n=19 in A, n=13 in B), CD 
ileitis: L1 (n=18). (C) MT1M mRNA induction 
in response to oxidative stress is higher in 
CD patients than in controls irrespective of
the disease location (P=0.0015). The mean 
value is shown as a bar. CD patients n=10,
healthy controls n=9.
A
C
B
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and resulting changes in MT1M mRNA expression were measured by qPCR (52). No 
difference in induction was found between CD patients and controls except following 
exposure to H2O2, which resulted in a significantly higher induction of MT1M in CD patients 
(P=0.0015, fig 1C). 
Reduced epithelial metallothionein expression is independent of inflammation in 
CD but not in acute enterocolitis 
In biopsies of healthy controls, MT expression was almost totally confined to the ileal 
epithelium, predominantly the crypt epithelium (Table 3, fig 2A). Some Paneth cells were 
positive, and showed cytosolic localization of the MT signal (fig 2B). Double staining of MT 
with the proliferation marker Ki67 revealed that nearly all Ki67 positive epithelial cells showed 
MT expression, whereas not all MT positive cells were Ki67 positive (fig 2A). At the 
subcellular level, immunogold electron microscopy showed reactivity of epithelial MT in the 
nucleus, cytosol, and endoplasmic reticulum (fig 2C-D). Mitochondria and Paneth cell 
granules were negative.
Table 3. Semi-quantitative score for epithelial expression in non-inflamed biopsies 
 Ileum Colon 
 Score P-value Score P-value 
healthy control 2.500 ± 1.4§  0.700 ± 1.6§
CD 0.750 ± 2.1 0.007** 0.313 ± 1.0 0.401 
 L1 1.000 ± 2.4 0.084 0.875 ± 1.7 0.808 
 L2 + L3 0.750 ± 2.1  0.015* 0.063 ± 0.7 0.128 
acute enterocolitis 2.500 ± 2.9 0.923 ND  
Scores are expressed as medians ± interquartile range. L1: ileal involvement only, L2: colonic involvement only, 
L3: ileal and colonic involvement. §P<0.001 between colon and ileum. P-values are compared to healthy controls. 
ND = not determined.  
Biopsy samples of normal tissue of CD patients showed a reduced MT expression in the ileal 
epithelium as compared to healthy control tissue (Table 3, fig 3A-B), predominantly in 
patients with colonic disease (L2+L3). This result confirms the qPCR data. This difference in 
MT expression in non-inflamed tissue was not seen in acute enterocolitis, where the reduced 
epithelial MT expression was only found in inflamed tissue. In these samples, a negative 
correlation was found between the grade of inflammation and epithelial MT expression (R: -
0.668, P<0.001, fig 3C-E). This was not the case in CD samples, where moderately active 
inflammation seemed to slightly induce MT expression (fig 3F). 
THESIS_ANOUK.indd   108 05-03-2009   10:58:22
chapter 4.1    MT deficiency in Crohn’s disease I 109
Figure 2. Normal intestinal expression of MT protein.
(A) In biopsies of healthy controls, MT (green) is predominantly expressed in the crypt epithelium. Double staining 
with Ki67 (red) did not reveal a correlation with proliferating cells. (B) Immunofluorescence and (C, D) immunogold 
labelling of MT shows cytosolic MT in Paneth cells and in the rough endoplasmic reticulum but no signal was 
detected in the granules. Magnification: A=200x; B=600x, C-D=12000x 
Extracellular metallothionein is reduced in sera of CD patients 
To test whether extracellular MT is also reduced in CD patients, we measured the protein 
content in sera by ELISA. A significantly reduced MT concentration was seen in sera from CD 
patients (17.6±10.4 μg/μl, N=46) as compared to healthy controls (26.7±13.9 μg/μl, N=15,
P=0.009). No correlation was found between MT expression and sex, age or CRP level. 
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Figure 3. Epithelial MT expression is basally reduced in CD and decreases during 
inflammation.
MT expression in ileum from (A) healthy control and (B) normal tissue from CD patient. Decreased epithelial MT in 
(C) mild and (D) severe acute ileitis. (E,F) Boxplots showing the IHC score for epithelial MT in function of the 
grade of inflammation. Epithelial MT is negatively correlated with grade of inflammation in (E) acute enterocolitis 
but (F) not in CD. Magnification=100x 
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Metallothioneins are predominantly expressed in fibroblasts of granulation 
tissue
With increasing inflammatory activity, more MT-positive cells arose in the lamina propria 
(R:0.636, P<0.001, fig 4A-B). Those cells were spindle cells (fibroblasts) and polygonal cells 
belonging to the inflammatory infiltrate and/ or granulation tissue. Double 
immunofluorescence for MT and the macrophage marker CD68 revealed that (polygonal) 
macrophages were weakly positive (fig 4C). Granulation tissue was almost always positive 
(62 out of 77 cases), and no correlation was found between MT and Ki-67 staining (fig 4D). 
Figure 4. MT expression in granulation tissue.
MT expression in granulation tissue (A) was almost always positive for MT and (B) showed a positive correlation 
with grade of inflammation in both CD and acute enterocolitis (boxplots of the IHC score for lamina propria MT in 
function of the grade of inflammation, * represent extremes). (C) Double immunofluorescence with CD68 shows 
that some macrophages are weakly positive for MT (yellow/orange), whereas strong MT staining (red) was noticed 
in spindle cells (fibroblasts). (D) No correlation was found between Ki-67 and MT. Magnification: A=100x; C-
D=600x 
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Epithelial metallothionein expression is induced in the early phase of 
experimental colitis 
To determine the role of MT in experimental colitis, we first evaluated its colonic expression in 
a time course after induction with dextran sodium sulphate (DSS). After one day of DSS 
administration, a mild up-regulation of MT in epithelial cells was observed, which diminished 
from day 2 and was completely absent at days 5 and 7. In contrast, MT-positive inflammatory 
infiltrate/granulation tissue was present in the mucosa and submucosa from day 5 onward 
(fig 5A-B).
Absence of metallothionein influences the course of experimental colitis 
To investigate whether the absence of MT influences the initiation or progression of 
inflammation, we induced acute DSS colitis in MT-/- and wild type (WT) mice. In basal 
conditions, MT-/- mice had shorter colons (P=0.006), and showed higher MPO activity 
(P=0.003) without microscopic inflammation. After DSS treatment, the disease activity index 
(DAI) significantly increased in both MT-/- and WT mice (P<0.001), but progressed slower in 
MT-/- mice (P=0.017).
Histologically, inflammation was more severe in MT-/- mice on day 3 (P=0.0148, fig 5C), 
which is the time-point where in WT mice MT expression in intact epithelium is inhibited and 
before its expression in lamina propria begins to increase (fig 5A-B). No significant difference 
was observed between MTnull and WT mice for MPO and colon length. 
The presence of metallothioneins reduces the survival of severe DSS colitis 
WT mice subjected to DSS treatment died from day 7 onward, whereas MT-/- mice showed an 
extended survival (P=0.0017, fig 6A), suggesting that the absence of MT conferred some 
type of protection against mortality. To determine whether elevated levels of MT would lead 
to the reverse case, or a reduction in survival, zinc was administered to the mice before the 
induction of colitis. In WT mice, a low dose of zinc (2 mg/kg) slightly reduced survival 
(P=0.1001), whereas a high dose of zinc (30 mg/kg) resulted in a significant drop in survival 
rate (P=0.0002, fig 6B). MT-/- mice were not susceptible to the combined effect of DSS and 
zinc administration. 
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Colonic epithelial cells defective in metallothionein expression secrete less IL-8 
in response to adherent-invasive E. coli
Small interfering RNA (siRNA) was used to create a MT-deficient HT29 colonic epithelial cell 
line (HT29MTkd). The siRNA target sequence was present in MT1B, MT1E, MT1J and 
MT1M, while it differed by two nucleotides in MT1F, MT1A and MT2A. The mRNA expression 
levels of MT1A, MT1B, MT1E, MT1M and MT2A were significantly reduced in the HT29MTkd 
cell line as compared to a siRNA control cell line expressing a non-sense RNA sequence with 
the same base pair composition (fold reduction: 1.7±0.26, 2.8±0.41, 3.7±0.12, 1.8±0.53 and 
Figure 5. Epithelial MT expression is
important in the early phase of
acute DSS colitis. 
Immunohistochemical staining of MT showed
single positive epithelial cells in control colon,
while MT-/- tissue was negative. (A+B) Semi-
quantitative scores for immunohistochemical
staining. (A) Epithelial MT was present at day 0
to 3. From day 5 on, epithelial expression
diminished, and (B) a positive MT signal was
seen in the infiltrate and granulation tissue in
the (sub)mucosa. (C) On day 3, histological
inflammation was significantly higher in MT-/-
mice (P=0.0148), coincident with the highest
epithelial MT expression. n=8 per genotype per
day.  
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Figure 6. The presence of MT decreases survival.
Mortality was seen from day 7 on in a survival experiment of 8 days of DSS administration (n=16 mice per 
genotype in DSS groups; n=8 per genotype in control groups). (A) Kaplan Meier analysis shows that MT-/- mice 
are less sensitive to mortality (P=0.0017). (B) DSS was given for 10 days (n=10 per genotype in mice receiving 
DSS, n=5 per genotype in control mice). When zinc was administered to induce intestinal MT, mortality in WT 
mice was increased in a dose dependent manner (P=0.1001 for 2 mg/kg zinc, P=0.0002 for 30 mg/kg zinc). 
3.8±0.19, respectively). MT1J and MT1F were not significantly reduced (fold reduction: 
0.5±0.14 and 1.1±0.13, respectively). The specificity and lack of off target effects of the 
siRNA were evaluated through an expression analysis of the interferon-inducible gene MX1, 
which is frequently found to be induced in such systems (53). The expression of MX1 was 
unaffected in the knockdown cells (fold change 0.4±0.2). Diminished protein expression was 
shown by immunofluorescence using the monoclonal anti-MT antibody (Additional fig. 1). 
Interleukin 8 (IL-8) secretion in response to stimulation with adherent-invasive E. coli (AIEC
LF82) was measured. The secretion of this cytokine was significantly lower in HT29MTkd 
cells than in the siRNA control cell line (P<0.001, fig 7). 
Figure 7. IL-8 secretion in response to bacterial challenge is reduced in HT29 cells 
expressing low MT levels.
Each value is the mean of three dilutions ± SD. HT29MTkd: HT29 cells expressing shRNA targeted against MT; 
siRNA control: HT29 cells expressing shRNA as an irrelevant scrambled sequence with the same base pair 
composition. P<0.001. This experiment was repeated five times. 
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DISCUSSION
In this study, we identified 18 novel potential candidate genes for CD by the integration of 
transcriptome analysis of macroscopically normal colon biopsies with previously determined 
CD-associated genomic loci. We performed a microarray analysis of unaffected tissues to 
target basal differences in gene expression due to genetic variation rather than inflammation-
related events. A similar study was performed by Lawrance and colleagues, with the 
exception that they used moderately inflamed resected colonic tissue (14). 
Two of the candidate genes belong to the family of closely related metallothioneins (MT). 
They are located within the IBD1 locus in a tandem arrangement and arose by non-
processed gene duplications (54). There are several possible mechanisms by which MT 
might play a role in CD. Deregulated MT levels in CD patients might indicate a hampered 
maintenance of free radicals produced during the inflammatory process. Anti-bacterial 
properties of MT could be important in the process of CD progression, as bacteria are 
considered to be involved in initiating and propagating the inflammatory process (55). In 
addition, extracellular MT has been found to promote tissue repair, a process which is 
disturbed in CD (56;57). 
This study showed a down-regulation of MT mRNA and protein expression in serum and in 
unaffected tissue of CD patients as compared to healthy controls. We further demonstrated 
that although basal MT levels were reduced in CD patients, they were still inducible by 
conventional stimuli in PBMCs. Unexpectedly, MT induction by oxidative stress was higher in 
CD patients. This relative overreaction in CD patients might reflect the fact that lower basal 
levels of MT result in a higher concentration of unscavenged free hydroxide radicals when 
hydrogen peroxide is applied. This would lead to the activation of the MT transcription factor, 
MTF1, which in turn would result in an overall increased transcription of MT (58). The 
physiological relevance of this observation in the intestine of CD patients is not clear. 
Detailed immunohistochemical analysis showed that the reduction of MT expression in CD 
patients was due to impaired epithelial expression. In healthy tissue, MT expression was 
predominantly epithelial and higher in the ileum than in the colon. Epithelial cells were only 
positive in the base of the crypts, where proliferation is highest. MT expression in vitro is cell 
cycle dependent (59). Nevertheless, we could not find a correlation between the proliferation 
marker Ki67 and MT, indicating that expression in the crypts is not solely explained by 
proliferation.
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Paneth cells, specialized crypt enterocytes secreting antimicrobial peptides and enzymes, 
were positive for MT, an observation that has also been described in rats (60). Since MT has 
been accredited antimicrobial properties in vitro (61), it seemed likely that the protein would 
be secreted by the Paneth cells. However, immunofluorescence and immunogold electron 
microscopy showed an absence of granular enrichment in Paneth cells. Moreover, the 
expression in these cells was similar to the expression in surrounding crypt cells, suggesting 
a similar role for MT in both cell types. Localization of MT in the endoplasmic reticulum 
suggests the possibility of MT secretion via this pathway. However, secretion via this pathway 
seems unlikely since 1) the protein does not contain any (known) signal peptide and 2) the 
majority of mRNA is translated on free polysomes (2). 
Active inflammation in acute enterocolitis patients resulted in a decrease in epithelial MT 
expression, and an influx of MT positive inflammatory infiltrate and granulation tissue. Mainly 
fibroblasts were moderately to strongly positive for MT, independent of the grade of 
inflammation. MT expression in fibroblasts surrounding mucosal ulcerations was previously 
reported in human chronic gastric and small intestinal ulcers (62). 
Down-regulation of MT in inflammatory bowel disease (IBD) has been reported and 
implicated in the pathogenesis of both ulcerative colitis (UC) and CD (9-15). In the present 
study, the significant reduction of MT expression in the epithelium of non-inflamed tissue of 
CD patients suggests that impaired epithelial function may be an aetiopathogenic mechanism 
in CD.
The exact cause of the down-regulation of epithelial MT during inflammation remains 
unknown and is not consistent with data indicating that MTs are up-regulated by pro-
inflammatory cytokines. To further investigate this inconsistency, we studied the time course 
of MT expression during DSS-induced colitis in WT mice. A very rapid up-regulation of MT 
was seen in colon epithelia, which was inhibited after three days. Following this event, the 
inflammatory infiltrate and granulation tissue appeared and was shown to express MT. These 
results suggest different roles of MT in epithelium and fibroblasts.
The role of epithelial MT during induction of colitis was further clarified by the more severe 
histological inflammation on day 3 in MT-/- mice as compared to WT mice. Since colonic MT 
expression is restricted to the epithelium until day 3, we hypothesize that epithelial MT has an 
immunomodulating role in the early phase of colitis. A DSS study in MT-/- mice performed by 
Oz and colleagues noted no histological differences between the knockouts and WT mice; 
however, they examined the mice at day 8 (63). The more deleterious role of MT during the 
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late phase of induction was suggested by the lower survival rate of WT mice. Especially mice 
that were treated with zinc, which induces endogenous MT in the intestine, were at risk.
In order to clarify the role of epithelial MT, we generated MT-knockdown HT29 cells using 
siRNA. In response to bacterial challenge with a CD-associated E. coli strain, reduced 
expression of MT in epithelial cells correlated with reduced IL-8 secretion (64). This 
observation is in accordance with the recent finding that IL-8 up-regulation is impaired in 
response to acute trauma to the colon or skin of CD patients (65). IL-8 is a potent 
chemoattractant and activator of neutrophils, which respond rapidly to different types of 
infections, and play an essential role in the inflammatory response. They release 
antimicrobial peptides as well as reactive oxygen intermediates that may cause tissue 
damage. We hypothesize that the intestinal epithelial cell lining of CD patients expresses less 
MT and initially secretes less IL-8 in response to bacteria. A delay in neutrophil accumulation 
might lead to the persistence of the exogenous stimulus and an exaggerated secondary and 
compensatory immune response.
In conclusion, we propose deficient epithelial MT expression in CD patients as a possible 
aetiopathogenic mechanism. Our in vivo and in vitro studies point to an immunomodulatory 
role for epithelial MT in early intestinal inflammation. However, the dual roles of MT during the 
complete inflammatory cascade and especially the events accompanying MT expression in 
the epithelium and fibroblasts need to be clarified. 
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APPENDICES
Supplementary Table 1. Sequences of qPCR primer sets  
Supplementary Table 2. Histological evaluation of inflammation 
Group Normal Mild active  Moderate active  Severe active  Chronic quiescent Total 
control 32 0 0 0 0 32
CD 39 27 20 23 16 125
acute enterocolitis 5 7 6 3 0 21
Total 76 34 26 26 16 178
Active inflammation was subdivided in mild (1 or 2 crypt abscesses, small number of infiltrated granulocytes), 
moderate (multiple crypt abscesses, moderate number of infiltrated granulocytes) and severe (presence of ulcers, 
large granulocytic infiltrate). Chronic quiescent inflammation was based upon structural changes only.
Gene
symbol 
Reference
sequence
Forward primer  Reverse primer 
GAPDH NM_002046 TGC ACC ACC AAC TGC TTA GC GGC ATG GAC TGT GGT CAT GAG 
MT1A NM_005946 GCA AAG GGG CAT CAG AGA AGT G AAA TAC AGT AAA TGG GTC AGG GTT G 
MT1B NM_005947 AAG TGC TGC TGC TCT TGC TG TGG TTG CTC TAT TTA TGT CTG GGA G 
MT1E NM_175617  GCA TCC TCT GGG TCT GGG TTC AAC AGC AGC CTG GGG AAG AAG 
MT1F NM_005949 GCG ACT GAT GCC AGG ACA AC CAC AGG AAA AGG AAT GTA GCA AAT G 
MT1J AF348994 GCT GTG CCT GAT GTG GGA AC AAA TGC AGC AAA TGG CTC AGT ATT G 
MT1M NM_176870 CTG CAA AGG GAC GTT GGA GAA C CAG CAA ATG GCT CAG TAT CGT ATT 
MT2A NM_005953 AAA GGG GCG TCG GAC AAG TG GAA TAT AGC AAA CGG TCA CGG TCA G 
MX1 NM_002462 TCC GAA GTG GAC ATC GCA AAA GGG AAG GGC AAC TCC TGA C 
MTF1 NM_005955 TGT TGC TTC TCT TCT GTG TCT G GCT GCC CGC TAG GAC TAA G 
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Supplementary Table 3. Clinical characteristics of CD patients analyzed by 
microarrays  
Patient Familial 
CD
Age of 
onset
Behaviour Disease 
location
CARD15
status
Operation Medication 
1 no A1 B2 L3 WT no immunosuppressives
2 no A1 B3 L3 ND no no 
3 no A2 B3 L3 mutant no 5-ASA 
4 yes A1 B3 L3 WT resection corticosteroids 
5 no A1 B3 L3 mutant fistula 5-ASA 
6 no A1 B3 L2 mutant resection remicade 
7 no A1 B2 L1 WT resection 5-ASA 
8 no A1 B3 L3 WT resection immunosuppressives 
9 yes A1 B3 L3 WT fistula immunosuppressives 
10 yes A2 B2 L1 WT resection immunosuppressives 
11 no A1 B3 L3 mutant fistula immunosuppressives 
12 no A1 B1 L2 WT resection 5-ASA 
13 no A1 B3 L3 WT no immunosuppressives 
14 no A1 B1 L3 WT no 5-ASA 
15 no A1 B3 L3 WT fistula, resection corticosteroids 
16 no A1 B3 L3 WT fistula, resection 5-ASA 
A1: <40; A2: 40; B1: non-stricturing, non-penetrating; B2: stricturing; B3: penetrating; disease location is defined 
as maximal extension of inflammation before first resection of patients with L1: ileal involvement only, L2: colonic 
involvement only, L3: ileal and colonic involvement; mutant CARD15: carriage of at least one mutant allele for 
rs.2066844, rs.2066845 or rs.5743293; WT CARD15: not carrying a mutant allele for rs.2066844, rs.2066845 or 
rs.5743293; 5-ASA: 5-aminosalicylates; ND: not determined. 
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Supplementary Table 4. Chromosomal regions with repeated significant linkage to CD  
IBD
locus
chromosomal
position
marker at highest 
lod score 
population reference
IBD7 1p13.1 D1S252 Flemish IBD 24 
IBD7 1p33-32.3 D1S197 Flemish IBD 24 
IBD7 1p36.13-36.11 D1S552-D1S234 Non-Jewish American IBD 46 
1q21.3 D1S305 Flemish IBD 24 
IBD9 3p14.2-14.1 D3S1766-D3S1285 Canadian IBD 23 
IBD9 3p21.31 D3S1573 North European IBD 25 
IBD9 3p24.1-22.3 D3S1266-D3S1298 North European IBD 26 
IBD9 3p26.3 D3S1297 American IBD 28 
IBD9 3p26.1-25.3 D3S3591 North European IBD 26 
IBD9 3p26.2-26.1-25.3 D3S3706-D3S3591 European IBD 26 
3q25.1-26.31 D3S1279-D3S3725 European CD 28 
3q26.31 D3S3053-D3S2427 American IBD 46 
4q25 D4S406 Finnish IBD 29 
4q25 D4S406 Flemish IBD 24 
4q25 D4S2623 American IBD 47 
IBD5 5q31.1-31.3 D5S816-D5S1480 Canadian CD 23 
IBD5 5q33-35  Jewish American CD 30 
IBD3 6p D6S197 North European CD 31 
IBD3 6p21.31 D6S291 European IBD 32 
IBD3 6p22.2 D6S2439 Caucasian CD 16 
IBD3 6p22.2-21.2 D6S1281-D6S1019 Canadian IBD 23 
IBD3 6p23-22.3-22.2 D6S289-D6S276 North European IBD 33 
IBD3 6p22.3 D6S461 North European IBD 34 
6q24.1 D6S314 Flemish IBD 24 
6q25.2-26 D6S2436-D6S305 Caucasian IBD 16 
7q21.11 D7S669 North European IBD 25 
7q32.1-31.33 D7S40-D7S648 American IBD 50 
8q12.1-13.1 D8S1113-D8S1136 Caucasian IBD 16 
8q24.13 D8S198 Flemish IBD 24 
10p12.1 D10S197 Flemish IBD 24 
10p12.1 D10S197 North European CD 31 
10p12.31-12.32-12.1 D10S548-D10S197 North European CD 33 
11q22.1-22.3 D11S35-D11S927 Flemish IBD 24 
IBD2 12q12 GATA91H06 Caucasian IBD 16 
IBD2 12q14.1 D12S83 North European IBD 25 
IBD2 12q21.1-21.2 D12S303-D12S326 North European CD 33 
IBD2 12q21.1-21.33 D12S303-D12S351 European CD 35 
IBD2 12q23.3 D12S78 Finnish CD 29 
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IBD4 14q11.2  American CD 30 
IBD4 14q11.2 D14S261 American CD 50 
IBD4 14q11.2 D14S50 Flemish IBD 24 
IBD4 14q11.2 D14S261  multicenter (IBDIGC) 36 
IBD4 14q12 D14S80 Flemish IBD 24 
IBD4 14q13.1 D14S49 Flemish IBD 24 
IBD8 16p11.2-12.1 D16S409-D16S753 Australian CD 37 
IBD8 16p12.1 D16S3145  European CD 49 
IBD8 16p12.1 D16S769 American CD 38 
IBD8 16p13.13 D16S748 American CD 46 
IBD1 16q  English IBD 39 
IBD1 16q  American CD 38 
IBD1 16q12.2 D16S306 European CD, IBD 49 
IBD1 16q12.1 D16S409 Ashkenazi Jews CD 40 
IBD1 16q12.2 D16S408 Italian CD, IBD 47 
IBD1 16q12.2 D16S408 Italian IBD 41 
IBD1 16q12.1 D16S411 American non-Jewish CD 42 
IBD1 16q12.1 D16S3136, D16S3117, D16S770 European CD 43 
IBD1 16q12.1 D16S409-D16S411 European CD 34 
IBD1 16q12.1-12.2 D16S409, D16S419 Caucasian CD 44 
IBD1 16q12.1-12.2 D16S409-D16S408 European CD 35 
18p11.31 D18S62 Flemish IBD 24 
IBD6 19p13  UK Caucasian 45 
IBD6 19p13.3 D19S591-GATA21G05 Canadian CD 23 
IBD6 19p13.3-13.2 D19S1034-D19S586 American IBD 46 
 20p12.3 D20S192 Flemish IBD 24 
 22q11.23-12.1 D22S315-D22S421 European IBD 34 
 22q12.1 D22S689 Caucasian IBD 16 
 22q13.31 D22S274 Flemish IBD 24 
 Xp22.11-21.2 DXS1226-DXS1214 North European CD 28 
 Xp21.2-21.3 DXS1202-DXS1214 European IBD 34 
 Xq21.32 DXS1203 Flemish IBD 48 
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ABSTRACT 
Introduction: Metallothioneins (MTs) are small proteins that are involved in zinc metabolism 
and have antioxidant features. They are rapidly induced upon stress and inflammation and are 
thought to possess a cytoprotective potential. Different studies report aberrant expression in 
inflammatory bowel diseases although some findings seem contradictory. Furthermore, these 
studies have not investigated whether aberrant MT expression is a primary aetiopathogenic 
event or secondary to inflammation. We have recently reported a basal down-regulation of MTs 
in Crohn’s disease compared to normal patients. The aim of this study was to clarify the 
expression pattern of MT in ulcerative colitis and to compare it with its expression pattern in 
normal patients and in other inflammatory conditions. 
Materials and methods: Immunohistochemistry for MT was performed on 128 biopsy and 
surgical specimens from control, ulcerative colitis, diverticulitis, ischaemia, and acute 
enterocolitis samples. Each sample was given a semi-quantitative score for MT expression and 
this was correlated with microscopic inflammation. Double immunofluorescent stainings for MT 
and markers for proliferation, macrophages (CD68), and fibroblasts (vimentin and smooth 
muscle actin/SMA) were performed. Ex vivo intestinal cultures were stimulated with zinc and 
transforming growth factor (TGF)-ȕ.
Results: In histologically normal intestinal tissue from ulcerative colitis patients, MTs are 
predominantly expressed in epithelium, which corresponds with MT expression in control tissue. 
In all inflammatory disorders studied, active inflammation causes a shift towards a weak to 
absent epithelial expression and a moderate to strong expression in the lamina propria. This 
latter positivity originated mainly from cells of the inflammatory infiltrate and the granulation 
tissue. Double stainings with cell markers revealed that the MT-positive cell population in the 
lamina propria consisted of some weakly positive macrophages and a majority of vimentin-
positive fibroblasts, part of which were SMA-positive. The expression pattern in these cells was 
independent of grade of activity and no relationship was found with mitotic activity. Ex vivo
stimulation showed that TGF-ȕ down-regulated epithelial MT expression in a dose-dependent 
manner. 
Conclusion: The MT expression pattern in ulcerative colitis corresponds with that observed in a 
‘normal’ inflammatory reaction in the intestine, and as such MT defects are not specific for this 
disease. MT up-regulation in the lamina propria fits with their expected induction upon 
inflammation. The associated down-regulation of MT in epithelium reveals a different regulation. 
Epithelial MT might be down-regulated by TGF-ȕ, which is reported to be increased in inflamed 
intestinal mucosa, especially near epithelial cells. 
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INTRODUCTION 
Metallothioneins (MTs) are a family of ubiquitously expressed, highly conserved, small proteins 
that can bind divalent metal ions. Although they are not essential for life in mammals, the 
sequence and structural homology between MT proteins in different species highlights their 
important biological role (for review, see (1)). Initially, the biological function of MTs was mainly 
linked to their metal-binding capacity, i.e. protection from acute heavy metal toxicity and 
involvement in Zn2+ metabolism. However, their amino acid composition also provides them the 
ability to sequester reactive oxygen species (ROS), thus granting them an antioxidant function 
(2). They are rapidly induced by stress and inflammatory mediators, such as metals, cytokines, 
stress hormones, ROS, and chemicals. The MT promoter contains responsive sequences to 
glucocorticoids (3), interleukin-6 (4), phorbol esters (5) and hydrogen peroxide (6). Other known 
inducers and inhibitors of MT expression are reactive oxygen intermediates (7), nitrogen 
monoxide (8), epidermal growth factor and transforming growth factor (TGF)-ȕ (9), interleukin-1 
(10), interferon-Į (11) and tumor necrosis factor (TNF)-Į (12). The regulation of MT synthesis in 
inflammation is complex and is the result of a combination of factors that act synergistically in 
different tissues. 
In the intestine, aberrant MT expression has been described in patients with ulcerative colitis 
(UC) and Crohn’s disease (CD). Two studies report elevated MT levels in CD and UC (13;14), 
but most studies report decreased MT expression in CD as well as UC, using 
immunohistochemical techniques (15-18), radioimmunoassay (18;19), and a silver-saturation 
assay (20). None of these studies addresses the issue whether these changes in MT expression 
are inflammation-dependent or specific for CD and/or UC. In a previous study, we were able to 
show a decreased MT expression at basal levels in colon and ileum biopsies and in whole blood 
samples of CD patients (Laukens et al submitted). This lowered mRNA expression correlated 
with lowered epithelial protein expression in biopsies taken at another time point, suggesting a 
genetic involvement. The aim of this study was to elucidate the expression pattern of MT in UC 
and to compare it with its expression pattern in healthy conditions and in other intestinal 
inflammatory conditions (acute and ischaemic enterocolitis, and diverticulitis). 
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MATERIAL AND METHODS 
Tissue specimens 
Formalin fixed, paraffin embedded tissue from the archive of the clinical department of Pathology 
of the Ghent University Hospital was used. A total of 128 biopsy and surgical specimens was 
studied, including 31 control samples, 39 UC samples, 11 diverticulitis samples, 26 ischaemia 
samples and 21 samples of acute enterocolitis. Sample characteristics are summarised in Table 
1. UC samples were chosen from patients that were diagnosed with disease according to 
clinical, endoscopic and histological criteria. Six of the UC patients did not receive medication 
before biopsies were taken or surgery was performed, five received aminosalicylates (5-ASA), 
two received corticosteroids, two received aminosalicylates and immunosuppressive agents, 
four received aminosalicylates and corticosteroids, four received immunosuppressive agents 
and corticosteroids, and one patient received aminosalicylates, immunosuppressive agents and 
corticosteroids. Control tissue was obtained from patients who underwent ileocolonoscopy for 
follow up of polyp detection or screening for colorectal carcinoma. All other samples were 
chosen on the basis of clinical and histopathological features and controlled for absence of 
clinical features suggestive of CD or UC. Patient characteristics are summarised in Table 2. This 
study was approved by the local ethics committee (EC UZG 2006/362). 
Table 1. Characteristics of samples 
type of specimen 
tissue       group biopsy surgical Total 
ileum control 16 0 16
UC 9 0 9
ischaemia 0 16 16
acute enterocolitis 12 1 13
Total 37 17 54
colon control 15 0 15
UC 27 3 30
diverticulitis 0 11 11
ischaemia 0 10 10
acute enterocolitis 8 0 8
Total 50 24 74
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Table 2. Characteristics of patients 
gender 
group 
female male 
median age (range) 
control 10 11 41 (24-65) 
UC 13 15 34 (13-68) 
diverticulitis 3 6 60 (44-82) 
ischaemia 9 9 68 (0-79) 
acute enterocolitis 6 8 42 (6-71) 
Histological assessment 
Haematoxylin and eosin staining was carried out according to routine procedures. The 
histological evaluation of inflammation of all samples is summarised in Table 3. Active 
inflammation was subdivided in mild (1 or 2 crypt abscesses, small number of infiltrated 
granulocytes), moderate (multiple crypt abscesses, moderate number of infiltrated granulocytes) 
and severe (presence of ulcers, large granulocytic infiltrate). Chronic quiescent inflammation 
was based upon structural changes only. 
Table 3. Histological evaluation of samples 
histological evaluation 
            group normal
mild active 
inflammation 
moderate 
active 
inflammation 
severe active 
inflammation 
chronic
quiescent 
inflammation Total 
control 31 0 0 0 0 31
UC 8 10 6 10 5 39
diverticulitis 3 1 1 6 0 11
ischaemia 5 3 1 17 0 26
acute enterocolitis 5 7 6 3 0 21
Total 53 21 14 36 5 128
Immunohistochemistry 
Paraffin embedded sections were rehydrated in serial immersion in xylene and ethanol. 
Immunohistochemical staining was carried out on the NexES IHC automated staining system 
(Ventana Medical Systems, Tucson, AZ) with the mouse monoclonal anti-metallothionein clone 
E9 (Zymed Laboratories, San Francisco, CA). An isotype-specific irrelevant antibody (mouse 
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IgG1 negative control, DakoCytomation, Belgium) was used in a matched concentration to 
control for non-specific binding of the primary antibody. Stained sections were coded and 
analyzed by two independent observers who were blinded for diagnosis and clinical data. 
Relative proportions of positive staining epithelial cells and non-epithelial cells were separately 
measured using the following semi-quantitative grading system: 0: no MT-positive cells; 1: single 
MT-positive cells or foci (1 to 5%); 2: moderate number of foci of MT-positive cells (6 to 40%); 3: 
large number of cells are MT-positive (40 to 70%); 4: majority of cells are MT-positive (>70%). In 
case of active inflammation, granulation tissue was scored using the same grading system. 
Cohen’s kappa was calculated for the scores obtained by the two observers and showed 
excellent agreement with kappa = 0.65 (21). 
Immunofluorescence 
Paraffin embedded sections were rehydrated in serial immersion in xylene and ethanol. After 
heat induced epitope retrieval with 0.01M citrate buffer pH 6.0 (sodium citrate tribasic dehydrate, 
Sigma, St Louis, MO), autofluorescence was quenched with ammoniumchloride (50mM, UCB, 
Drogenbos, Belgium) and non-specific binding sites were blocked with 1% bovine serum 
albumine (Sigma). Sections were incubated with a mixture of two primary antibodies (mouse 
monoclonal IgG1 anti-MT clone E9, Invitrogen, Carlsbad, CA; rabbit monoclonal anti-Ki67 clone 
SP6, Lab Vision, Fremont, CA; mouse monoclonal IgG2a anti-vimentin clone Vim3B4, 
DakoCytomation; mouse monoclonal IgG2a anti-SMA clone 1A4, BioGenex, San Ramon, CA), 
and secondary antibodies applied were Alexa 488 anti-mouse IgG1, Alexa 594 anti-rabbit, Alexa 
594 anti-mouse IgG2a, and Alexa 594 anti-mouse antibodies (Molecular Probes, Eugene, OR). 
Double-staining with anti-CD68 included a tertiary step using FITC-anti-CD68 (clone KP1, 
DakoCytomation). Appropriate negative controls were included to verify that no cross-reactions 
occured. 
Ex vivo stimulation 
For ex vivo stimulation, macroscopically normal rest tissue (taken at areas distant from diseased 
tissue) was obtained from ileal resection specimens that were sent to the pathology department 
for diagnostic investigation. Immediately upon arrival, tissue specimens of approximately 1cm2
were placed in RPMI medium (Invitrogen) containing antibiotics (Invitrogen), foetal calf serum 
(PAA Laboratories, Pasching, Austria), and 100μg/ml gentamycin (Schering-Plough, Brussels, 
Belgium). After two rinses in this medium followed by pre-incubation in medium containing 
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50μg/ml gentamycin, tissue cultures were stimulated with 1, 5 or 10ng/ml recombinant human 
TGF-ȕ1 (R&D Systems), or 200μM ZnSO4.7H2O (VWR, West Chester, PA) supplemented with 
10ng/ml TGF-ȕ1 for 15 hours.  
Statistical analysis 
The means of the scores from the two observers were used to compare different subsets with 
the Mann-Whitney U test. Scores are expressed as medians ± interquartile range. Differences 
were considered significant at a P value of < 0.05. Since MT positivity was significantly higher in 
ileal epithelium than in colonic epithelium (P < 0.001), all comparisons for epithelial scores were 
split according to type of tissue. Since scores for MT positivity in non-epithelial cells (cells from 
inflammatory infiltrate and granulation tissue) was significantly influenced by the type of 
specimen (biopsy versus resection specimen, P = 0.001), all comparisons for scores of non-
epithelial cells were split according to specimen type. Correlations were calculated with the 
Spearman’s rho test. 
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RESULTS 
Metallothionein expression in normal intestine 
In samples of control biopsies, MT was moderately to highly expressed in the epithelium. This 
expression was stronger in the ileum than in the colon (semi-quantitative score ileum: 2.5 ± 1.4 
versus colon: 0.7 ± 1.6; P < 0.001). More cells from the villus base and crypt cells were positive 
than cells in the upper part of the villi or superficial epithelium (Fig. 1a,b). Sometimes Paneth 
cells were positive. Some samples showed strong positivity in isolated epithelial cells, 
reminiscent of enteroendocrine cells. When positivity was encountered in the lamina propria, it 
originated from macrophages, as was shown by double immunofluorescence with CD68 (Fig. 
1c). Double staining of MT with the proliferation marker Ki67 revealed that almost all Ki67 
positive epithelial cells showed MT expression, whereas not all MT positive cells were Ki67 
positive or proliferating (Fig. 1d). 
Figure 1. MT
expression in normal
intestine.  
MT is strongly
expressed in ileum (a)
and moderately to
weakly in colon (b).
Expression is higher in
crypt and basal part of
the villus than in the
top of the villi (ileum).
Double staining with
CD68 (c, ileum; MT =
red, CD68 = green,
nuclei = blue) showed
that positive cells in the
lamina propria were
macrophages. Double
staining with Ki67 (d,
ileum; Ki67 = red, MT =
green, nuclei = blue)
did not reveal 100%
correlation. Scale bars:
a, b: 100μm; c: 25μm;
d: 50μm. 
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Tissue of UC patients that shows no active inflammation displays normal MT expression 
Since we previously found a decreased MT expression in normal ileal tissue of CD patients, 
even in patients with no ileal involvement, (Laukens et al. submitted) we wondered if UC would 
show a similar decrease. Biopsy samples of normal ileal tissue of UC patients showed normal 
MT expression. Semi-quantitative scores for ileal expression were 2.5 ± 1.4 for healthy control 
tissue, 2.5 ± 1.0 for tissue from UC patients (P = 0.431). The expression pattern of MT was 
similar in all samples and corresponded with the pattern in healthy controls (see earlier). 
Active inflammation causes down-regulation of epithelial MT expression 
Next, we investigated the influence of mucosal inflammation on epithelial MT expression. We 
found that epithelial MT expression diminished as histological inflammation progressed (Fig. 
2a,b). When epithelial MT expression was plotted against the degree of inflammation, a negative 
correlation was found in these samples (Fig. 2c; Spearman’s rho = -0.455, P = 0.004 for ileum; 
Spearman’s rho = -0.184, P = 0.167 for colon). Surgical specimens containing both healthy and 
inflamed areas elegantly illustrated this inverse association: areas with normal histology showed 
(normal) moderate to high epithelial expression, whereas epithelium covering inflamed areas 
was only weakly positive or negative. In the case of ischaemic inflammation, epithelium 
bordering necrotic regions was even completely negative in all cases (n=23). 
After the disappearance of active inflammation, epithelial MT immunoreactivity reappeared. 
Colon biopsies of UC patients that showed chronic quiescent but no active inflammation were 
compared with colon biopsies without inflammation from controls. UC tissue demonstrated a 
trend towards higher expression (scorecontrol = 0.5 ± 1.5, scoreUC = 2.0 ± 1.8, P = 0.142). 
Active inflammation positively correlates with non-epithelial MT expression 
With increasing activity of inflammation, more positive cells emerged in the lamina propria (Fig. 
2a,b,d). Positive cells were mostly cells of the inflammatory infiltrate and granulation tissue, 
judging by the morphology fibroblasts and macrophages (Fig. 2e). This appearance was 
positively correlated with the degree of active inflammation (Fig. 2f; Spearman’s rho = 0.493, P <
0.001). Lymphocytes, granulocytes and neutrophils appeared to be negative. Double 
immunofluorescence with cell markers for macrophages and fibroblasts confirmed that the 
positive cell fraction was composed of some mildly positive macrophages and a majority of 
strongly positive fibroblasts. These fibroblasts were positive for vimentin and a minority was also 
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Figure 2: MT expression in inflamed intestine.  
Epithelial MT expression decreases following inflammation, while positive cells emerge in the lamina propria. (a) 
active UC, (b) ischaemic inflammation, (d) active diverticulitis. In ischaemia, there was a moderate expression in 
fibroblasts, macrophages, pericytes and nerve tissue regardless of presence of inflammation.  (c) Boxplots of semi-
quantitative scores of epithelial MT expression in the ileum during inflammation showing decreased epithelial MT 
expression. (e) Magnification of (a) showing MT positive spindle and polygonal cells. (f) Boxplots of semi-quantitative 
scores of MT expression in the lamina propria during inflammation showing increased MT expression. Double 
stainings showed that fibroblasts (spindle cells) were positive for vimentin (g; MT = green, vim = vimentin = red, nuclei 
= blue), while a small proportion was also positive for SMA (h; MT = green, SMA = red, nuclei = blue). Inflammatory 
infiltrate consists of moderately to strongly positive MT cells, independent of proliferative status as illustrated by 
doublestaining with Ki67 (i, Ki67 = red, MT = green, nuclei = blue). Scale bars: a, b, d: 100μm, e, g, h, i: 25μm. 
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positive for SMA (Fig. 2g,h). When granulation tissue was present, it was almost always positive 
(62 out of 77 cases). The degree of expression in the granulation tissue itself did not differ in 
mild, moderate or severe inflammation. MT expression was not dependent on the proliferative 
status of these cells, since we found no relationship between MT and Ki-67 (Fig. 2i). In surgical 
samples from patients with ischaemic enterocolitis, there was a moderate expression in stromal 
cells regardless of presence of inflammation (2 out of 6 cases without inflammation, 11 out of 23 
cases with inflammation). These cells were fibroblasts, macrophages, pericytes and nerve tissue 
(Fig. 2b). 
Stimulation with TGF-? down-regulates epithelial MT expression 
Ex vivo cultures of small intestinal tissue showed moderate to strong epithelial MT expression 
without stimulation (Fig. 3a). Stimulation with zinc resulted in an increase in MT staining (Fig. 
3b). Administration of TGF-ȕ1 caused a decrease in epithelial MT expression which was most 
clearly visible with the highest dose (Fig. 3c-e). The highest dose of TGF-ȕ1 neutralized the MT 
induction by zinc (Fig. 3f). Stimulation did not result in signal in the lamina propria. 
Figure 3: Ex vivo stimulation.  
MT staining on stimulated intestinal tissue
showing normal expression in unstimulated
(control) tissue (a) and higher signal after
stimulation with 200μM zinc (b). Administration
of TGF-ȕ could decrease MT expression in a
dose-dependent manner (c: 1ng/ml, d: 5ng/ml,
e: 10ng/ml) and even counter MT induction by
zinc (f: 10ng/ml TGF-ȕ + 200μM zinc). Scale
bars: 50μm.
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DISCUSSION 
MT expression in normal conditions was predominantly epithelial and was highest in the ileum 
and in crypts. In these sites of the intestine, antibacterial effects are most critical, supporting an 
antibacterial role of MT in these regions (22). However, the proliferative status of crypt cells 
might also explain high MT expression, since MT is known to be cell-cycle dependent and up-
regulated in proliferating cells in vitro (23). Double staining for MT and the proliferation marker 
Ki67 could not confirm this correlation in intestinal epithelial cells. A lot of MT positive cells were 
Ki67 negative, which indicates that expression in the crypts cannot be (solely) explained by 
proliferation.
In contrast to Crohn’s disease, MT expression was not reduced in samples of UC patients that 
showed no active inflammation. In all tested conditions, active histological inflammation caused 
a decrease in the epithelial expression of MT. Simultaneously, an up-regulation was noticed in 
infiltrating cells in the lamina propria. Our findings could explain why some conflicting 
conclusions regarding MT expression in IBD were drawn in previous studies. First, it is important 
to recognize that MT expression varies in epithelium and lamina propria cells. Therefore, 
analyses of whole tissue lysates will yield different results than analyses of different cell 
fractions. Secondly, MT expression is dependent on the severity of active inflammation. The 
sampling during an inflammatory course is in that regard equally important. Our results 
demonstrate that the inflammation-dependent MT expression pattern is normal in ulcerative 
colitis, and comparable with that in diverticulitis, ischaemic and acute enterocolitis. In contrast, it 
differs from that in Crohn’s disease, where we found decreased epithelial MT expression in spite 
of absence of inflammation in a previous study (Laukens et al. submitted).  
An inflammation-dependent decrease in MT expression is not consistent with the accepted 
knowledge that MTs are rapidly up-regulated in conditions of stress and inflammation. Most 
molecules that are present during inflammation induce MTs, such as IL-1, TNF-Į, IL-6, nitrogen 
monoxide, reactive oxygen radicals, and others (7;8;10;12). One of the few molecules that has 
been shown to be able to inhibit MT expression is transforming growth factor (TGF)-ȕ. This 
pleiotropic cytokine inhibited induction of MT by epidermal growth factor in vitro in rat 
hepatocytes (9). TGF-ȕ is a good candidate for epithelial regulation in inflammation, since an 
increase is found in mucosa with active intestinal inflammation, with the highest concentration in 
inflammatory cells closest to the luminal surface, near epithelial cells (24). When we stimulated 
human intestinal tissue with TGF-ȕ1 this resulted in a dose-dependent decrease in epithelial MT 
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expression. These results suggest that TGF-ȕ1 might be a regulator for epithelial MT expression 
during inflammation. TGF-ȕ1 inhibits enterocyte proliferation (25) and can induce apoptosis (26), 
two processes where MTs have an opposite association. In addition, the induction of TGF-ȕ by 
ROS (27) and by MTs in T lymphocytes (28) stresses the need to further investigate the 
relationship between MTs and TGF-ȕ.
Contrary to the decrease in the epithelium, an increase in MT-positive cells occurred in the 
lamina propria during inflammation. This positive cell fraction was shown to consist of some 
weakly positive macrophages (that were also present in non-inflamed tissue) and a majority of 
fibroblasts. These fibroblasts, present in the granulation tissue, were vimentin-positive and a 
small proportion was SMA-positive. They probably represent a subset of fibroblasts, a cell-type 
which is known to have different possible phenotypes during physiologic and pathologic 
conditions (29). MT expression in granulation tissue surrounding mucosal ulceration has 
previously been reported in human chronic gastric and small intestinal ulcers (30). The 
expression level in the infiltrate itself is not dependent on the activity of inflammation and the 
higher scores for MT expression in the lamina propria in actively inflamed tissue are due to the 
elevated proportion of infiltrating inflammatory cells and fibroblasts. The fact that the majority of 
these cells is moderately to strongly positive for MT, independent of proliferative status, denotes 
a specific function for MT in inflammation and not only a reflection of mitotic activity. A possible 
function might be found in the antioxidant features of MT. Inflammatory cells (neutrophils and 
macrophages) produce free oxygen radicals upon stimulation by locally produced cytokines 
(interleukin-1 and interferon-Ȗ) to kill bacteria and parasites. These free radicals are also 
extremely cytotoxic and are capable of causing local host bystander tissue necrosis (31). Given 
the antioxidant properties of MT, it is possible that, together with other known molecules such as 
super oxide dismutase, vitamin E and ascorbate, MTs provide a cytoprotection for host cells, 
preventing cellular damage and allowing survival and growth in an inflammatory environment 
and protection against chemical or ischaemic injury (30). Interestingly, in non-affected surgical 
specimens of patients with ischaemic enterocolitis, an up-regulation of MT was found in 
fibroblasts in the submucosa, a pattern that was maintained during active inflammation. Also 
pericytes and nerve fibres were found more positive in ischaemic conditions, suggesting that 
MTs are rapidly up-regulated in these cell types in stress conditions and have a cytoprotective 
effect against ischaemic injury. 
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The expression profile of MTs in normal ileum and colon hint at a cytoprotective/antibacterial role 
in epithelium, maybe indirectly through its antioxidative and/or Zn-binding capacities, but does 
not explain a decrease in epithelial MT expression induced by inflammation. The explanation 
might lie in the capacities of MTs to modulate the activation of the transcription factor nuclear 
factor (NF)-țB, which has a fundamental role in inflammation. This modulation might be 
regulated directly (32) or indirectly through modification of the redox balance (33;34) or 
regulation of zinc concentrations (35). Since zinc is a structural and/or catalytic element in many 
other transcription factors and enzymes as well, it can be implicated in metabolic regulation on 
many levels. A decrease in MT would increase zinc ion availability against stressor agents and 
inflammation (for review see (36)). 
In conclusion, we showed that the MT expression pattern in ulcerative colitis corresponds with 
the pattern encountered in other intestinal inflammatory disorders. Intestinal expression of MT 
shifts from mainly epithelial in normal circumstances towards a reduced epithelial expression 
and a pronounced expression in cells of the granulation tissue during progression of active 
inflammation. These results indicate a difference in regulation in the epithelium versus the 
granulation tissue during inflammation. 
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ABSTRACT
Metallothioneins (MT) are ubiquitous metal-binding proteins that are highly conserved 
throughout evolution. Although the exact physiological function is not completely understood, 
they are involved in a variety of processes including metal homeostasis, heavy metal 
detoxification, free radical scavenging, inflammation and cell proliferation. The human MT 
gene family consists of at least 19 isoforms, containing pseudogenes as well as genes 
encoding functional proteins. Most of these genes can be induced by a wide variety of 
substances, such as metals, cytokines and hormones. In addition, different cell types express 
discrete MT isoforms, reflecting the specifically adapted functions of MT isoforms, and hence 
a divergence in their regulation. Aberrant expression of MT has been described in a number 
of apparently diverse diseases, including Crohn’s disease, cancer, Alzheimer’s disease, 
amyotrophic lateral sclerosis, Menkes disease and diabetes. Therefore, a thorough 
understanding of the regulation of MT expression is imperative. To date, the regulation of 
transcription of these genes has primarily been studied in mice. However, the situation in 
mice is somehow less complicated, since only four isoforms are expressed. Nevertheless, 
the high homology between mouse and human MTs allows us to evaluate regulatory regions 
in their respective promoters. In this article, we review the aberrant expression of human MT 
in disease, and the mechanisms that regulate MT expression. 
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INTRODUCTION
Metallothioneins (MTs) are a family of small, highly conserved proteins with the specific 
capacity to bind metal ions. The MT protein was first purified from the equine renal cortex in 
1960 (1). Since, they were described in a wide variety of species, including vertebrates, 
invertebrates, plants, fungi and some prokaryotes. A great deal of sequence and structural 
homology exists between MT proteins in different species, underlining their important 
biological role. Mammalian MT proteins typically consist of 61 to 68 amino acids, with a high 
content of polar, highly catalytic cysteine residues. These cysteines are strictly conserved 
and arranged in motifs that form the framework of two distinct metal-binding domains, linked 
by a short peptide (Figure 1). Eleven cysteine residues are located in the C-terminal Į
domain, nine cysteine residues are located in the N-terminal ȕ domain, and the two domains 
can incorporate four and three divalent metal atoms, respectively. These two domains most 
probably account for distinct functional structures, given the marked differences in metal-
mobilities found for the two domains. The Į domain tightly binds metals and is involved most 
likely in detoxification, while the more labile metal binding in the ȕ domain is probably 
implicated in metal homeostasis (2). Attempts to elucidate the exact order of metal binding 
were deterred by the observation of domain specific metallation such that only M4-Į or M7-Įȕ
species were observed and not the intermediate sequentially metallated species. However, 
based upon the crystal structure of rat MT and studies with a peptide fragment containing 
residues 49-61 of rabbit MT2, the C-terminus of the protein encompassing four cysteine 
residues is put forward as the site of nucleation during the folding of MT upon metal 
sequestration (3).
Originally, reports investigating the biological role of MTs were centralized to their exceptional 
metal-binding capacity. This characteristic can establish a function for MTs in two ways. First, 
they can provide homeostasis of metal ions within the cell, and are able to protect them from 
acute heavy metal toxicity. Indeed, in normal conditions, excessive concentrations of 
essential and nonessential metal ions like cadmium, mercury, and lead can be toxic. 
Therefore, most organisms use a redundant array of cellular mechanisms to limit toxicity of 
metal ions (4), one of which is sequestration by MT. Secondly, through participating in zinc 
metabolism, MTs can regulate the activity of fastly exchanging metalloproteins, such as     
NF-țB (5;6), the zinc finger-containing factor Sp1 (7), and the tumour suppressor gene p53 
(8). Zinc is a necessary component of NF-țB for its DNA binding activity, thus regulating its 
activity (9). Nevertheless, it is now clear that the function of MTs is not restricted to this metal-
binding activity. Because they are rapidly induced by various stimuli such as metals, 
hormones and cytokines, MTs are believed to participate in different protective functions. In 
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addition, MTs are capable of scavenging free radicals and thus play a role in protection of 
tissues against oxidative injury, including radiation, lipid peroxidation and inflammation. 
Although MTs are believed to be active intracellularly, extracellular MT has been shown in 
brain tissue (10), and similarly, they are found in serum and urine samples of cadmium-
exposed individuals (11). However, the importance of the exact physiological role of 
extracellular MT is only recently emerging (12). It was shown that MTs in the extracellular 
environment may act as a “danger-signal” promoting movement of leukocytes to the site of 
inflammation (13), and thus act as a kind of chemokine. A receptor for MT has not been 
identified yet, but is a work of great interest. Interestingly, various immune functions have 
been attributed to extracellular MT. Therefore, they might be involved during the process of 
inflammation, which is further supported by their up-regulation by inflammatory cytokines 
such as interleukin 1 and tumour necrosis factor alpha (TNF). Moreover, MTs are thought to 
down-regulate the inflammatory response by interfering with nitric oxide (NO) synthesis, an 
important “end” mediator of inflammation (14).
The significance of a strictly controlled regulation of MT in both growth of cells and in their 
response towards several stimuli is obvious. It is therefore plausible that defects in one of 
these restricted mechanisms can lead to pathological situations, for example tumour growth 
or excessive inflammation. Good knowledge of their regulation is thus crucial in 
understanding their role in pathogenesis. 
Figure 1 Homology model
of human metallothionein
1A.
Cysteine residues are shown as
yellow sticks, metal ions are shown
in red (Cd2+), green (Zn2+) and
orange (Na+). The model was
constructed using the Swiss Model
web server (Schwede et al. 2003)
with the crystal structure of the rat
metallothionein 1A protein (PDB ID
4MT2) as template structure. 
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THE HUMAN METALLOTHIONEIN FAMILY 
The classification of metallothioneins has been revised in 1999 and is based on phylogenetic 
relationships between protein and nucleotide sequences of the isoforms (15). Rodents 
express four MT isoforms, MT1 to MT4, while all primates examined so far contain multiple 
copies of the MT1 isoform. The situation is most complex in humans: a total of 19 MT 
isoforms and 5 MT-like genes have been cloned so far, many of which only differ in distinct 
amino acids (Table 1). So far, eight of the MT isoforms are classified as non-processed 
pseudogenes. It is, however, not clear whether some of these genes are nonetheless 
functional: MT1JP and MT1DP contain a promoter, are transcribed, but contain a premature 
stop codon. Fifteen out of 19 isoforms cluster together on chromosome 16q13 (Table 1) (16). 
Apparently, chromosome 16 is one of the most enriched chromosomes for intrachromosomal 
duplications (17). Similarly, the cadherin gene cluster is also located on this chromosome.
Table 1. Annotated human metallothionein genes and their characteristics 
Symbol Chromosomal 
location
Aliases Protein length Refseq status Expression 
MT:      
MT4 16q13  62 provisional squamous epithelium 
MT3 16q13 GIF 68 validated brain, kidney, reproductive system
MT2A 16q13 MT2 61 provisional ubiquitous 
MT1A 16q13 MT1S, MTC 61 validated ubiquitous 
MT1B 16q13 MT1Q, MTP 61 provisional ubiquitous 
MT1E 16q13 MTD 61 validated ubiquitous 
MT1F 16q13  61 provisional ubiquitous 
MT1G 16q13  61 provisional ubiquitous 
MT1H 16q13 MT-0 61 validated ubiquitous 
MT1M 16q13 MT1K, MT1Y 61 validated ubiquitous 
MT1X 16q13 MT1l 61 provisional ubiquitous 
MT pseudogenes:     
MT1JP 16q13 MT1IP, MT1NP - provisional         - 
MT1L 16q13 MT1R, MTF - validated         - 
MT1CP 16q13  - inferred         - 
MT1DP 16q13 MTM - provisional         - 
MT2P1 4q13  - inferred         - 
MT1P1 9q22.32   inferred         - 
MT1P2 1q43   inferred         - 
MT1P3 20q11.2   inferred         - 
MT-like:      
MTL1 1p  ?          ? 
MTL2 1p22  ?          ? 
MTL3 18  ?          ? 
MTL4 20  ?          ? 
MTL5 11q13 TESMIN 178  reviewed testis 
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The various MT isoforms differ mainly in their expression pattern (see also Table 1): MT3 and 
MT4 are constitutively expressed in specific cell types, while MT1 isoforms, and to a lesser 
extend MT2, are highly inducible. The MT1 and MT2 genes are ubiquitously expressed. By 
comparing the coding sequences of rodent and primate MT genes, it was shown that human 
MT1 isoforms show less divergence from human MT2 than from mouse MT1, suggesting that 
the MT1 and MT2 isoforms arose after the emergence of primates (18). On the other hand, a 
phylogenetic analysis including mouse and human MT3 and MT4 proteins shows that these 
isoforms probably diverged prior to the primate/rodent divergence (Figure 2). In addition, 
human as well as mouse MT1 and MT2 isoforms are clearly separated from the MT3 and 
MT4 clusters, most likely reflecting the distinct regulation of expression of these isoforms in 
both organisms. Interestingly, this could signify that MT1, MT2, MT3 and MT4 proteins have 
similar functions in mice and men. 
Figure 2. Phylogenetic tree of human and mouse metallothionein protein isoforms.
Metallothionein 3 and 4 probably arose prior to the divergence of primates and rodents, while MT1 and MT2 
genes arose later. Mouse MT genes are designated as mMT1, mMT2, mMT3 and mMT4. 
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METALLOTHIONEIN IN DISEASE
Since cellular zinc homeostasis is extremely important for normal functioning, it is not 
surprising that MT deregulation has been implicated in natural processes such as ageing 
(19), but also in pathological conditions. Unfortunately, the role of these proteins in disease 
aetiology is not clear as a result of at times conflicting reports. Incompatible data can partly 
be explained by the fact that expression data obtained by immunohistochemistry, semi-
quantitative PCR or more recent techniques such as quantitative PCR (qPCR) are not strictly 
comparable. The early studies on MT expression relied on immunohistochemistry using 
antibodies, which cannot distinguish between MT isoforms. Only for MT3 a specific antibody 
has been generated against a unique eight amino acid sequence not shared by any other MT 
isoform (20). Using non-distinguishing antibodies, strong staining can be found in 
pathological tissues, especially in tumors (21). However, in normal tissues, MT expression is 
usually undetectable by immunohistochemistry except in myoepithelial (22), renal (23), ileal 
epithelial cells (24), pancreas (25) and fetal liver (26). Real-time qPCR analysis is much more 
sensitive than staining procedures. Furthermore, highly specific primers can be designed to 
study the expression of every MT isoform individually. Another issue which complicates the 
interpretation of MT in disease between studies is the gathering of tissues for analysis (e.g. 
resection versus biopsy material, delay time between sampling and storage). Since MTs are 
stress proteins, their expression is largely determined by the handling of tissues. This also 
applies for in vitro analysis of MT expression, because cultured cells are very sensitive to 
changes in pH, temperature and addition of serum (27). Here, we summarize data of 
abnormal MT expression in several diseases. 
Metallothionein and Crohn’s disease 
Crohn’s disease (CD) is a chronic inflammatory disease of the gastro-intestinal tract. The 
complete bowel wall of the ileum and/or colon is affected. In the normal intestine, we found 
that MT mRNA and protein expression is highest in the ileum as compared with the colon 
(24). Metallothionein is localized in the enterocytes, predominantly at the base of crypts. 
Although the high proliferative state of these cells might explain their high MT expression, we 
could not find a correlation between MT expression and the proliferation marker Ki67 (28). 
We propose that MT might have an antibacterial role in these cells, given that antibacterial 
effects are most critical in these sites of the intestine. Focal staining is often observed in the 
intestine, as a result of the uniform staining in distinct single crypts. Based on a mutagen-
induced mouse model it was suggested that this staining pattern is the result of somatic 
mutations in stem cells, leading to strong clonal expression of MT in the entire crypt (29;30). 
There is thus far no evidence that this process exists in the human intestine. Aberrant mRNA 
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and protein expression was found in tissue samples originating from CD patients. Down-
regulation as well as up-regulation have been reported. Two papers reported an up-
regulation (31;32), while we and others found a down-regulation of MT in CD (24;33-36). 
Moreover, MT quantification in CD based on radioimmunoassay (36;37) and microarray (24) 
also showed a down-regulation. Using qPCR, we provided evidence for a decreased 
expression of a large proportion of MT1 isoforms and MT2 at basal level in colon biopsies, 
ileum biopsies and whole blood samples of CD patients (24). This lowered mRNA expression 
level correlated with protein expression, even though biopsies were not acquired at the same 
time. These results suggested that the deficient MT expression in CD patients with colonic 
disease is at least partly genetically determined. Interestingly, the MT gene cluster is located 
in the IBD1 chromosomal region, which was significantly associated to CD in many genome 
scans (38).
There are several possible mechanisms by which MT might play a role in CD. Deregulated 
MT levels in CD patients might indicate a hampered maintenance of free radicals produced 
during the inflammatory process. Anti-bacterial properties of MT could be important in the 
process of CD progression, as bacteria are considered to be involved in initiating and 
propagating the inflammatory process (39). We found evidence that the decreased epithelial 
MT level correlated with reduced secretion of the neutrophil chemokine interleukin-8 in vitro
upon stimulation (40). This observation was in accordance with the recent finding that IL-8 
up-regulation is impaired in response to acute trauma to the colon or skin of CD patients (41). 
We hypothesize that the intestinal epithelial cell lining of CD patients expresses less MT and 
initially secretes less IL-8 in response to bacteria. A delay in neutrophil accumulation might 
lead to the persistence of the exogenous stimulus and an exaggerated secondary and 
compensatory immune response. In a murine model for acute colitis, based on the oral 
administration of dextran sodium sulphate, the role of epithelial MT was further clarified by 
the more severe histological inflammation on day 3 in MT deficient mice as compared to wild 
type mice (24). Since colonic MT expression was restricted to the epithelium until day 3, this 
corresponds with an immunomodulating role for MT in the early phase of colitis. A more 
deleterious role of MT during the late phase of induction was suggested by the lower survival 
rate of wild type mice. Especially mice that were treated with zinc, which induces 
endogenous MT in the intestine, were at risk.
Serum zinc concentrations are often decreased in CD patients. This element plays an 
important role in the prevention of free radical formation and in protection of biological 
structures from damage (42). It was shown that dietary zinc causes an MT increase in all gut 
regions in rats (43;44). On the other hand, CD patients receiving a zinc supplementation 
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during 4 weeks did not change the concentration of MT in their plasma and erythrocytes (45), 
and the MT concentration in both inflamed and non-inflamed intestinal mucosa was only 
slightly higher. Histological inflammation scores of intestinal biopsies, plasma albumin levels, 
and the disease activity index of the patients did not change during the trial. Notably, in this 
study, only disease-inactive to moderately active patients were included. 
Next to Crohn’s disease, the inflammatory bowel diseases comprise ulcerative colitis. As 
opposed to Crohn’s disease, MT expression was not reduced in samples of ulcerative colitis 
patients without active inflammation. Active inflammation caused a decrease in epithelial MT 
expression and an increase in non-epithelial MT expression that was also noted in other 
intestinal inflammatory conditions (28). These findings emphasize that MT regulation is 
inflammation-dependent and future studies will be directed on the regulation and role of MT 
in inflammation. 
Metallothionein and cancer 
Immunocytochemically detectable MT overexpression was described in a variety of human 
tumours (21). However, the expression of MT is not universal to all human tumours, but may 
depend on their differentiation status and proliferative index. Metallothionein overexpression 
is associated with resistance to anticancer drugs and is combined with a poor prognosis. 
However, its use as a marker of tumour differentiation, cell proliferation and prognosis 
predictor remains unclear. On the other hand, gastric carcinomas and colorectal adenomas 
are apparently accompanied by a decreased expression of MT, however, those with a 
relatively high level seem to have an increased malignant potential (46).
Cell-type specific differential regulation of human MT genes was found in different cancer cell 
lines, correlating with DNA methylation and chromatin structure (see later) (47). Tumour cell-
lines arising from paraxial mesoderm and endoderm have MT2A and MT1E genes in fully 
inducible form and the MT1F in the refractory state (18). On the other hand, tumours 
originating from ectoderm, intermediate and lateral mesoderm exhibit MT2A and MT1F 
genes in inducible form and the MT1E gene in a refractory form.
Using 53 adherent cell lines of the National Cancer Institute (NCI) tumour panel, Woo et al. 
(48) studied the basal MT content and subcellular localization in human tumour cells with 
immunofluorescence and tried to correlate this basal MT phenotype to responsiveness to 
anticancer drugs. Among the cell types, they found a 400-fold range in the basal MT levels 
and a tenfold range in the ratio of nuclear to cytoplasmic (N/C) staining that was independent 
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of basal MT content. Ovarian- and breast-derived cell lines all had mean MT levels lower 
than the overall mean MT level. Approximately half of the cell lines had a karyophilic (N/C > 
1) phenotype, and tissue specificity of MT localization was observed with breast cancer cell 
lines, which were all seven cytoplasmophilic (N/C < 1), whereas the two tested prostate cell 
lines were karyophilic. Both basal MT levels and subcellular distribution appeared to be 
determinants of resistance to metal-containing compounds. 
Metallothionein, Alzheimer’s disease and amyotrophic lateral sclerosis 
Metallothionein 3 was first cloned as growth inhibitory factor (GIF), which showed a 
decreased RNA expression in Alzheimer’s disease (AD). Metallothionein 3 suppresses the 
neurotrophic activity present in the normal human brain (49). The down-regulation of MT3 in 
AD has been confirmed by two recent studies. In the first study, MT3 expression was 
determined in a large number of AD cases by qPCR as well as by immunohistochemistry and 
Western blotting (50). In the second study, DNA microarrays were used to compare RNA 
levels from control and AD hippocampal regions and found, amongst others, MT3 down-
regulation (51). However, Erickson and colleagues (52) disputed that neuronal changes in 
AD are related to a decrease in MT3, since they could not find a significant down-regulation 
in neither RNA nor protein expression in their AD population. There is more consensus on 
the overexpression of MT1 and MT2 in the astrocytes from AD as well as other neurological 
disorders (53-56). In the brain, astrocytes are the main source of MT1 and MT2, although 
other cell types, such as choroid plexus epithelia, endothelium and meningeal cells may also 
express these isoforms (57). In neurodegenerative diseases such as AD, astrocytes become 
abundant and activated in the affected areas. While in other organs, the main function of MT 
is related to zinc metabolism and protection against heavy metal and/or oxidative damage, 
the key role of MTs in the brain seems to be a protection in the cellular response to neuronal 
injury. It was suggested that the specific increase in MTs was associated with the initial 
stages of the disease process (54). The precise mechanisms downstream of MT have not 
been fully established, but convincing data showed that they are essential in dealing with 
neuropathology and for brain recovery in AD as well as other brain pathologies. MTs might 
even be used as therapeutic and/or preventive drugs for a range of brain disorders (57). 
Amyotrophic lateral sclerosis (ALS) is a progressive, invariably fatal neurological disease due 
to degeneration of the nerve cells responsible for controlling voluntary muscles. In ALS, 
motor neurons in the brain stem, spinal cord and motor cortex degenerate or die, ceasing to 
send messages to muscles. Consequently, the muscles gradually weaken, waste away, and 
twitch. Fifteen to 20% of cases of familial ALS are associated with mutations in the 
THESIS_ANOUK.indd   158 05-03-2009   10:59:08
chapter 4.3    mechanisms of MT gene regulation I 159
superoxide dismutase 1 gene (SOD1), an enzyme that converts harmful superoxide radicals 
into oxygen and hydrogen peroxide.
Elevated levels of MT have been found in spinal cord, kidney and liver of patients with ALS 
(58-60), but not in serum (60). A detailed study on MT isoform expression revealed no 
evidence for either the induction of a specific MT repertoire, or for the inability of glia to 
express any MT gene (61). Probably, the enhanced expression of MT in ALS reflects an 
early protective function. This was also concluded from a study on MT expression in mice 
carrying the SOD1 mutation (62). These mice were backcrossed with MT-knockout mice. The 
offspring reached the onset of clinical signs significantly earlier in response to the reduction 
of protein expression. These results indicated that the copper-mediated free radical 
generation derived from mutant SOD1 might be related to the degeneration of motor neurons 
in ALS and that MT might play a protective role against the expression of the disease (63). 
Recently, MT3 was screened for mutations in 20 patients with ALS, but no functionally 
relevant polymorphism could be associated with the disease (64).
Metallothionein, Menkes disease and Wilson disease 
Menkes disease is an X-linked, recessive disorder of the copper metabolism that occurs in 
less than 1 in 200,000 live births. The condition is characterized by early retardation in 
growth, peculiar hair, focal cerebral and cerebellar degeneration, skeletal abnormalities, and 
patient mortality in early childhood (65). Three independent research groups cloned the 
Menkes gene, a copper transporting ATPase, ATP7A, to the long arm of the X chromosome 
(66-68). A spectrum of mutations adversely affecting protein expression have been observed 
in severely affected Menkes patients (69). The genetic defect in Menkes syndrome leads to a 
progressive copper deficiency and copper-dependent enzymes fail in most tissues.
Using cultured fibroblasts, it was shown that low extracellular copper concentrations induce 
synthesis of MT in Menkes' cells but not in normal cells (70). Therefore, in the early studies 
on tissue abnormalities in Menkes disease, MT were believed to be involved in pathogenesis 
(71;72). Now, it is clear that a defect in efflux and consequently intracellular accumulation of 
copper, due to mutations in ATP7A, is responsible for this up-regulation in Menkes’ cells. As 
a result of accumulation of copper in the cell MTs are up-regulated, but they are as such not 
causative for pathogenesis in Menkes disease. In affected cells, copper accumulates bound 
to MT in the cytosol, while its transport to the organelles, as well as copper efflux, is 
disturbed. The low activity of metalloenzymes is believed to contribute significantly to the 
pathogenesis of this condition. 
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Wilson disease is an autosomal recessive disorder characterized by dramatic build-up of 
intracellular hepatic copper with subsequent hepatic and neurologic abnormalities. Copper 
toxicity occurs when the liver is overloaded and non-ceruloplasmin-bound copper is released 
into the bloodstream, from where it can diffuse into the brain. Today, the treatment of Wilson 
disease is no longer aimed at ‘decoppering’, the removal of accumulated copper, but at the 
normalization of the free copper concentration in blood, to reverse the copper poisoning. 
Therefore, new therapy is aimed at administration of zinc to these patients, because this 
increases MT expression and sequesters the excess of copper in the blood (73). 
HUMAN METALOTHIONEIN GENE REGULATION 
Because MT expression is involved in a number of pathological conditions, the transcriptional 
control of MT has become a major topic. Metallothioneins are induced by a wide variety of 
physiological and chemical agents like cytokines, metals, hormones, and stress in general 
(74). Furthermore, they are transiently induced after tissue injury caused by e.g. inflammation 
or irradiation (75). It is generally accepted that MT1 and MT2 genes are inducible, while MT3
and MT4 are constitutively expressed. Metallothionein 1 isoforms have a restricted and 
transient role, perhaps in the process of the cell cycle, in stress or during infection. On the 
other hand, MT2A is ubiquitously expressed, and plays a general role in cellular physiology, 
possibly in zinc metabolism. Metallothionein 3 is predominantly expressed in the central 
nervous system (49;61), but also in the kidney (76), prostate (77), retina (78), salivary glands 
(79) and reproductive system (80). The mouse MT4 is expressed in stratified squamous 
epithelium of the tongue (81), but there are so far no data on human MT4 expression. 
Most of the functional studies on MT transcription were performed in mice. However, in mice, 
MT1 and MT2 isoforms are co-ordinately regulated (82), while the human MT isoforms are 
regulated in a cell-type specific manner (24;83;84). This probably resulted in the adaptation 
of MT genes to more specific functions throughout evolution. Phylogenetic tree analysis of 
the promoter region of mouse and human MT isoforms shows that MT2, MT3 and MT4 
promoters are highly homologous between mouse and human (Figure 3), which might reflect 
their more strictly regulated expression pattern. Human MT1 isoforms are dispersed into two 
groups. Interestingly, these two clusters correlate to the physical location of the genes on 
chromosome 16. On the other hand, the mouse MT1 promoter region is relatively unrelated 
to the human MT1 group (Figure 3). It is thus plausible that regulatory regions in the mouse 
and human promoter have adapted differently. Therefore, care must be taken when 
evaluating MT expression and maybe even MT function in the mouse, when addressing 
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Figure 3. Phylogenetic tree analysis of the promoter regions of human and mouse MT 
isoforms.
Promoter regions are defined from nucleotides -800 to -1 relative to the transcriptional start site. 
questions related to human circumstances. Nevertheless, if common transcription factor 
binding sites are found in human and mouse promoters, extrapolation of the experimental 
data on mouse MT regulation is likely.
We performed a comparative study on the transcriptional control of MT in mice and humans, 
using in silico data of promoter transcription factor binding sites. Based on these common 
regulatory sites, we review the MT regulatory mechanisms. 
In silico analysis of human and mouse MT1 promoters 
Although marked sequence conservation exists, the RNA level for each MT isoform is 
unique. This is largely due to inherent differences in promoter regulatory sequences. 
Promoters are organized with a variety of elements that contribute to promoter function. The 
elements found in any promoter differ in number, location and orientation.
A difference distance matrix approach (85) was used to identify a set of transcription factor 
binding sites that are specifically present in following MT isoforms: MT1A, MT1B, MT1E, 
MT1F, MT1G, MT1E, MT1J, MT1M and MT1X (Table 2). Many of these binding sites and 
their transcription factors have been described in MT regulation, however, we found a 
number of unexplored regulatory regions. We next searched for these transcription factor 
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binding sites in the mouse MT1 promoter. In addition, well-known mouse MT1 promoter 
binding sites (USF, MLTF) were explored in the promoters of human MT1 isoforms. Below, 
we describe the involvement of these transcriptional regulators in more detail. 
Table 2. Transcription factor binding sites in 800 bp of the promoter of human and 
mouse metallothionein 1 isoforms 
Transcription
factor
MT1A MT1B MT1E MT1F MT1G MT1H MT1J MT1M MT1X mMT1 
basal TBP + + - - + - - - + + 
TFII-I 2 2 1 3 1 2 2 4 0 1 
Sp1 5 1 1 8 5 2 2 4 3 3 
AP2 0 1 1 1 1 3 1 0 0 0 
USF/Nrf2 0 0 0 0 1 0 0 0 0 1 
induction ChCh 9 3 6 8 6 5 8 9 5 3 
HELIOS 2 8 2 6 6 7 4 3 9 3 
E2F 3 0 4 4 3 2 6 5 3 3 
Spz1 4 4 5 4 2 5 3 6 1 2 
Egr_1 4 0 3 5 0 0 3 8 4 1 
GR 1 1 6 0 0 3 1 2 2 3 
STAT 1 0 4 2 1 1 1 1 2 0 
MTF1 2 4 1 5 2 5 2 2 3 3 
RAR-a 2 5 1 5 3 3 3 2 3 3 
repression ETF 6 2 3 9 6 2 6 6 6 4 
NFI 1 0 1 3 4 2 1 2 2 4 
The number of hits as found by MatchTM  (TRANSFAC PRO 8.4) using a core matrix match of 100% and a matrix 
match of 85%. Exceptions are IL6RE and MLTF for which consensus sequences were used in combination with 
PatchTM (TRANSFAC PRO 8.4). The Match procedure introduces false positives; therefore, the number of hits 
listed is an overestimation of the real hits. The MT isoforms with TBP consensus sequences located close tot the 
transcription start site are denoted with a plus (+). Those that do not contain a TBP close to the transcription start 
site are denoted with a minus (-). mMT1= mouse MT1 
Basal expression 
RNA polymerase II is responsible for transcribing genes coding for messenger RNA (mRNA). 
The first step in transcription is the binding of the TFIID complex to a region upstream of a 
sequence called the TATA box. The TFIID complex consists of the TATA-binding protein 
(TBP) and TBP-associated factors (TAF). The location of the TATA box with respect to the 
start point is relatively fixed, usually located ~25 bp upstream of the transcriptional start site. 
Therefore, TATA box consensus sequences located further upstream are probably not 
functional.
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Metallothionein 1E, MT1F, MT1H, MT1J and MT1M contain TATA-less promoters. This could 
partly explain the observation that the MT1G promoter is five times more active than the 
MT1F promoter in transfection studies (86;87). GC boxes, common promoter components 
involved in basal transcription, are frequently found in MT promoters, often clustered together 
close to the start site. It has been proposed that the Sp1 factor binds to multiple GC boxes, 
resulting in an interaction of GC box-bound Sp1 factors with each other to synergistically 
stimulate transcription. Furthermore, basal level enhancer sequences, binding activator 
protein-2 (AP2), are found in some human MTs, but not in the mouse MT1. TFII-I binds 
specifically to initiator elements (Inr), supporting basal transcription. An E box, binding the 
upstream stimulatory factor (USF) was only found in the mouse MT1 and the human MT1G. 
It was shown that TFII-I also binds to upstream E box, and that TFII-I and USF interact co-
operatively at both Inr and E box sites (88). The USF sequence overlaps with an antioxidant 
response element (ARE). These AREs are usually found in genes responsive to free 
radicals, through interaction of ARE with NF-E2-related factor 2 (Nrf2). However, this 
sequence is only found in the mouse MT1 and human MT1G, suggesting that they might be 
more responsive to free radical exposure. Nevertheless, response to oxidative stress can 
also be mediated by metal responsive elements (MRE) in the promoter (89). MREs are 
recognized by the MRE-binding transcription factor 1 (MTF1), and are classically required for 
metal induction of MTs (see below). Nevertheless, they also participate in basal transcription. 
Indeed, the basal expression of MT is highly correlated to the activity of MTF1 (90). 
Furthermore, we have recently shown that basal MT levels in whole blood vary considerably 
between individuals, but they correlate well with MTF1 expression (24).
Inducible expression 
Metal induction. Metallothionein 1 and MT2 isoforms are highly inducible by many metal ions, 
including zinc, cadmium, bismuth, mercury, copper, nickel and cobalt.  The concentration of 
metal ions to induce MTs depends on the type of ion and MT isoform. Metallothioneins are 
capable of binding most of these elements, however, they do not bind nickel and cobalt. The 
transcriptional regulation responsible for this metal induced expression, is controlled by 
MREs, present in the promoter of MT as multiple, non-identical copies. The mouse and 
human transcription factor that binds to these MRE elements is the MRE-binding 
transcription factor 1 or MTF1. When this factor was first cloned (91), it was shown that the 
human MTF1 was more effective than the mouse equivalent. MTF1 is absolutely necessary 
for both basal and metal inducible MT expression (92). Moreover, although MTF1 is activated 
by a number of metals, it absolutely requires zinc for its activity. It was hypothesized that 
inducing non-zinc metals can displace zinc from its storage proteins, resulting in a pool of 
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free zinc available for activation of MTF1 (93). These storage proteins could be MT itself, 
leading to a complex feedback interaction between MTF1 and MTs.
Interestingly, treatment of cells with cadmium increases MT expression, although it does not 
influence the DNA binding activity of MTF1 to the MRE. This suggests that additional 
mechanisms play a role in metal induction. For example, cadmium induces oxidative stress, 
which could activate binding of USF to the E box. Alternatively, as stated before, cadmium 
might replace the intracellular zinc in storage proteins, which results in more free zinc to 
activate MTF1. Recently, it was shown that cadmium induction of MT1 and MT2A mRNA 
isoforms in human thyroid carcinoma cells is mediated through ERK signalling, and is 
dependent on intracellular calcium rise (94). The responses of each individual MT isoform is 
not identical, reflecting the different transcriptional regulation of isoforms. 
In addition, posttranslational modification of MTF1 has been shown. Phosphorylation of 
MTF1 plays a critical role in its activation by zinc and cadmium (95). Several phosphorylation 
sites are present throughout the complete MTF1 protein. This was thought to be mediated 
through a complex pathway involving protein kinase C, tyrosine kinase, and casein kinase II.
Stress and inflammation mediated induction. Similar to acute phase proteins, MT is induced 
by inflammation, bacterial infection and stress. Stress in general often results in the synthesis 
of glucocorticoid hormones, resulting in the suppression of inflammation and an increase in 
blood sugar levels. These steroid hormones are synthesized by the adrenal gland, and can 
enter the cell by simple diffusion. Within the cell, it binds to its receptor, the glucocorticoid 
receptor (GR), which in turn gets activated and translocates to the nucleus. There, it has high 
affinity for a consensus sequence called the glucocorticoid response element (GRE), and 
activates transcription from MTs and other GRE containing genes. Glucocorticoid hormones 
have been known for a long time as inducers of MT (96;97). The human MT2 gene contains 
one GRE, while the mouse MT1 and MT2 genes contain two tandem copies ~1kb upstream 
of the MT2 gene and ~7 kb of the MT1 gene (98). In humans, MT2A is significantly more 
inducible by glucocorticoids as compared with MT1 isoforms (83). It was shown that 
dexamethasone, a synthetic glucocorticoid agonist, appears to have no significant effect on 
the expression of MT1F (84). This can be explained by the fact that there is no GRE 
sequence in the promoter of MT1F. 
During acute inflammation, such as after tissue damage or during infection, macrophages are 
recruited and activated to the site of inflammation. They secrete pro-inflammatory cytokines 
such as IL6, TNF, IL1Į and IL1ȕ. These cytokines are able to induce MT (99). Fast MT up-
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regulation after challenge with IL1 is probably mediated through glucocorticoids (100). 
Interleukin 6 is one of the most potent inducers of MT (101). Metallothioneins have IL6 
response elements (IL6RE) in their promoter. These DNA stretches bind STAT transcription 
factors. A synergistic effect was demonstrated between IL6 and glucocorticoid in MT 
induction (102), which is possibly mediated by the close proximity of the GRE and the IL6RE 
in the MT promoters.
Interestingly, it was reported that MTs inhibit the release of pro-inflammatory cytokines 
(103;104). This could be explained by the regulatory role of MT in NF-țB activation (5). 
Cell cycle. Metallothionein expression appears to be cell cycle dependent, and is used as a 
marker for cell proliferation (21). A tenfold rise of MT synthesis was described in 
exponentially growing human hepatocytes (105;106), and peaks of MT expression were 
found in late G1 and G1/S transition in HT29 epithelial cells (105). Similarly, in placental 
tissue, positive immunostaining for MT was found only in trophoblast and proliferating cells 
(107). We have recently described that MT expression in the intestine was most apparent in 
the rapidly proliferating cells of the crypts (24). Moreover, it was suggested that MT 
transcription is altered by the differentiation process. Indeed, it was shown that the 
differentiation of teratocarcinoma cells using retinoic acid is associated with a rise in MT 
expression. Retinoic acid receptors (RAR) are nuclear receptors related to the steroid and 
thyroid hormone receptors, a family of proteins that functions as ligand-dependent 
transcription factors. Retinoic acid is a regulator of differentiation at various stages of 
vertebrate embryogenesis. In accordance, multiple RAR receptor binding sites are found in 
human and mouse MT1. However, whether this codependence is initiated by MTs is not 
known: is the overexpression of MT in many tumors the cause of cell cycle progression, or is 
a rapid cell growth causing MT to be highly expressed? 
Although MT expression is generally cytosolic, nuclear translocation has been observed at 
G0/G1 to early S-phase (108). This nuclear and cytoplasmic localization of MT was also 
observed in several tumours, especially in regions of high proliferation. Moreover, antisense 
down-regulation of MT1 in endothelial cells resulted in the cell cycle arrest at the G1 phase 
(109), and cell growth was inhibited in MT1 antisense tumor cells (110). Hesketh and 
colleagues have shown that the nuclear translocation is determined by the 3’ untranslated 
region of MT1 (111). Recently, they identified a 11 nucleotide sequence in the 3’UTR, 
containing a CACC repeat, that is necessary for the nuclear translocation of MT1 (112).
In the human and mouse MT1 promoters, potential binding sites for the E2F transcription 
factor are present. This transcription factor is a critical determinant of the G1/S-phase 
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transition during the mammalian cell cycle, serving to activate the transcription of a group of 
genes that encode proteins necessary for DNA replication. In addition, E2F activity appears 
to be directly regulated by the action of retinoblastoma protein (Rb). Human DP-1 and E2F-1 
associate both in vivo and in vitro, and this interaction leads to enhanced binding to E2F 
DNA-binding sites (113). The association of E2F-1 and DP-1 leads to co-operative activation 
of an E2F-responsive promoter. It was also demonstrated that trans-activation by E2F-1/DP-
1 heterodimers is inhibited by RB. Nevertheless, the actual binding of E2F to MT promoters 
needs to be determined.
The nuclear need for MT at specific stages of the cell cycle might point towards a critical 
function of MT in regulating metalloproteins, or protection from DNA damage and apoptosis 
(114).
Development. Metallothionein expression is tightly regulated and activated during 
mammalian embryonic development, with high levels of MT1 and MT2 mRNA in both 
maternal and fetal liver, and the visceral yolk sac (115). During early development of the 
mouse embryo, expression of MT1 is induced specifically in the endoderm cells of the 
visceral yolk sac (116). It was shown that MTF1 is absolutely essential for up-regulation of 
MT1 gene expression in visceral endoderm cells and that optimal expression also involves 
the binding of USF to the promoter. Only the human MT1G promoter contains an E box, 
therefore, it is not known whether the human USF binding is necessary in development.
Inhibition of transcription 
Contrary to the activation of MT expression, their down-regulation by cis-acting events has 
not been extensively studied. However, a reduced expression has been frequently found in 
many types of cancers and in CD. Three factors are probably involved in suppression of MT: 
nuclear factor 1 (NFI), ZBTB11 and EGFR-specific transcription factor (ETF). Overexpression 
of NFI in human hepatoma cells suppressed both constitutive and metal induced activation of 
the MT1 promoter (117). NFI binds to an MRE-c’ sequence in the mouse promoter (118). NFI 
sites are present in the mouse and all human promoters except MT1B. One study reports a 
120 kDa zinc finger protein (PZ120) repressing the transcription of the human MT2A gene by 
binding to its transcription initiation site (119). The PZ120 gene is now replaced in the NCBI 
database as the zinc finger and BTB domain containing 11 (ZBTB11). So far, no additional 
reports describing this transcription factor were published since. ETF is present in all MT 
isoforms, and has not been described in the context of MT inhibition. Overexpression of this 
factor in primate kidney CV1 cells showed that it represses expression originating from both 
the EGFR and beta-actin gene promoters (120).
THESIS_ANOUK.indd   166 05-03-2009   10:59:14
chapter 4.3    mechanisms of MT gene regulation I 167
The influence of environmental factors on MT expression was illustrated by the inhibition of 
zinc induced MT induction by chromium, a major environmental carcinogen (121). This 
inhibition was working through interfering with MTF1. Treatment of mammalian cells with 
cycloheximide, a protein synthesis inhibitor, resulted in increased MT1 transcription (122). 
Recently, the presence of a labile inhibitor of MT1 expression was suggested (123). This 
repressor negatively controls agonist-induced turnover of the MTF1 protein. 
Promoter methylation 
Methylation of cytosine residues in promoter sequences is generally associated with a low 
transcriptional level of the respective gene. In mammals, methylation is mainly found within 
so-called CpG islands, regions of high CG content, thought to be involved in transcriptional 
regulation. The general rule is that CpG islands are not methylated, except for genes on the 
inactive X chromosome and at imprinted loci. Generally, to study the methylation status of a 
gene in a cell line or in tissue, its expression is correlated to the amount of methylated CG 
dinucleotides in genomic DNA isolated from the same source. If a correlation is found, e.g. 
low gene expression and a hypermethylation of the CpG island, the cells or tissue specimens 
are subjected to a demethylation agent, such as 5-azacytidine. If the demethylation results in 
an increased expression of the gene, a role for methylation in expression regulation of the 
gene is established. 
Rodent and human MT genes contain a CpG island in their promoter. Tissue specific 
methylation of MT1B has been demonstrated (124). The MT1B gene is only expressed in 
human hepatoma and renal carcinoma cell lines, and not in HeLa cells, where the 5' flanking 
region of MT1B is highly methylated. MT3 hypermethylation has been shown in gastric 
cancer (125) and in oesophagal squamous carcinoma (126). 
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CONCLUSION
The persistent differential expression of MTs in stress reaction and in pathological conditions 
suggests a strict regulation of these proteins. It is plausible that a change in e.g. cell cycle 
regulation of MT could influence cancer development. In addition, cell-type specific 
expression of MTs may indicate a divergence in functions within cell types or organs. For 
instance, disability of the tightly controlled proliferation of stem cells in the intestinal crypts 
may render individuals more susceptible for developing colon cancers. Similarly, a disturbed 
immune balance in the intestine due to changes in MT expression could be a prerequisite for 
CD. Our in silico search for transcriptional regulatory regions in the MT promoters revealed 
new potential targets that could help to unravel some of the MT regulatory mechanisms. 
Future studies on the expression and regulation of MT genes are likely to provide insights to 
their role in both health and disease. Ultimately, novel strategies for manipulating intracellular 
MT levels could lead to new therapies, and are already being investigated for the treatment 
of skin wounds (127), rheumatoid arthritis (128), central nervous system injury and disease 
(129), and diabetes-induced organ dysfunction (130). 
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Inflammatory bowel diseases (IBD), comprising Crohn’s disease and ulcerative colitis, are 
characterised by chronic, non-specific inflammation of the gastrointestinal tract. Conventional 
therapy for IBD mostly entails lifelong treatment with systemically administered medications, 
which exhibit possible side effects. Much research has been conducted on the pathogenesis 
of IBD in order to design new therapeutic strategies (chapter 1). Although a clear 
involvement of environmental triggers exists, especially bacteria, the most important 
progress has been made in the field of genetic risk factors. During the last few years, 
polymorphisms in several genes have been associated with IBD, especially with Crohn’s 
disease where the genetic component is the strongest. The relevance of most of these 
polymorphisms is just starting to be explored, but has already provided a critical turn of the 
focus on IBD research.
For years, studies have been concentrating on the role of the adaptive immune system in the 
pathogenesis of both Crohn’s disease and ulcerative colitis. However, with the identification 
of NOD2/CARD15 as the first susceptibility gene for Crohn’s disease, much interest has 
been dedicated to the role of the innate immune system. More recently discovered 
polymorphisms highlight the importance of innate immunity in the dysregulated host-bacterial 
interactions implicated in the pathogenesis of IBD. In this regard, two theories have evolved. 
The first one states that an exaggerated innate response and a loss of tolerance for the 
commensal intestinal microflora are caused by defective down-regulation of pattern 
recognition receptor (PRR) signalling. The second theory encompasses a defective innate 
immunity originating from failure of recognition of bacterial threats or an ineffective response, 
which results in persistence of the exogenous stimulus and an exaggerated secondary 
immune response (1). In the innate immune system, the intestinal epithelial cell lining has 
received more and more interest as it became clear that these cells exert an important role in 
the identification of bacteria and the appropriate counteraction. Furthermore, the epithelium 
must also maintain a physical barrier between the lumen and the underlying mucosa. Defects 
in the mucus layer, integrity, and permeability are found in IBD and are thought to have direct 
implications on disease initiation and/or progress. Many of these findings emanate from 
animal models of IBD that, although never representing human disease entirely, can shed 
light on several aspects of the disease and thus help to uncover its pathogenesis, piece by 
piece.
The research that was conducted in this thesis focussed on two topics that were related to 
the defective mucosal barrier in IBD. The first topic focussed on the mechanism of action of 
therapeutic interleukin (IL)-10 producing bacteria related to their interaction with the 
chapter 5    general discussion I 179
THESIS_ANOUK.indd   179 05-03-2009   10:59:21
180 I  chapter 5    general discussion
damaged barrier. In the second part, the metallothioneins, which can be considered 
immunomodulatory proteins, were studied in different human and animal inflammatory 
conditions.
Interaction with therapeutic bacteria 
Genetically modified Lactococcus lactis bacteria secreting IL-10 were developed in order to 
provide a local mucosal delivery of IL-10. The principal function of this cytokine is to contain 
and eventually terminate inflammatory responses by suppressing the expression of 
proinflammatory cytokines, chemokines, adhesion molecules, and antigen-presenting and 
co-stimulatory molecules in monocytes/macrophages, dendritic cells, neutrophils, and T cells 
(2). The fact that IL-10 is an essential immune modulator in the intestinal tract was supported 
by the observation that IL-10-deficient mice spontaneously develop a chronic enterocolitis, 
histologically characterised by infiltration with inflammatory cells, mucus cell depletion, and 
architectural crypt distortion (3). Studies in animal models of IBD showed that systemic IL-10 
administration was successful in preventing intestinal inflammation and established the base 
of its use as a therapeutic agent in IBD (4-6). However, these positive results could not be 
achieved in human trials (7-9). This was likely due to the low bioavailability of injected IL-10 
in the gastrointestinal tissues and in its short half-life in the circulatory system. Although safe 
and well-tolerated at multiple tested dosages (10), increasing the dose of systemically 
administered IL-10 was not possible because of side effects probably mediated by interferon-
Ȗ induction (11;12). Attempts to provide a local mucosal delivery of IL-10, including gene 
transfer (6;13), gelatine microspheres (14), and active synthesis in situ by Lactococcus lactis
bacteria (15), proved to be more efficacious. Most advances have been made with the last 
approach, which is currently the subject of further development and commercialisation in the 
VIB-UGent spin-off company ActoGeniX as its lead product AG011. After being successfully 
tested in a phase 1 clinical trial with Crohn´s disease patients (16), clinical-grade AG011 has 
recently been produced and formulated. ActoGeniX has initiated a multicentre phase 2A 
study in ulcerative colitis patients in Europe and North America and also plans a phase 2 
study with the same product in Crohn´s disease patients in 2009 (17;18). 
The exact mechanism by which IL-10-producing L. lactis mediates a beneficial response on 
the mucosa is mostly unknown. Since local delivery of the cytokine in the tissue seems 
primordial, we focused on the in vivo interaction of the bacteria with intestinal murine mucosa 
and observed differences between an intact and an inflamed (damaged) epithelial barrier 
(chapter 3, figure 1). In healthy intestinal tissue, transmission electron microscopy showed 
an occasional transcellular uptake in follicle-associated epithelium, similar to the recently 
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Figure 1. Interaction of the mucosal barrier with therapeutic bacteria. (adapted and adjusted 
from (19))
In healthy intestinal tissue, IL-10 producing L. lactis only occasionally enter the mucosa through transcellular 
uptake in follicle-associated epithelium and possibly through dendritic cell sampling (left). In inflamed mucosal 
tissue, the damaged mucosal barrier causes an enhanced uptake of bacteria, resulting in the presence of viable 
and IL-10 producing L. lactis in the lamina propria, close to responsive immune cells (right). IL-10-producing        
L. lactis probably modulate CD4+ T cell function indirectly via down-regulatory effects on DCs. 
reported uptake of non-pathogenic bacteria (20). We also recognised transepithelial 
dendrites close to luminal lactococci, suggestive of dendritic cell (DC) sampling (21), but we 
found no arguments for sampling by M cells. In inflamed mucosal tissue, both confocal and 
electron microscopic analysis suggested an enhanced uptake of lactococci through the 
paracellular route leading to an accumulation in the lamina propria. This enhanced uptake is 
likely to be a result of the damaged mucosal barrier, a feature that, as pointed out earlier 
(chapter 1), is also characteristic of human IBD. We were able to show the presence of 
viable and IL-10 producing lactococci in ileal and colonic tissue of which the epithelial layer 
was removed, thus providing evidence that these bacteria are capable of entering inflamed 
intestinal mucosa and delivering IL-10 in the lamina propria. The absence of lactococci in 
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mesenteric lymph nodes or in the spleen exclude a systemic circulation of the bacteria, being 
safe for administration in patients. 
The results of our study correspond with earlier studies that detected small amounts of IL-10 
in intestinal tissue homogenates (15). No IL-10 was detected in the lumen in those studies. 
Together with arguments that the bacterial context of IL-10 presentation seems necessary for 
the therapeutic action of the IL-10 producing lactococci (16), our data prompted us to 
formulate the hypothesis that an important source of the IL-10 acting as a therapeutic on the 
mucosa is produced by those bacteria that have entered the nutrient-rich mucosa. The 
production of IL-10 in the lumen followed by diffusion to responsive cells in the epithelium or 
the lamina propria may not be excluded as a mechanism, but the effect of the latter may not 
be as considerable as IL-10 production directly in situ in intestinal tissue, in the close 
proximity of responsive cells.
Future perspectives 
Our study only addresses a small aspect of the therapeutic mechanism of IL-10-producing L.
lactis. Further investigation on the downstream targets of IL-10 in the mucosa is/was carried 
out by the group that designed the bacteria. They found that DCs that were exposed to IL-10 
producing L. lactis and maturation factors could strongly suppress the proliferation of 
responder CD4+ T cells (22). Therefore, it is reasonable to presume that However, other 
cellular targets may not be excluded. It is well-known that IL-10 suppresses the expression of 
proinflammatory cytokines and chemokines in monocytes/macrophages and neutrophils as 
well. Furthermore, IL-10 has direct effects on T cells through its regulatory functions, down-
regulating antigen-specificity in T-effector responses (2). All these pathways could lead to the 
down-regulation of an intestinal proinflammatory T-cell response, which was observed in 
experimental colitis (4-6). 
Roles for metallothioneins as immunomodulators (figure 2) 
Genetically-determined abnormalities at the mucosal level are a critical hallmark of gut 
inflammation in IBD, particularly in Crohn’s disease. By integration of transcriptome analysis 
of unaffected colon biopsies with previously-documented susceptibility loci, we identified 18 
potential new candidate genes for Crohn’s disease (chapter 4.1). Two of these genes, MT1F
and MT1M, belong to the metallothioneins (MTs). With attributed antioxidant and 
antibacterial functions and as keepers of zinc homeostasis, this family of highly-conserved 
proteins promised to be possibly relevant in the pathogenesis of Crohn’s disease. Although 
some studies have already examined the expression of MTs in IBD over the last 20 years, no 
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consensus has been reached on their expression pattern. The majority of studies report a 
down-regulation in either Crohn’s disease, ulcerative colitis, or both (23-28), but others 
described elevated MT levels (29;30). Furthermore, all of these studies used affected tissue, 
from mildly to severely inflamed, and as such give no information about whether aberrant MT 
expression is a primary, aetiopathogenic event, or an inflammation-dependent event. 
In order to clarify these two issues, we first studied both mRNA and protein expression of 
MTs in Crohn’s disease in detail. We performed a detailed analysis of the inducible mRNA 
expression of MT1 and MT2 isoforms on endoscopically normal colon biopsies and blood 
leukocytes of patients with Crohn’s disease and healthy controls. We found a significantly 
lower expression of MT1M in Crohn’s disease colon tissue and of MT1F in Crohn’s disease 
blood leukocytes, predominantly in patients with colonic disease involvement. The significant 
correlation between the expression of MT1M mRNA and the other isoforms tested implies 
that the inducible MTs are basally down-regulated in Crohn’s disease patients as a group. 
This makes the chance that polymorphisms are the cause of MT down-regulation unlikely, 
since finding polymorphisms in all of these MT genes is not likely. Furthermore, we found no 
defective MT induction in peripheral blood mononuclear cells from Crohn’s disease patients. 
This suggests the involvement of an upstream regulator of MT expression, which might be 
found in the presence of a transcription factor since the promoter region of MT isoforms is 
duplicated during evolution. The unaffected MT expression in other cell types, such as 
fibroblasts and macrophages (see next), suggests that this upstream regulator acts 
differently in different cell types. 
An immunohistochemical study of ileal and colonic tissue samples demonstrated a reduced 
expression of MT in epithelium of unaffected Crohn’s disease samples as compared to 
normal controls. To study the functional consequences of this reduction, we created an MT-
deficient HT-29 colonic cell line with small interfering RNA. Challenges with invasive bacteria 
resulted in a significantly lower secretion of IL-8, a potent chemokine for neutrophils, 
compared with control cells. This observation is in accordance with the recent finding that IL-
8 up-regulation is impaired in response to acute trauma to colon and skin of Crohn’s disease 
patients (31). These results suggest that a decreased MT expression causes disturbed cell 
migration, which could lead to a defective acute inflammatory response in Crohn’s disease. 
We have preliminary data showing that a decreased epithelial MT level is also associated 
with the decreased secretion of another chemokine (granulocyte-macrophage colony-
stimulating factor) and with impaired chemoattraction of neutrophils (32). 
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Figure 2. Roles for metallothioneins as immunomodulators in intestinal inflammation.
(adapted and adjusted from (19)) 
The intestinal mucosa of a patient not suffering from Crohn’s disease (left) shows a moderate to high expression 
of MTs in the epithelium (1). Epithelial MT might have an antibacterial function or might be involved in the 
chemotaxis of neutrophils. During the course of inflammation, MT-positive fibroblasts appear in the lamina 
propria, where MT possibly protects the cells against the oxidative inflammatory environment. An inflammation-
dependent decrease in epithelial MT is observed, which could be mediated by TGF-ȕ, found to be increased in 
inflammatory cells near the epithelium in actively inflamed mucosa (2). The intestinal mucosal barrier of a Crohn’s 
disease patient (right) is found to be damaged as a result of multiple defects (discussed in chapter 1). Deficient 
epithelial MT expression can be added to these defects. This deficient expression could result in a reduced 
antibacterial function or a reduced chemotaxis-modulating function of MTs, further impairing bacterial clearance 
and the acute immune response. These defects in innate immunity can result in activation and accumulation of 
pathogenic CD4+ T cells that mediate chronic intestinal inflammation. 
Further evidence for the involvement of inducible MTs in the acute immune response was 
found in in vivo experiments with MTnull mice, which lack MT1 and MT2 expression. A time 
course study of DSS-induced colitis taught us that MTnull mice showed a significantly more 
severe histological inflammation in the early phase of colitis compared with wild type mice. 
We attribute this difference to epithelial MT, since colonic MT expression is restricted to and 
even mildly up-regulated in the epithelium the first days after the start of colitis induction. 
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Thus, we hypothesize that MTs have an immunomodulatory role in the early intestinal 
immune response.
The down-regulation in the epithelium observed later in the course of experimental colitis, 
when the inflammatory infiltrate and the granulation tissue appeared, was also noticed in 
human samples of ulcerative colitis, acute infectious enterocolitis, diverticulitis, and 
ischaemic intestinal inflammation (chapter 4.2). In those samples, as opposed to samples of 
Crohn’s disease patients, histologically normal regions showed an epithelial MT expression 
comparable with normal control tissue. This expression was highest in the ileum and in 
epithelium of crypts and the base of the villi, which are the regions where antibacterial 
properties are most critical. Therefore, a possible function of MTs in epithelial cells might be 
related to their antibacterial properties (33). Support for a non-cell-cycle related function is 
the fact that this MT expression pattern did not correlate with proliferation. 
The inflammation-dependent down-regulation in the epithelium is probably a reflection of the 
different events occurring during an immune response. It is, however, surprising that 
(epithelial) MTs are down-regulated during inflammation, since it is known that 
proinflammatory cytokines and reactive oxygen intermediates, which are produced during 
inflammation, rapidly induce MT expression (34). We found that transforming growth factor 
(TGF)-ȕ, one of the few inhibitors identified for MTs (35), could decrease epithelial MT 
expression in a dose-dependent manner in ex vivo experiments. TGF-ȕ is a good candidate 
for epithelial regulation in inflammation, since this pleiotropic cytokine was increased in 
affected mucosa from patients with active intestinal inflammation. The highest concentration 
was found in inflammatory cells near epithelial cells (36). Furthermore, epithelial cells bear 
the TGF-ȕ receptor (37). 
Contrary to the decrease in the epithelium, an increase in MT-expressing cells occurs in the 
lamina propria during inflammation. While in normal conditions and during inflammation 
some mildly positive macrophages are present in the lamina propria, the inflammation-
related increase is predominantly caused by strongly MT-expressing fibroblasts of the 
granulation tissue. The granulation tissue consists at least partially of activated 
myofibroblasts. Double stainings with the myofibroblast marker SMA showed that the 
majority of MT positive spindle cells were negative for this marker. These MT positive 
fibroblasts probably present a subset of this cell type which is known to have different 
possible phenotypes during physiologic and pathologic conditions (38). MT positive 
fibroblasts have also been noticed by other research groups in human chronic gastric and 
small intestinal ulcers (39). The allocated functions for MTs in these cells were either a 
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cytoprotective or a proliferation-dependent role. Since we did not find a correlation with 
proliferation in our study, we are inclined towards a cytoprotective role that would be 
beneficial for host cells in the inflammatory environment which is rich in free radicals. 
Taken together, the results presented in chapters 4.1 and 4.2 reveal two major findings. First, 
a genetically-determined impaired epithelial expression of MTs could provide a possible 
aetiopathogenic mechanism in Crohn’s disease. Second, MT expression is differentially 
regulated in intestinal epithelium and granulation tissue during a ‘normal’ inflammatory 
reaction. In chapter 4.3, we reviewed the regulation of MT expression and gave an overview 
of known aberrant MT expression in diseases. The existence of several MT isoforms 
complicates MT research, especially on the protein level since these different isoforms are 
indistinguishable by the antibodies currently available. Their high homology makes it even 
hard to design specific primers or probes for the detection of different mRNA isoforms. 
Nevertheless, it is at this level that differential expression and regulation of MT isoforms are 
recently being elucidated. Metallothioneins are induced by many cytokines, metals, and 
hormones, and their promoters contain several regulatory sequences. We performed an in
silico analysis of transcription factor binding sites of the mouse and human MT1 promotors. 
Based on these common regulatory sites, we reviewed the MT regulatory mechanisms. 
As noticed earlier, the down-regulation of several MT isoforms indicate that an upstream 
regulator of MT expression is responsible for the impaired expression in Crohn’s disease. 
Hence, transcription factors of MTs are good candidates to study in this disease. Actually, 
our group has preliminary data that a polymorphism in the MTF1 gene, located within the 
susceptibility locus IBD7 and coding for an important transcription factor of MTs, is 
associated with disease location in Crohn’s disease. Furthermore, this polymorphism showed 
less transactivation potential in an in vitro reporter assay (40). 
Future perspectives 
Revealing the cell-type specific regulation of MT expression in the inflammatory course and 
in Crohn’s disease will be an interesting challenge for our future research. First of all, further 
analysis of MTF1 and other upstream regulators of MT expression will hopefully reveal the 
cause of genetically-determined impairment of epithelial MT expression in Crohn’s disease. 
Examination of the methylation status of the MT promoters is an alternative mechanism we 
will investigate, given the appearance of tissue specific MT methylation and the hereditary 
properties of these modifications. On the other hand, we will attempt to find the regulator that 
causes the inflammation-dependent epithelial MT decrease. A parallel inflammation-
dependent decrease of a transcription factor (such as MTF1) might be a possible 
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mechanism. Recognized inhibitors of MT induction are possible candidates, but this regulator 
may presently be unknown to influence MT expression. Besides further exploring the role of 
TGF-ȕ, we will test other regulatory cytokines or molecules that are expressed during 
inflammation. Especially those that are known to be expressed near or by the epithelium are 
attractive. Parallel induction studies in fibroblasts will have to be carried out to find out 
whether the regulation of MTs is cell-type specific or the reflection of a site-specific 
distribution of MT regulator(s) in the inflamed mucosa. In addition, examining MT expression 
in inflammatory disorders in other organs might shed more light on their regulation in 
inflammation in general. It would be interesting to know if the pattern we observed is specific 
for the intestine (which harbours numerous bacteria in its lumen) or not. For this purpose, 
immunohistochemical stainings for patient groups with inflammatory disorders in other 
organs will be repeated, and if a group shows inflammation-dependent MT immunoreactivity, 
we could then try to induce a corresponding experimental model in MTnull mice. 
A weakness in the immunohistochemical studies is that we cannot with full certainty state 
that the immunoreactivity of the antibody used is a reliable measure for MT protein 
expression, given the possibility that the immunodominant epitope of MT is destroyed by 
oxidation in the local oxidative/inflammatory environment. We will test the susceptibility of the 
epitope to oxidation by subjecting recombinant MT protein to oxidative reagents and 
subsequently analyzing antibody-binding in ELISA. 
The function of MTs in the epithelium and in fibroblasts is very intriguing. While the normal 
high expression of MTs in ileal epithelium might reflect a cytoprotective/antibacterial role in 
this part of the intestine that tries to keep bacterial numbers low as opposed to the colon, 
these same cytoprotective functions should provide a benefit in an inflammatory 
environment, and thus an up-regulation is expected. The observed down-regulation 
insinuates that epithelial MTs could possess a different function. Again, this function might be 
explained by the observed influence of the epithelial MT level on the secretion of IL-8 (and 
maybe other chemokines). In the acute anti-bacterial response, a quick and sufficient 
recruitment of innate immune cells, especially neutrophils, is necessary. Later on, the 
immune response is down-regulated and thus a decrease in MTs could help to reduce the 
chemoattractant activity of the epithelium and the influx of neutrophils. The involvement of 
MTs in chemotaxis will be further elaborated in vivo in an infectious colitis model. The 
expression of MTs will be examined by immunohistochemistry and quantitative PCR during 
the course of the infection-induced inflammation. We will assess disease activity, histological 
inflammation, bacterial colonization, neutrophil activity, and chemokine production in MTnull 
mice and compare these parameters with those of wild type mice. We will also try to 
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establish the role of MTs in fibroblasts. Although a cytoprotective role seems obvious in 
these cells, studies on the relation between the MT-level and a possible anti-oxidant capacity 
of fibroblasts are necessary to prove this hypothesis. Furthermore, we should examine 
whether different MT levels could have effects on the chemokine release of fibroblasts. We 
will study chemokine secretion of both epithelial cells and fibroblasts upon stimulation ex vivo
in isolated intestinal epithelial cells and fibroblasts of MTnull and WT mice. The ultimate 
model to study the role of MTs in these different cell types would be conditional and tissue-
specific gene-knockdown mice, which we could then subject to experimental colitis. 
The mechanism of the modulating effects of MTs on IL-8 secretion is an interesting issue and 
certainly material for future investigations. Could it be found in the anti-oxidative and/or zinc-
binding capacities of MTs? By quickly modulating small changes in the concentrations of 
reactive oxygen species or zinc levels in the epithelial cells, MTs could serve as 
immunomodulators in intestinal inflammation. Small, non-toxic concentrations of reactive 
oxygen species have been found to act as second messengers on e.g. NF-țB, a central 
immune modulator (41). The first way to investigate this is to search for a correlation with 
localized increased oxidation, i.e. via staining for malondialdehyde (MDA, reflecting lipid 
peroxidation), and nitrotyrosine (NITT, reflecting protein tyrosine nitration). This will be 
performed on serial sections of the samples used for the immunohistochemical study on 
human intestinal inflammation and on samples of the DSS model. A greater challenge will be 
to try to correlate inflammation-dependent MT expression in intestinal epithelial cells with the 
activity of NF-țB, given the complex composition of this transcription factor. An indication of 
this activity might be its nuclear localization and DNA binding. This could be checked in 
stimulated MT-deficient cells versus stimulated siRNA control cells. Next to modulating 
reactive oxygen species concentrations, the purpose for down-regulation might also be the 
release of zinc. Zinc is a structural and/or catalytic element in over 300 enzymes and in that 
way is strongly implicated in metabolic regulation (42). Zinc indicators exist that can measure 
intracellular free zinc concentrations in the range of 1 to 100nm (Molecular Probes, 
Invitrogen, Carlsbad, CA). Of course, all of these speculations need thorough investigation, 
but could form the basis of future research objectives.
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we ooit nog collega’s (maar nu wil ik toch me toch nog wat verdiepen in de darmen…) 
Ik wil ook mijn familie en vrienden bedanken. Een leuke uitstap ?, bezoekjes, even sporten, 
telefoontjes ?,… allemaal dingen waardoor ik stoom kon aflaten, zomaar of als het me 
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deugd. Bedankt daarvoor, en ook om zo goed voor mijn kindjes te zorgen als het nodig is! Ik 
hoop dat ik voor hen een even goeie mama zal zijn als jij voor mij bent, mama. 
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eigen zeggen amper een woord uit begrijpt, zit er toch ook een deel van jou in. Ik wil je 
bedanken, niet alleen voor je liefde en steun, maar ook voor je hulp en advies om te 
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